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Summary
In this study gene regulation by MLL fusion proteins was investigated. Inducible cell
lines using the estrogen receptor system were established that allowed for analysis
of the early events after activation of an oncogene. A fusion of the
MLL aminoterminus and the activation domain of Herpes simplex VP16 was used to
imitate leukemic MLL translocation events, the majority of which fuses the
aminoterminal part of MLL to a transcriptional activator. It could be demonstrated that
expression of biological targets of MLL and MLL fusion constructs increased
following activation of the inducible protein MLL–VP16–ER–HA. The regulatory
sequence of Hoxa9, expression of which is critically depending on MLL, was
investigated in detail in order to understand the mechanism of MLL activation.
Episomal reporter constructs were used to analyze the activation of different regions
of the human Hoxa9 promoter by MLL–VP16–ER–HA. A fragment comprising
nucleotides –118 / +46 was identified as sufficient for the response to induction of the
fusion protein. Monoclonal antibodies were raised against MLL and used to monitor
the recruitment of MLL–VP16–ER–HA to the episomal as well as to the chromosomal
Hoxa9 promoter. Site–directed mutagenesis of the regulatory sequences of Hoxa9
led to identification of short sequence motifs that are important for gene activation by
MLL–VP16–ER–HA. Three different motifs in the Hoxa9 promoter could be
characterized, some of which are also present in the upstream sequences of other
MLL target genes. Furthermore it was demonstrated that core promoter sequences
are critical for the effect of MLL–VP16–ER–HA pointing out a global role for MLL in
transcription. Comparison of Hoxa9 with p21 and c–myc, two new target genes that
have been identified in this study, provided insights into the mechanism of MLL
recruitment to promoters. This analysis showed that the promoter sequences of
these target genes share a bipartite structure, in which two modules containing one
or more putative binding sites for MLL and MLL fusion proteins cooperate to mediate
gene activation. In many cases the binding sites either contain CpG dinucleotides or
are located next to CpGs. Mutation of these cytosine residues to guanosine led to
increased activation of Hoxa9 indicating that guanosine residues, but not cytosine
residues are important for the effect. Based on this observation a model is proposed
in this study for recruitment of MLL and MLL fusion proteins to GC rich regions where
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cytosine residues have a negative regulatory function, which hints at a mechanism
involving DNA methylation.
In a genome–wide analysis new candidate target genes were identified. A murine
hematopoietic stem cell system was used to study the global effects of induction of
MLL–VP16–ER–HA. More than 200 genes were found to be significantly
upregulated, some of which have been found to be overexpressed in human
leukemias deriving from 11q23 translocation. A host of new candidates, however,
has not been described before as MLL target genes. These genes await further
analysis that will clarify their role in MLL leukemogenesis.
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1. Introduction
1.1 From gene to protein
The individual life cycle of any living matter is based on the sum of genetic
information, which is inherited from the parental generation. This collection of
hereditary material is referred to as the genotype. What defines an organism in the
context of its environment, however, is the so–called phenotype, the complete set of
characteristics that are observable under certain conditions. Therefore the inherited
genetic information has to be translated into biological processes in a way that
serves certain purposes in a given environment. This process is called gene
expression. The material encoding the genetic information is deoxyribonucleic
acid (DNA). A process termed transcription generates a blueprint of the information,
which is stored in the genomic DNA. This blueprint, the so–called
messenger RNA (mRNA), leaves the nucleus, the cellular compartment where DNA
is stored, and travels to the cytoplasm. It is there where the information contained in
the mRNA molecule is decoded and translated into proteins.
At a given time point only a fraction of the total amount of genes encoded in the
genome of an organism is expressed. Especially in metazoans gene expression
profiles vary dramatically over the course of development. The essential function of
the coordination of these changes in gene expression becomes obvious in fatal
diseases and failures in development that are due to deregulated or wrongly timed
expression of certain genes. Nature found multiple ways to control gene expression
on different levels. Most protein–coding genes, however, are regulated on the
transcriptional level. This is reflected in the genomic structure where protein–coding
genes are interspersed with regulatory regions, which do not by themselves contain
information that can be translated into protein but are necessary for proper
expression of adjacent coding sequences.
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1.2 Regulatory elements of protein–coding genes
Generally speaking there are two different classes of regulators that influence the
transcription rate: gene–specific elements that control expression of a single gene
only and global regulators, which in contrast control groups of genes.
Gene–specific regulators are called promoters, which consist of proximal and distal
elements. The DNA region immediately upstream of the transcriptional start point of a
given gene is often referred to as UAS (upstream activating sequence) or
URS (upstream repressing sequence). These proximal promoter sequences are
sufficient for initiation of transcription and determine the basal transcription
rate (Smale and Kadonaga 2003). One feature that is frequently found promoters of
the start site is the so–called TATA–box, which is usually located 30 nucleotides
upstream of the start site. Another common motif is the pyrimidin rich initiator (Inr)
sequence, around which the start site is centered. There is considerable variability,
however, amongst different promoters: additional elements that are found sometimes
but in other cases the promoters lack a well–conserved TATA–box or an
Inr sequence. This influences in turn the basal transcription rate. Distal promoter
elements can have a stimulatory (enhancers) or an inhibitory effect (silencers) and
function over a distance of several kilobases independently from their
location (upstream or downstream of a gene) and their orientation. Like proximal
promoter elements they are bound by transcription factors in a sequence–specific
manner that influence the transcription rate.
Global regulators are widespread in Metazoa. Matrix attachment regions (MARs) and
scaffold attachment regions (SARs), respectively, are thought to influence the
localization of large chunks of DNA by linking them to the nuclear matrix (Francastel
et al. 2000; Bell et al. 2001; Fernandez et al. 2001). The details behind this type of
transcriptional regulation are only poorly understood but it seems likely that the
specific localization of the chromosome region in the nucleus has an effect on the
chromatin structure. Certain sequences termed insulators have been found to
separate euchromatic from heterochromatic regions. Locus control regions (LCRs)
are aggregates of enhancer sequences and exert an effect on a large chromosomal
regional while at the same time they control transcription in a gene–specific
manner (Li et al. 2002).
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1.3 Eukaryotic RNA polymerases
The vast complexity of eukaryotic genomes illustrates the requirement of enzymes
that can process the stored information. Three different types of polymerases are
responsible for transcription of different classes of RNA (Roeder and Rutter 1969).
While RNA polymerase I transcribes ribosomal RNA and RNA polymerase III mainly
synthesizes tRNA, it is RNA polymerase II that is responsible for transcription of all
mRNAs generated in a living cell. It is possible to distinguish these enzymes
biochemically according to their sensitivity to α-amanitin (Table 1).
Table 1: Eukaryotic RNA polymerases. Pol I,Pol II and Pol III stand for the three DNA–dependent
polymerases. rRNA: ribosomal RNA; mRNA: messenger RNA; snRNA: small nuclear RNA, tRNA:
transfer RNA.
Type Genes Transcripts Localisation Response to α-amanitin
Pol I class I 18S-, 5.8S- and 28S-rRNA nucleoli none
Pol II class II pre-mRNA, snRNA nucleoplasm strong, KD=10-8 M
Pol III class III tRNA, 5S-rRNA, snRNA nucleoplasm weak, KD=10-6 M
RNA polymerase II is a protein complex that contains 12 subunits (Rpb1 - 12), four of
which are homologous to subunits from polymerase I and III complexes and four of
which are identical to subunits found in these enzymes (Cramer et al. 2000; Asturias
2004; Cramer 2004). The largest subunit of eukaryotic RNA polymerase II contains
the so–called CTD (carboxy–terminal domain). This domain is made up by a
species–specific number of heptapeptide repeats and contains binding sites for
proteins that regulate processes like transcriptional initiation, elongation, termination
and mRNA processing (Palancade and Bensaude 2003).
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1.4 General transcription factors
Eukaryotic as well as prokaryotic RNA polymerases cannot recognize promoters and
transcription start sites by themselves. Furthermore RNA polymerase II needs a
helicase activity for the opening of doublestranded DNA around this start site. The
proteins required for transcription from model promoters in vitro have been defined
as general transcription factors (GTFs, Table 2) (Hampsey 1998; Lee and Young
2000).
Table 2. General transcription factors.
Factor Function
TBP promoter recognition (TATA–box)
recruitment of TFIIB
TFIID
TAFIIs promoter recognition; positive and negative regulatory functions
TFIIA stabilization of TBP–DNA complex; stabilization of TAFII –DNA interactions;
antirepression
TFIIB recruitment of RNA polymerase II and TFIIF; determination of transcriptional
start site
TFIIF recruitment of RNA polymerase II; destabilization of unspecific
RNA polymerase II–DNA interactions
TFIIE recruitment of TFIIH; modulation of kinase, helicase and ATPase activities of
TFIIH; facilitation of strand separation
XBP/
ERCC3
3' – 5' helicase; promoter melting, open complex formation
XPD/
ERCC2
5' – 3' helicase; DNA repair (nucleotide excision repair)
Cdk7/
MO15
CTD phosphorylation
TFIIH
CyclinH regulation of Cdk7
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1.5 Mechanism of transcriptional initiation
The process of transcription can be formally divided into the three steps initiation,
elongation and termination. Using in vitro transcription systems it was shown that
initiation is starting with a process called pre–initiation complex (PIC) formation (Van
Dyke et al. 1988; Buratowski et al. 1989). This event could be dissected and it was
demonstrated that PIC formation is achieved through step–wise binding of GTFs and
RNA polymerase II to the DNA template.
TFIID binds to the promoter region in a sequence specific manner forming a binary
complex with DNA, which is stabilized through binding of TFIIA. This ternary complex
is the binding site for TFIIB that in turn is recruiting RNA polymerase II and TFIIF.
Finally TFIIE and TFIIH bind to the complex. The helicase activity can now convert
the so–called closed PIC into an open PIC by creating a single stranded DNA region
between –9 and +2. Besides this function as "PIC isomerase" TFIIH is exerting
another important effect during initiation and early elongation: the so–called
CAK sub–complex of TFIIH (Cdk7, cyclin H, MAT1) phosphorylates the CTD of
Rpb1. The phosphorylation status of CTD is critical for interactions with a series of
factors. The non–phosphorylated isoform of CTD is bound by the Mediator cofactor
complex. During initiation CTD becomes phosphorylated at serine 5 by TFIIH and
later during elongation pTEFb phosphorylates CTD at serine 2 (Pinhero et al. 2004).
Furthermore CTD is the binding site for factors involved in polyadenylation thus
representing a link between transcription and mRNA processing.
1.6 Activators of transcription
Activators are regulatory proteins that by definition meet two different criteria: on one
hand they specifically recognize target sequences on the DNA, on the other hand
they interact with the transcriptional machinery. This functional dualism is usually
reflected in the modular structure of these proteins: a DNA binding domain can
usually be separated from one or more activation domains that work indepently from
each other. This functional independence is also underlined by the existence of
activators that lack an intrinsic DNA binding activity but interact with DNA binding
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factors, e. g. β–catenin that is recruited to promoters via LEF–1 (Eastman and
Grosschedl 1999).
Activators can bind to DNA in a variety of different ways and the molecular structure
of DNA binding domains is used for the classification of these factors (Harrison 1991;
Pabo and Sauer 1992):
• Zinc finger proteins (e. g. SP1, GAL4) are characterized by DNA binding domains
that are stabilized by a metal ion. The Zinc–ion is complexed by two cysteine and
two histidine residues. The residues in between loop out and form a finger–like
structure, which contacts DNA. Very often this motif is repeated several times
creating an array of several zinc fingers that are separated by short α–helical
stretches.
• Helix–turn–helix (HTH) motifs were initially identified in DNA binding domains of
repressors in bacteriophages. Two a–helices are connected by a short
linker (4 aa). One helix contacts the major groove of the DNA while the other helix
is taking a position perpendicular to the DNA double strand. This type of
DNA binding domain functions as a dimer. A variant of this motif is found in
vertebrates: the homeobox contains three a-helices. One binds the major groove
of the DNA, while the other two are positioned perpendicular to the DNA molecule.
Homeobox proteins can bind DNA both as monomer and as dimer. They are
found not only in vertebrates (e. g. Hox proteins) but also in
Drosophila (e. g. antennapedia, ultrabithorax) and function as important regulators
of development. The family of POU proteins (e. g. Pit1, Oct1, Oct2) is
characterized by the presence of a homeobox and a POU domain, which is
another variant of the HTH motif. In contrast to the homeobox the POU domain
contains four helices, however.
• Another group of activators (e. g. MyoD, E12) have in common a basic
helix–loop–helix (bHLH) motif. Two amphipathic a–helices are connected by a
short loop and a basic region is found in the immediate vicinity that binds to DNA.
bHLH factors function as homo– or heterodimers, in which the helical regions
mediate dimerization.
• Also the basic leucine zipper (bZIP) motif contains an amphipathic a–helix in
combination with a basic region. Every seventh residue of the a-helix is leucine
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and like that this residues form an interaction surface with another bZIP protein:
the two a–helices bind to each other where the leucines work like a zipper to form
a coiled coil. This brings the basic regions into a fork–like position to each other,
which bind to the DNA from opposite sides contacting the major groove.
Mammalian examples for bZIP proteins are c–jun, c–fos and CREB that can
homo– or heterodimerize, respectively.
• bHLH–bZIP proteins like c–myc, Max, Mad or USF resemble the bZIP family. In
between the amphipathic a–helix and the basic region, however, a HLH motif is
found.
• The T–box motif is an extraordinarily large DNA binding domain (200 aa) and
consists of a b–barrel and four a–helices. In contrast to DNA binding by
HTH factors a–helices of T–box factors (e. g. Tbx1, Tbx3) contact the minor
groove, however. Formation of a dimer leads to further contacts involving the
b–sheets and the major groove of the DNA.
The structural variability of activation domains, however, does not allow for this type
of classification. Activation domains usually consist of 30 to 100 amino acids and it
was observed that very often there is a dominance of certain chemical properties
amongst these residues. This led to the definition of so–called glutamine rich (SP1,
GAGA), proline rich (Oct2, EKLF), serine / threonine rich (Sox–2, v–Rel) and
acidic (VP16, E1A, NFkB) activation domains.
Activation domains can interact with components of the basal transcription machinery
or elongation factors to influence the transcription rate. Alternatively they can bind to
coactivators, which mediate between activators and the basal machinery, or to
cofactors that modify the chromatin state (Lemon and Tjian 2000; Orphanides and
Reinberg 2002). These interactions lead to increased recruitment of GTFs, changes
in PIC conformation and to a more open chromatin structure around the start site.
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1.6.1 Nuclear hormone receptors
There are two different classes of nuclear hormone receptors:
• Steroid hormone receptors (glucocorticoid, androgen, estrogen and corticoid
receptors) are retained in the cytoplasm by binding to heat shock proteins that
mask their nuclear localization signals. Upon ligand binding they can translocate
to the nucleus where they bind as a homodimer to palindromic target sequences
on the DNA to regulate gene expression.
• The second class of hormone receptors (e. g. thyroid hormon receptor,
vitamine D receptor, retinoic acid receptor) is usually found bound to DNA also in
absence of the ligand where these proteins exert a negative effect on
transcription. In contrast to steroid hormone receptors this class binds as
heterodimer to target sequences, which consist of direct repeats.
Both classes have some characteristics in common, however: the DNA binding
domain of these proteins consist of two zinc finger motifs and two a-helices, one of
which contacts the hormone response element (HRE) on the DNA. Furthermore they
have two activation domains. While the N–terminal domain (AF1) is constitutively
active, the C–terminal domain (AF2) is only active in presence of the
ligand (Warnmark et al. 2003).
1.6.2 The viral activator VP16
The activation domain (aa 411 – 490) of the Herpes simplex virus protein 16 (VP16)
is well–studied model for acidic activators (Triezenberg et al. 1988). It was shown
that only upon binding to its interaction partners the unstructured activation domain is
converted into an a-helix (Uesugi et al. 1997), a mechanism that has been termed
induced fit.
A host of cellular factors have been shown to interact with the VP16 activation
domain:TFIIA (Kobayashi et al. 1995), TFIID (Goodrich et al. 1993), TFIIF (Zhu et al.
1994), TFIIH (Xiao et al. 1994), PC4 (Kretzschmar et al. 1994), MED25 (Mittler et al.
2003), CBP / p300 (Ikeda et al. 2002), yeast SAGA and NuA4 complexes (Utley et al.
1998), yeast Swi / Snf complex (Neely et al. 1999).
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1.7 Repressors
Besides the passive repression that is due to a lack of transcriptional activators for
example in certain cell types there are also proteins that actively contribute to
transcriptional silencing of a gene. Several different mechanisms can be
distinguished in eukaryotes:
• Repressors can compete directly with GTFs for binding to the promoter. A
prominent example is NC2, which binds to TBP and prevents recruitment of TFIIA
and TFIIB to the promoter (Goppelt et al. 1996).
• Another class of repressors competes with activators for the same binding site on
DNA. The homeodomain protein Cutl1 (CCAAT displacement protein) for example
prevents CTF and C/EBF from binding to the CCAAT motif present in many
promoters (Ottolenghi et al. 1989; Neufeld et al. 1992).
• Masking the activation domain of a transcription factor is another way to repress
transcription. The yeast protein GAL80 for example can bind to the GAL4
activation domain and thereby prevent transcriptional activation.
• The recruitment of corepressors promotes a closed chromatin structure that
renders chromosomal regions less accessible for transcription factors (Courey
and Jia 2001). mSin3a as well as N–CoR (nuclear receptor corepressor) and
SMRT (silencing mediator for retinoid and thyroid hormone receptors) all recruit a
complex of histone deacetylases (HDACs) that modify histone tails and lead to a
more closed chromatin structure.
• A less direct way of transcriptional repression is represented by factors that
sequester activators in the cytoplasm preventing them from entering the nuclear
compartment and binding to target sequences. An example is IkB, which binds to
NFkB (Silverman and Maniatis 2001). Only after phosphorylation and degradation
of IkB can NFkB migrate to the nucleus and induce transcription of target genes.
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1.8 Transcriptional Cofactors
While some activators can directly interact with GTFs others need accessory proteins
to establish a contact with the basal transcriptional machinery. These so–called
cofactors of transcription usually lack a sequence specific DNA binding activity.
1.8.1 TBP–associated factors (TAFs)
Cloning of TBP facilitated biochemical studies that led to the identification of
TBP–associated factors (TAFs) (Dynlacht et al. 1991). Members of this group
function as coactivators in activated transcription, facilitate promoter opening and
display enzymatic activity. TAF1 for example has three different activities:
phosphorylation of RAP47 (TFIIF), HAT activity, ubiquitin–activating / conjugating
activity for modification of histone H1 (Dikstein et al. 1996; Mizzen et al. 1996;
Wassarman and Sauer 2001). It seems that several TAFs contribute to binding of
TFIID to the promoter. Different TAFs inside the TFIID complex can contact different
activation domains thereby increasing complexity of regulatory pathways (Verrijzer
and Tjian 1996).
1.8.2 Cofactors of the USA fraction
The observation that increased purity of GTFs isolated from nuclear extracts has a
negative influence on activator–driven transcription led to discovery of proteins that
can mediate between activators and the basal transcription machinery (Flanagan et
al. 1991; Meisterernst et al. 1991). USA (upstream stimulatory activity), a protein
fraction from nuclear extracts containing this activity was further characterized and a
series of cofactors were identified that were initially classified as positive (PC) or
negative cofactors (NC) even though later it became clear that some of them play
dual roles (Kaiser and Meisterernst 1996). The group of positive cofactors comprises
PC1 (poly (ADP–ribose) polymerase, PARP), PC2 (a human mediator complex),
PC3 (DNA topoisomerase I), PC4, PC5 and PC6. NC1 and NC2 together with
HMG proteins 1 and 2 and Ada1 / Mot1 have been classified as negative cofactors.
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1.8.3 Mediator complexes
The search for proteins that could reconstitute activated transcription in vitro also led
to identification of the yeast mediator complex and finally to its purification (Flanagan
et al. 1991; Kim et al. 1994). Despite a low level of sequence homology among
different species this protein complex seems to be conserved throughout
evolution (Bourbon et al. 2004). Over the last 15 years several different approaches
were made to purify the mammalian complex, which led to the isolation of a range of
complexes (TRAP, ARC / CRSP, DRIP, PC2, SMCC) that share most of the subunits
but also exhibit subtle differences that are probably due to the purification
method (Fondell et al. 1996; Ito et al. 1999; Naar et al. 1999; Naar et al. 2001; Sato
et al. 2004; Blazek et al. 2005). The complex consists of 22 – 28 subunits and binds
to activators as well as to the CTD of RNA polymerase II. Mediator promotes CTD
phosphorylation in a two–fold manner: Cdk8 phosphorylates serine 5 of CTD but it
also phosphorylates cyclin H, which in turn stimulates the activity of the
TFIIH associated kinase Cdk7. The discovery of factors interacting with this huge
complex is still ongoing and indicates that the complex plays a major role in
modulating transcription in metazoan organisms.
1.9 Chromatin
The genetic material as it is found in the nucleus of eukaryotic cells is usually not
present in the form of naked DNA but rather in a nucleoprotein complex that is
termed chromatin. One obvious purpose of the formation of this structure is the
compaction of about 2 meters of DNA. The proteins that bind to DNA to form
chromatin are five types of histones: an octamer consisting of H2A, H2B, H3 and H4
are forming the protein core around which 146 bp of DNA are wrapped twice to form
a nucleosome, the basic unit of chromatin (Thomas and Kornberg 1975; Luger et al.
1997). A stretch of about 50 nucleotides connects two adjacent nucleosomes. This
linker is bound by histone H1, which is contributing to further compaction of the
chromatin by contacting H2A and tethering neighboring nucleosomes together.
Finally another level of compaction is achieved through binding of HMG and SIR
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proteins that induce formation higher order chromatin loops and ultimately
chromosomes.
1.9.1 Histone modifications
Histones fold into globular proteins that form the nucleosome core. An unstructured
N-terminal unstructured tail is protruding from this structure, however. These histone
tails are the targets for a range of different modifications. A directed link between
these modifications and transcriptional regulation was established through the
observation that certain co–activators are capable to modify residues in histone tails.
Over the past years the efforts of many laboratories world–wide led to identification of
a wide spectrum of different modifications and their relevance for the regulation of
transcription. The picture emerging from these studies is suggesting a histone code,
i. e. a scenario in which a combination of different histone tail modifications render
chromatin regions more or less poised for transcription (Fig. 1) (Jenuwein and Allis
2001).
Fig. 1. The histone code. Tails of the nucleosome core histones H2A, H2B, H3 and H4 are shown
together with the possible modifications that can take place on these residues (Jaskelioff and Peterson
2003). AC: acetylation, Me: methylation, P: phosphorylation, Ub: ubiquitination.
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1.9.1.1 Histone acetylation
Acetylated histone tails are associated with transcriptionally competent chromatin
regions (Peterson and Laniel 2004). It is speculated that the acetyl–groups weaken
the interaction between DNA and nucleosomes. Many transcription factors can bind
acetylated histones through the so–called bromodomain. It has also been shown that
chromatin remodeling complexes work more efficiently with acetylated nucleosomes.
The enzymes responsible for modifying histones in the nucleus are called histone
acetyltransferases (HATs) and can be roughly categorized in three
classes (Marmorstein and Roth 2001):
• GNAT (GCN5 related N–acetyltransferases) family members (e. g. GCN5,
PCAF) have a C–terminal bromodomain and preferentially acetylate histone H3 at
position lysine 14.
• Most of the members of the MYST (MOZ, Ybf2 / Sas3, Sas2, Tip60) family of
HATs contain a chromodomain, which binds RNA and methylated histones. With
the exception of Ybf2 / Sas3 these enzymes preferentially modify histone H4.
• CBP and p300 are two HATs with a very high degree of sequence homology.
They do not only acetylate histones but a wide range of transcription
factors (e. g. p53, TFIIE, TFIIF, E2F1) can function as substrates as well.
Histone deacetylases (HDACs) are the enzymes that remove acetyl–groups from
histones thereby counter-acting the activating function of HATs (Khochbin et al.
2001). There are three classes of HDACs:
class I HDACs comprise HDAC1, HDAC2, HDAC3 and HDAC8. HDAC1 and HDAC2
are components of Sin3 / HDAC and NurD / Mi2.
class II HDACs (HDACs 4–7) are poorly characterized.
The function of class III HDACs could be shown to depend on NAD+ in vitro providing
possibly linking these enzymes to metabolism. The yeast Sir and the mammalian
SIRT proteins (SIRT1–SIRT7) are representatives of this group.
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1.9.1.2 Histone methylation
Both arginine and lysine residues of histone tails can be methylated (Fig. 1).
Therefore two different types of histone methyltransferases (HMTs) are
distinguished (Jenuwein 2001): PRMTs (protein arginine methyltransferases)
methylate arginine residues in the H3 and H4 histone tails, which usually facilitates
transcription from these chromatic regions. Both mono– and dimethylation has been
reported. Lysine methyltransferases in contrast lead to mono–, di– or trimethylated
residues in histone tail (Zhang et al. 2003). With the exception of Dot1 lysine HMTs
have a SET domain, which has first been identified in Drosophila and which is also
found in yeast. Histone lysine methylation can influence transcription in both
directions: while for example H3K4 methylation is usually stimulating transcription,
H3K9 methylation is a marker for transcriptionally repressed loci. The complete
picture, however seems to be very complex with a multitude of different modified
positions and crosstalk amongst them (Jenuwein and Allis 2001).
For a long time histone methylation has been seen as a stable mark that stays
imprinted on chromosomes. This view was changed completely with the discovery of
the first demethylase (LSD1) that demethylates H3K4 residues (Shi et al. 2004).
Recently enzymes could be identified that remove methyl groups from H3K9 and
H3K36 (Chen et al. 2006; Tsukada et al. 2006).
1.9.1.3 Additional histone modifications
Besides acetylation and methylation there is a range of other modifications that
histone tails can undergo (Peterson and Laniel 2004). Serine and threonine residues
seem to be phosphorylated in a cell–cycle dependent manner. H2A, H2B and H3 are
subject to ubiquitination and ubiquitinated histones correlate with actively transcribed
gene loci. ADP–ribosylation has been reported to be linked to transcription, apoptosis
and genomic stability. SUMOylation and biotinylation have also been reported.
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1.9.2 Chromatin remodeling
ATP–dependent chromatin remodeling machines do not covalently modify histone
tails but rather introduce conformational changes at sites of transcriptional activity
that increase the accessibility of DNA for transcription factors (Johnson et al. 2005).
The replacement of nucleosomes involves breaking and reformation of histone–DNA
contacts. This process requires energy, which is reflected in the presence of
ATPases in all known remodeling complexes. Different types of these complexes
have been found throughout Eukarya and groups of complexes have been classified
according to their ATPases: Swi / Snf, ISWI, Mi2.
1.10 Transcriptional maintenance
In the context of development and cell differentiation it becomes particularly evident
that certain transcriptional events affect the fate of daughter cells. Genes that have to
be expressed transiently in embryogenesis for example need to be stably silenced.
Other gene products are required in certain tissues but not others. If therefore
transcription was initiated in a given cell there needs to be a way for the cell to
transmit this information to daughter cells. Since this type of inherited information is
adding another layer of regulation on top of the information that is contained in the
genetic material per se it has been termed epigenetic regulation. While there are
many open questions regarding the mechanisms of this process the picture emerging
from the work presented in the last years suggests cooperativity of several molecular
events.
1.10.1 DNA methylation
Cytosine residues in DNA from multicellular organisms can be methylated and this
modification correlates with a repressed chromatin state and inhibition of gene
expression (Bird and Wolffe 1999). Targets for methylation are usually found as
CpG dinucleotides, which often appear clustered in regulatory regions.
The DNA modifying enzymes are called DNA methyltransferases (DNMTs) and two
groups are distinguished based on the preferred DNA substrate: de
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novo methylases (DNMT3a, DNMT3b) introduce cytosine methylation at previously
non–methylated regions. The maintenance enzyme DNMT1 in contrast methylates
newly synthesized DNA strands during replication using the methylation pattern of
the parental strand as a template.
There seem to be several mechanisms to target DNMTs to their genomic target sites.
It was shown that the PWWP domain of DNMT3b is necessary for binding of the
protein to chromatin (Ge et al. 2004). The PWWP domain binds DNA in a
sequence–independent fashion (Qiu et al. 2002) and its structure resembles the
tudor domain found in 53BP1, a protein that binds to the tail of histone H3 methylated
at lysine 79 (H3K79) (Huyen et al. 2004).
Two different mechanisms have been described for gene silencing via DNA
methylation:
• Some DNA–binding factors are blocked from binding to methylated target
sequences (e. g. USF) (Watt and Molloy 1988).
• Methyl–CpG–binding proteins (MBPs, e. g. MBD2, MeCP2) recruit co–repressors
to methylated DNA–regions (Boyes and Bird 1991; Hendrich and Bird 1998).
These molecules affect the chromatin structure through histone
deacetylation (Jones et al. 1998; Nan et al. 1998; Ng et al. 1999),
methylation (Sarraf and Stancheva 2004) or nucleosome remodeling (Wade et al.
1999; Zhang et al. 1999). It is not completely understood, however, what comes
first in this process. There is evidence for example for the positive feedback of
DNA methylation on H3K9 methylation (Fuks et al. 2003b; Sarraf and Stancheva
2004). On the other hand there have been reports showing the interaction of
DNMTs with HP1, which recognizes H3K9 methylation as well as with HMTs and
suggesting histone methylation as the primary event that recruits DNMTs in a
second step (Fuks et al. 2003a; Lehnertz et al. 2003)
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1.10.2 Polycomb and trithorax
Another class of epigenetic regulators comprises members of the Polycomb (Pc) and
trithorax (trx) groups of genes. These genes were initially identified in Drosophila as
proteins required for maintenance of spatial patterns of Hox gene expression, which
is initiated during early embryogenesis by segmentation genes (Kennison 2004).
Most of the Polycomb group (PcG) and trithorax group (trxG) genes have homologs
in mammalians that serve similar functions (Brock and Fisher 2005). In many cases,
however, gene duplication led to the existence of more than one mammalian
homolog for each Drosophila gene. Between these closely related proteins there
seems to be functional overlap to a certain degree as seen for example with
mammalian trithorax homologs (Glaser et al. 2006). PcG and trxG proteins are seen
as antagonists in transcription maintenance: while PcG proteins keep loci repressed,
trxG proteins are often required to maintain transcription (Hanson et al. 1999). Many
PcG and trxG proteins contain conserved domains that have been identified in
transcription factors or chromatin–associated proteins, e. g. chromodomains,
bromodomains, zinc fingers, WD40 repeats (Brock and Fisher 2005). Furthermore
some members display enzymatic activities that closely link them to processes like
chromatin remodeling and histone tail modification:
• Some trxG members like for example hBRM contain an ATPase domain and act
as the enzymatic subunit of chromatin remodeling complexes (Johnson et al.
2005).
• SET (Su(var)3–9, Enhancer of zeste) domains  are found in proteins from both
the PcG (e. g. ezh2) and the trxG (e. g. MLL) group (Alvarez-Venegas and
Avramova 2002). These SET domains confer HMT activities, through which
Polycomb and trithorax–like proteins influence histone tail methylation patterns.
While transcriptional repression through PcG is associated with
H3K27 methylation (Cao et al. 2002; Czermin et al. 2002; Kuzmichev et al. 2002;
Muller et al. 2002; Lee et al. 2006), the activating mark introduced into histone
tails by trxG is H3K4 methylation (Beisel et al. 2002; Milne et al. 2002; Nagy et al.
2002; Nakamura et al. 2002; Guenther et al. 2005; Milne et al. 2005c). While
methylation of H3K4 leads to an opening of the chromatin structure and facilitates
transcription H3K27 methylation is followed by chromatin compaction (Fig. 2).
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Figure 2. Transcriptional maintenance through trxG and PcG proteins. HMTases of the trithorax group
of proteins (e.g. MLL) introduce H3K4 methyl marks in the chromatin and interact with
HATs (e.g. CBP) that acetylate the same regions. These modifications lead to opening of the
chromatin and recruitment of other activating complexes (e.g. chromatin remodeling complexes). trxG
proteins (pink) maintain transcription after initial activation. PcG proteins (blue) antagonize these
functions by introduction of H3K27 methylation, recruitment of deacetylation complexes and
heterochromatin formation.
The exact mechanism of PcG and trxG action is not yet clear and the sequence of
events in particular remains to be clarified. Single members of these gene groups are
present in several protein complexes that play key roles in epigenetic regulation of
transcription (Brock and Fisher 2005). The emerging picture is reflected by the
so–called polarization model, according to which positive feedback loops involving
different regulatory pathways stimulate each other leading to establishment of more
or less stable chromatin states (Fig. 3) (Jaenisch and Bird 2003).
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Figure 3. Polarization model. Each circle represents a particular chromatin modification status. The
effect of positive feedback is to polarize domains at either the active or the inactive extremity. Broken
lines indicate positive feedback loops between products and reactions that interconvert intermediate
states. Negative interactions between the silent and active states of the gene occur but are not shown.
The likelihood that a chromatin domain will occupy a particular state is indicated by the color intensity,
with dark shades representing more probable states. (Jaenisch and Bird 2003)
1.10.2.1 MLL: a member of the human trithorax family
The protein MLL (ALL–1, MLL1, HRX) is the closest human homolog of Drosophila
trithorax. Even before its role in transcriptional regulation was investigated this gene
was already attracting the attention of scientists since it is involved in
leukemogenesis. Cloning of the MLL gene (Ziemin-van der Poel et al. 1991; Djabali
et al. 1992; Gu et al. 1992; Tkachuk et al. 1992) spurred research since many
domains involved in transcription are contained in this large protein (Daser and
Rabbitts 2005).
Two different regions have been identified that can mediate binding to DNA: three
AT hooks are located near the N–terminus (Fig. 4) and it was reported that they bind
the minor groove of AT–rich DNA (Zeleznik-Le et al. 1994). Another region
(aa 1053–1119) has been termed MT domain for its homology to DNMT1 (Ma et al.
1993) and binds to unmethylated CpG (Birke et al. 2002). This domain is located
inside a region (aa 1032-1395), which has been reported to repress
transcription (RD, repression domain) (Slany et al. 1998). The RD region is bound
not only by HDACs but also by the Polycomb repressor proteins HPC2 and BMI–1
and the co–repressor CTBP (Xia et al. 2003). In between the AT hooks and the
repressive domain two motifs (SNL1 and SNL2) have been identified that are
responsible for subnuclear localization of MLL (Yano et al. 1997). Site–specific
cleavage of MLL by a threonine protease (taspase 1) (Yokoyama et al. 2002; Hsieh
et al. 2003a) is taking place at two positions (CS1, CS2) (Hsieh et al. 2003b). After
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this process the two parts of the protein (p180, p300) are still found in one complex
and association is mediated through the FYRN and FYRC domains (Hsieh et al.
2003b).
The breakpoint cluster region (BCR) is marking the 3' border of the MLL moiety,
which is retained in fusion proteins resulting from translocations at that position. On
the 3' side of the breakpoint (and therefore lost in all fusions) are three PHD zinc
finger motifs and a bromodomain. The nuclear cyclophilin CYP33 has been reported
to bind to the third MLL PHD finger and negatively influence Hox gene
transcription (Fair et al. 2001). It has been shown that CYP33 is also binding HDAC1
bound to the repression domain thereby stabilizing the HDAC1–MLL interaction (Xia
et al. 2003). The transcriptional activation domain interacts with the co–activator CBP
and facilitates its binding to phosphorylated CREB (Ernst et al. 2001). The
C–terminal SET domain of MLL has been reported to methylate histone H3 at
lysine 4 (Milne et al. 2002; Nakamura et al. 2002) and to bind to Ini1, a component of
the Swi / Snf remodeling machinery (Cui et al. 1998), pointing out the importance of
the protein as an epigenetic regulator.
Figure 4. Domain structure of the MLL protein. Arrows are indicating points of cleavage through
Taspase. Not to scale. SNL: subnuclear localization, MT: methyltransferase homology,
BCR: breakpoint cluster region.
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1.10.2.2 MLL-containing complexes
Biochemical approaches using chromatographic techniques to purify MLL from
mammalian cell extracts led to the identification of three different
complexes (Nakamura et al. 2002; Yokoyama et al. 2004; Dou et al. 2005). The first
published report described a "supercomplex" containing proteins from six other
complexes that are involved in transcriptional regulation (Nakamura et al. 2002). The
HMTase activity associated with these complexes is specific for non– or
monomethylated lysines and failed to trimethylate H3K4. The second purified
complex is much smaller and there is not much overlap with the previously published
supercomplex (Yokoyama et al. 2004). No enzymatic activity was demonstrated for
this complex. It contains, however, the tumor suppressor protein Menin, which has
been shown to bind directly to the MLL aminoterminus and to be necessary for Hox
gene regulation (Yokoyama et al. 2005). Menin binds to both the MLL wild type
protein as well as to MLL fusion proteins and loss of Menin leads to impaired
Hox gene expression. Therefore it has been proposed that Menin is playing a role in
tumorigenesis as well as in normal transcriptional regulation by MLL (Yokoyama et
al. 2005).
The smaller MLL complex published by Yokoyama et al. seems to represent the
"core unit" of the complex found in the cell. This is illustrated by the fact that a third
complex that was purified in the Roeder laboratory is containing the same subunits
alongside 23 other proteins (Dou et al. 2005). Interestingly most of the proteins
initially identified in the MLL "supercomplex" are not present in this preparation. It
contains, however, components of TFIID and the MOF, a MYST family HAT. Dou and
coworkers demonstrated that the purified complex has HAT as well as HMT activity.
In this report it was also shown that H3K4 is trimethylated by the MLL complex. This
level of H3K4 methylation  is strongly associated with transcribed regions of active
genes in yeast as well as in higher eukaryotes (Krogan et al. 2002; Ng et al. 2003;
Santos-Rosa et al. 2003; Schneider et al. 2004). SET1, the only H3K4
methyltransferase in yeast and a relative of MLL is introducing this type of
modification suggesting that the MLL complex containing this enzymatic activity is the
physiologically most relevant one.
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1.10.2.3 Leukemic transformation by mutation of MLL
The human MLL gene is involved in acute leukemias, in particular infant leukemias
and treatment–related leukemias, which are generally associated with a bad
prognosis. More than 30 different fusion proteins have been described that arise from
translocations of MLL to more than 50 different gene loci. These events all take place
at the major break point region of MLL and result in fusions that consistently contain
the MLL aminoterminus including AT hooks and MT domain. PHD fingers,
bromodomain, transactivation domain and SET domain are lost on the other hand.
Some of the fusion partners are cytoplasmic proteins (e. g. LASP1) (Strehl et al.
2003), the vast majority, however, is represented by nuclear factors involved in
transcription (Daser and Rabbitts 2005).
Several models have been proposed for the mechanism of transformation through
MLL fusions:
1. The translocation could create a fusion protein, which is acting as a
dominant–negative allele and which represents a gain–of–function in comparison to
the wild type allele. This model is supported by the fact that both the wild type and
MLL fusion proteins target Hox gene promoters (Milne et al. 2002; Yokoyama et al.
2005). Since most of the fusion partners provide a transcriptional activation domain
one could speculate that MLL fusions lead to overexpression due to loss of the
C–terminal MLL moiety, which could have a regulatory role balancing the
transcription rates from Hox gene promoters.
2. One obvious argument against this theory is the activating effect of the
SET domain, which is lost in MLL fusion proteins together with a series of other
features that might mediate transcriptional activation. The loss–of–function model for
MLL leukemogenesis therefore proposes impairment of normal transcription by MLL
wild type in the heterozygous situation. To date, however, no target gene for wild
type MLL has been reported whose transcription rate is reduced by the presence of
MLL fusion protein.
3. Another model for transformation by MLL is claiming that dimerization of
MLL molecules might lead to deregulation of target genes. This model is supported
by the identification of partial tandem duplications of MLL in some leukemia
patients (Caligiuri et al. 1996; Schnittger et al. 2000). To test this hypothesis
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MLL aminoterminal constructs were employed that had been genetically manipulated
to form dimers or tetramers (Dobson et al. 2000; Martin et al. 2003) and transforming
capacity of these constructs was reported to be linked to multimerization. In two
MLL fusion partners (GAS7, AF1P) coiled–coil domains have been identified, that are
thought to be mediating dimerization. These domains have been shown to be
necessary for transformation suggesting that dimerization of MLL fusion proteins
might be involved in leukemogenesis (So and Cleary 2003).
1.10.2.4 MLL target genes
The question how MLL fusion proteins transform mammalian cells is closely linked to
the identification of target genes for the wild type protein as well as for the leukemic
fusions. Early studies showed the importance of MLL as a maintenance factor for
Hox gene transcription during mouse development (Yu et al. 1995; Yu et al. 1998).
Mouse embryonic fribroblasts (MEFs) lacking MLL (MLL – / –) also revealed impaired
Hox gene expression patterns (Schraets et al. 2003). Microarray analysis of
leukemias demonstrated overexpression of Hoxa cluster genes indicating that wild
type as well as leukemic fusion proteins act (at least in part) through the same target
genes (Armstrong et al. 2002; Kohlmann et al. 2005). The overexpression of Hoxa9
has some leukemogenic potential (Kroon et al. 1998; Calvo et al. 2000). However, it
has been reported that MLL fusion proteins can transform hematopoietic progenitor
cells in absence of Hoxa9 (So et al. 2004) pointing out the existence of more than
one pathway for cell immortalization. One step into the direction of identifying
additional targets of MLL was the observation that MLL is critical for the transcription
of cyclin–dependent kinase inhibitors p27 and p18 (Milne et al. 2005b). The authors
proposed a model in this report according to which MLL is recruited to the promoters
of these genes by the tumor suppressor Menin. Considering that both of these genes
are cell cycle regulators that have been reported to be lacking in tumors this
observation is providing some support for a loss–of–function model for
MLL leukemogenesis.
Recently a genome–wide location analysis (ChIP–chip) showed colocalization of MLL
with the vast majority of actively transcribed genes as assessed by detection of both
RNA polymerase II and trimethylated H3K4 (Guenther et al. 2005). The authors
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propose a role for MLL as a global transcription factor that binds to most of the
actively transcribed gene promoters.
Another recent publication, however, showed that promoter occupancy by
RNA polymerase II is not strictly correlated with MLL occupancy (Milne et al. 2005a).
On the single gene level it was demonstrated that a MLL knockout mutation leads to
decreased RNA polymerase II levels on the promoters of some direct target genes of
MLL (e. g. Hoxa7 and Meis1) but not on the promoters of other genes, which are
actively transcribed in an MLL–independent manner (e. g. GAPDH). These data
argue for a more specific role of MLL in transcription. It is becoming clear, however,
that the target gene spectrum might well exceed Hox genes. One of the most
important aspects of MLL research therefore remains the investigation of direct target
genes for MLL and in particular the differences between the target gene populations
of the wild type protein and leukemogenic fusions.
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1.11 Objectives of this study
In this study the process of gene activation by MLL fusion proteins should be
analyzed. In particular the question should be addressed, which binding sites are
required to target MLL fusions to a promoter and what are the mechanisms of this
recruitment. An inducible MLL fusion variant should be generated as a model system
for the investigation of this process in hematopoietic cells. Mutagenesis of the Hoxa9
promoter should be used to identify critical sequences for the recruitment of MLL
fusion proteins and for the characterization of the motifs that are involved in this
event. Furthermore the inducible system should be employed for identification of new
target genes of MLL fusion protein. On the single gene–level some candidates
should be investigated using reporter assays as well as RT–PCR. A global screen for
new MLL fusion protein target genes should be performed using Affymetrix
microarrays.
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2. Materials and Methods
2.1 Instruments and Accessories
Acrylamide gel electrophoresis Amersham / Hoefer / BioRad
Agarose gel electrophoresis BioRad
Analytical balance AE 100 and 163, Mettler
Centrifuges Avanti, Beckman
Multifuge 3L-R, Heraeus,
5417 / 5415R, Eppendorf
Developing machine Curix60, Agfa
Electroblot semi-dry BioRad
Geigercounter LB122, Berthold
Heatingblock Thermomixer compact, Eppendorf
Homogenizer Douncer, Wheaton
Incubator WJ311, Forma Scientific
Unequip, Unitherm B6200, Heraeus
Light microscope Axiovert 25, Zeiss
PCR-Thermocycler GeneAmp 2400, Applied
pH-Meter Calimatic 760, Knick
Photometer GeneQuant Pro, Amersham
Rotors JA10, JA25-50, SW41, SW28,
Beckman
Sonifier W250 and 250-D, Branson
Ultra-centrifuges L7, L8-M, Heraeus
UV-Illuminator Bachofer
2.2 Chemicals and Biochemicals
Acetic acid (p.a.) Roth
Acrylamide/Bisacrylamide 30% Roth
Acrylamide 30% / 40% Roth
Agarose Invitrogen
Ammonium persulfate (APS) Merck
Ampicillin Roth
Aprotinin Sigma
Bacto Agar Difco
Bacto Trypton Difco
Bacto Yeast Extract Difco
Benzamidine Sigma
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Bisacrylamide 2% Roth
Boric acide Roth
Bradford reagent BioRad
5-Bromo-4-Chloro-3-indolyl-phosphate (BCIP) Peqlab
Bromphenol Blue Sigma
BSA Roche
Caesiumchlorid Sigma
Calciumchloride Merck
Calciumhydrogenphosphate Merck
Calciumhydroxide Merck
CHAPS Sigma
Chloroform Merck
Coomassie brilliant blue R-250 Sigma
DAPI Sigma
Deoxycholat (DOC) Sigma
Dimethylsulfoxide Sigma
Dithiothreitol (DTT) Roth
Doxycycline Sigma
DMEM medium Invitrogen
dNTPs Roche
Ethanol Sigma
Ethanolamine Sigma
Ethidium bromide Sigma
Ethylendiamintetraacetate disodium salt (EDTA) Merck
Fetal calf serum (FCS) Invitrogen
Ficoll 1.077 Amersham
Fish DNA Sigma
G–CSF Aventis
Giemsa solution Merck
GM–CSF Aventis
Glucose Merck
Glykogen Sigma
Glycerol Roth
Glycine Roth
HEPES Biomol
4–Hydroxa–tamoxifen Sigma
Hygromycin Sigma
IGEPAL CA630 (NP-40) Sigma
IL3, murine recombinant Roche
IMDM medium Invitrogen
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IPTG Roth
Isoamyl alcohol Merck
Isopropanol Merck
Leupeptin Roche
Lithiumchlorid Sigma
Magnesiumchloride Merck
May-Gruenwald solution Merck
b-Mercaptoethanol Sigma
Methanol Merck
Milk powder Heirler, Roth
N-Laurylsarcosin Sigma
Nitro-blue-tetrazolium (NBT) Peqlab
Penicillin-Streptomycin Invitrogen
Phenol/Chloroform Roth
Phenylmethylsulfonfluoride (PMSF) Biomol
Phorbolmyristylester (PMA) Roche
Ponceau S Sigma
Protein G-Sepharose Amersham
Protein A-Sepharose Amersham
Puromycin Sigma
RPMI 1640 medium Invitrogen
Sodium azide Sigma
Sodium borate Roth
Sodium carbonate Merck
Sodium chloride Roth
Sodiumdodecylsulfate (SDS) Merck
Sodium fluoride Sigma
Sodium hydroxid Merck
Sucrose Sigma
Tetramethylethylendiamin (TEMED) Sigma
Thymidine Sigma
Trishydroxidimethyl-aminomethan (Tris; p.a.) Sigma
Triton X-100 Sigma
Trypsin-EDTA Invitrogen
Urea Roth
Xylene cyanole Fluka
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2.3 Additional material
Disposable plastic material Greiner, Nunc, TPP, Falcon
Dialysing tubes (Viking, MWCO 15 kDa) Roth
ECL Western Blot Kit NEN
Film X-OMAT, BioMax Kodak
Gel Drying Kit Promega
GFX Gel Band Purification Kit Amersham
Luciferase Kit Promega
RNeasy Kit Qiagen
Nitrocellulose membrane BioRad
NuPage LDS sample buffer Invitrogen
Nucleobond AX Plasmid DNA Kit Machery & Nagel
RT-PCR Kit Invitrogen
Siliconized Plastic tubes Sorenson
Silver Staining Kit PlusOne Amersham
Sterilfilters Roth
Bottle top filters Nalgene
Whatman 3MM Paper Whatman
TNT Kit Promega
2.4 Enzymes
Calf intestine phosphatase MBI Fermentas
Klenow Fragment MBI Fermentas
Lysozym Sigma
Pfu Polymerase MBI Fermentas
Restriction enzymes NEB or MBI Fermentas
RNase A Roche
T4 DNA ligase MBI Fermentas
T4 polynucleotide kinase MBI Fermentas
Taq polymerase MBI Fermentas
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2.5 Antibodies
Table 3. Primary antibodies
antibody origin provider dilution for WB
MLC 5A9 rat E. Kremmer 1 : 5
MLC 4G10 rat E. Kremmer 1 : 5
MLC 5C10 rat E. Kremmer 1 : 5
MLN 7D4 rat E. Kremmer 1 : 5
MLN 7E12 rat E. Kremmer 1 : 5
anti–HA 3F10 (ROO1) rat E. Kremmer 1 : 5
anti–dog–CD3 rat E. Kremmer 1 : 5
ER (sc-8002) mouse Santa Cruz 1 : 500
Table 4. Secondary antibodies
antibody provider dilution for WB
anti–rabbit Promega 1:5000
anti–mouse Promega 1:5000
anti–rat Biomol 1:3000
2.6 General buffers
10 x TBE: 1 M Tris 20 x PBS: 160 g NaCl
1 M Boric acid 4 g KCl
20 mM EDTA, pH 8.0 23 g Na2HPO4 x 2 H2O
4 g KH2PO4
10 x TGS: 250 mM Tris H2O ad 1000 ml
1.92 M Glycine pH 7.2 –7.4
1 % (w/v) SDS
BC-Puffer: 20 mM Tris-HCl, pH 7.3 10 x TBS: 24.2 g Tris
0.2 mM EDTA, pH 8.0 80 g NaCl
0 – 2000 mM KCl 2 g KCl
20 % (v/v) Glycerin H2O ad 1000 ml, pH 7.6
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2.7 Oligonucleotides
Table 5. Oligonucleotides
oligo sequence purpose
mllab4up CGAATTCTTGCGAGAACCGACATTTAG
mllab4down CCGGATCCCCTTCTTCCGCCCTGTCGT
PCR primers for cloning
of GST-MLLaa612-935
(pML13)
mllab5up CGAATTCACCCAAAATCCAGCAAATGAA
mllab5down CCGGATCCCTTAGTTGATGAACTTCCGGCA
PCR primers for cloning
of GST-MLLaa3620-3969
(pML14)
HAMCS
sense
AATTCTCGAGATCTGCGGCCGCTACCCATACGATGT
TCCAGATTACGCTCTTTGAG
HAMCS
antisense
CTAGCTCAAAGAGCGTAATCTGGAACATCGTATGGG
TAGCGGCCGCAGATCTCGAG
multiple cloning site for
vector pML3 (pML15)
VP16AD
XhoIup
CCGCTCGAGCGGTCGACGGCCCCCCCGACCGAT
VP16AD
XhoIup
GAAGATCTTCCCACCGTACTCGTCAATT
PCR primers for cloning
of VP16 activation domain
(pML16)
ERT2.2up GCGGCCGCGATCCATCTGCTGGAGACA
ERT2.2 down GCGGCCGCGAGCTGTGGCAGGGAAACCCT
PCR primers for cloning
of ERT2 (pML27)
HRXN1up TCGAATTCCGCCACCATGGCG
HRXN1 down CCGCTCGAGCGGCCTCCCATCTCCCA
PCR primers for cloning
of MLL aa1-1419
(pML26)
pREP4 MCS
sense4
GATCTGGTACCGCTAGCGCGGCCGCA
pREP4 MCS
antisense4
AGATCTGCGGCCGCGCTAGCGGTACCA
multiple cloning site for
vector pML94 (pML73)
p21 –2325 AGAGGTACCGCTTGGGCAGCAGGCTGTG
p21 –215 AGAGGTACCGCACGCGAGGTTCCGGG
p21 +8 GTCTGCTAGCACTTCGGCAGCTGCTCACACC
PCR primers for cloning
of human p21 promoter
(pML76, pML78)
hoxa9 –1953 AGAGGTACCGACTGCGGGGTATTTAGGACACGGTA
CCGACTGCGGGGTATTTAGGACACGGT
hoxa9 –1010 AGAGGTACCCTGGGAATCCTGATTGCCAGCTGATG
AGA
hoxa9 –510 AGAGGTACCCCAGCCTGTGTGGCTTCTGAAACAATA
AC
hoxa9 –207 AGAGGTACCCATCGTAGAGCGGCACGATCCCTT
hoxa9 +46 GTCTGCTAGCCCGACCCACGGAAATTATGAAACTGC
AGA
PCR primers for cloning
of human hoxa9 promoter
cons t ruc ts  (pML74,
pML82, pML84, pML86,
pML93)
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hoxa9 +98 GTCTGCTAGCCGACCCACGGAAATTATGAAACT
CpGmut_s CGGTGGGGAGTGATTTAGGGGTTATTGTTCTGCTG
GAGGGGCAC
CpGmut_as GTGCCCCTCCAGCAGAACAATAACCCCTAAATCACT
CCCCACCGGTAC
cloning of pML109
GCCCbox
mut_s
CCGTGCGGAGTGATTTACGCGTTATTGTTCTGCTGG
ACGTGCAC
GCCCbox
mut_as
GTGCACGTCCAGCAGAACAATAACGCGTAAATCACT
CCGCACGGGTAC
cloning of pML111
hoxa9site
mut_s
CCGTGCGGAGTGATGCACGCGTTATTGTTCTGCTG
GACGGGCAC
hoxa9site
mut_as
GTGCCCGTCCAGCAGAACAATAACGCGTGCATCAC
TCCGCACGGGTAC
cloning of pML113
a9_WT_s CCGTGCGGAGTGATTTACGCGTTATTGTTCTGCTGG
ACGGGCAC
a9_WT_as GTGCCCGTCCAGCAGAACAATAACGCGTAAAATCAC
TCCGCACGGGTAC
cloning of pML115
2xSP1FF _as GTGACCCCGCCCCGCTGCCCAGCACCCCGCCCCG
CGGTAC
2xSP1FF_s CGCGGGGCGGGGTGCTGGGCAGCGGGGCGGGGT
CAC
cloning of pML126
3xMZF1_as GTGTTCCCCACTGTTCCCCACTGTTCCCCACTGGCG
GTAC
3xMZF1_s CGCCAGTGGGGAACAGTGGGGAACAGTGGGGAAC
AC
cloning of pML128
2xGAL4_as GTGGCGGAGTACTGTCCTCCGAGCGGAGTACTGTC
CTCCGAGCGGGGTAC
2xGAL4_s CCCGCTCGGAGGACAGTACTCCGCTCGGAGGACAG
TACTCCGCCAC
cloning of pML134
3xSP1FFF
_as
GTGACCCCGCCCCACCCCGCCCCACCCCGCCCCG
CGGTAC
3xSP1FFF _s CGCGGGGCGGGGTGGGGCGGGGTGGGGCGGGGT
CAC
cloning of pML122
3xSP1FRF
_as
GTGACCCCGCCCCGGGGCGGGGTACCCCGCCCCG
CGGTAC
3xSP1FRF _s CGCGGGGCGGGGTACCCCGCCCCGGGGCGGGGT
CAC
cloning of pML124
3xEBOX _as GTGCCACGTGCTGGCCACGTGGCGCACGTGGCAG
CGGTA
cloning of pML132
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3xEBOX _s CGCTGCCACGTGCGCCACGTGGCCAGCACGTGGC
AC
3xUSF_as GTGGTCACGTGGTGTCACGTGGTGTCACGTGGTGC
GGTA
3xUSF_s CGCACCACGTGACACCACGTGACACCACGTGACCA
C
cloning of pML130
HA9F ATCCCAATAACCCAGCAG
HA9R CAGAAACTCTTTCTCCAGTTCC
RT–PCR primers for
human Hoxa9
B-actinFw TGCGTTGTTACAGGAAGTCCC
B-actinRev CTATCACCTCCCCTGTGTGGA
RT–PCR promers for
human beta-actin
p21-FW CATGTGTCCTGGTTCCCGTT
p21-Rev TCAGCATTGTGGGAGGAGC
RT–PCR primers for
human p21
hoxa9F–65 GCCGGCAACTTATTAGGTGACTG
lucR_short AGCTTACTTAGATCTGCGGCCG
ChIP primers for episomal
Hoxa9 promoter
hoxa9end2 ACGGGAGAGTACAGAGACAAGG
hoxa9end_r GGGGGAAGTACAGTCACCTAATA
ChIP  p r imers  fo r
chromosomal  Hoxa9
promoter
2.8 Plasmids
Table 6. Plasmids used in this work.
plasmid features remarks
pML1 pCMV–MLL gift from R. Slany
pML3 pCAG3SIP gift from T. Schroeder
pML9 pGEX–B
pML13 GST–MLL–aa613–935
pML14 GST–MLL–aa3620–3969
pML31 MLL–NTD–HA
pML33 MLL–VP16–HA
pML37 MLL–VP16–ER–HA
pML46 ER–VP–16–HA
pML73 episomal reporter vector (pREP4–luc)
pML51 MIG–MLL–AF4 gift from C. Buske
pML52 MIG–MLL–AF9 gift from C. Buske
pML56 pMSCV–FLAG–MLL gift from R. Slany
pML60 c–myc–luc   –2332/+513 pCG362 from D. Eick
pML61 c–myc–luc   –2332/+513/IgEnh pCG363 from D. Eick
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pML62 c–myc–luc   +66/+513 pRF235 from D. Eick
pML63 c–myc–luc   +66/+513/IgEnh pCG508 from D. Eick
pML64 c–myc–luc   –101/+66 pRF278–1 from D. Eick
pML65 c–myc–luc   –101/+66/IgEnh pCG5–2 from D. Eick
pML74 episomal Hoxa9 reporter plasmid
–1010/+46  luciferase
pML76 episomal p21 reporter plasmid
–2325/+8   luciferase
pML78 episomal p21 reporter plasmid
–215/+8   luciferase
pML82 episomal Hoxa9 reporter plasmid
–207/+46   luciferase
pML105 episomal Hoxa9 reporter plasmid
–78/+46   luciferase
pML107 episomal Hoxa9 reporter plasmid
–207/+98   luciferase
pML109 episomal Hoxa9 reporter plasmid
–118/+46
mutant oligo "CpGmut"
CpG mutant 2
pML111 episomal Hoxa9 reporter plasmid
–118/+46
mutant oligo "GCCCboxmut"
GGGC mutant
pML113 episomal Hoxa9 reporter plasmid
–118/+46
mutant oligo "hoxa9sitemut"
Hox site mutant
pML115 episomal Hoxa9 reporter plasmid
–118/+46
mutant oligo "a9_WT"
pML123 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 3xSP1FFF
MAZR1
pML124 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 3xSP1FRF
MAZR3
pML126 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 2xSP1FF
MAZR2
pML128 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 3xMZF1
MZF 1
Materials and Methods                                                                                               35
pML131 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 3xUSF
E–BOX1
pML133 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 3xEBOX
E–BOX2
pML135 episomal Hoxa9 reporter plasmid
–78/+46 with oligo 2xGAL
GAL
pML146 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055107
Hox site mutant
pML147 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055106
GC mutant
pML151 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055113
GGGC mutant
pML152 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055114
GGC mutant
pML153 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055115
SP1 sites up–mutant
pML154 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055112
CpG mutant 1
pML155 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055111
nt 9459 deleted from pML160
TATA–less mutant 1
pML156 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055110
AdML–TATA box
pML157 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055109
AdML–Inr
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pML158 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055108
core promoter C–stretch mutant
pML160 episomal Hoxa9 reporter plasmid
–207/+46
Geneart construct 055111
TATA–less mutant 2
pML161 Gal93–SP1.Q1
SP1 132–243 fused to Gal1–93
P. Halle
pML162 pBXG1 / pPF36
control vector for pML161
P. Halle
pML163 pCMV–SP1 / pPF27
full–length SP1
P. Halle
pML165 Gal–SP1
SP1 75–597 fused to Gal1–147
gift from W. Hammerschmidt
pML166 Gal only vector (control for pML165) gift from W. Hammerschmidt
pLS23 p21 reporter plasmid
–2325 / +8 luciferase
gift from T. Kardassis
pLS24 p21 reporter plasmid
–215 / +8 luciferase
gift from T. Kardassis
pLS25 p21 reporter plasmid
–143 / +8 luciferase
gift from T. Kardassis
pLS26 p21 reporter plasmid
–2325 / +8, delta –122 / –60 luciferase
gift from T. Kardassis
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2.9 Cloning
2.9.1 Polymerase chain reaction (PCR)
PCR reactions were performed using Pfu polymerase (MBI, cat.no. 1433) and the
following protocol: 10 µl buffer w/o MgSO4
10 µl DMSO 50%
1 µl dNTP 25mM
10 µl MgSO4 25mM
0.5 µl forward primer (100 pmol / µl)
0.5 µl reverse primer (100 pmol / µl)
10 µl template DNA (10 ng / µl)
2 µl Pfu Polymerase (2.5u / µl)
56 µl H2O
Duration of elongation cycles were adjusted according to the length of the desired
amplicon. Pfu polymerase is thought to have a processivity of 500 bp / min.
2.9.2 Restriction digests, fragment isolation and ligation of DNA
Restriction digests were done using enzymes from MBI Fermentas and the
accompanying buffer solutions following the manufacturer´s protocol. In general 5 µg
of DNA were digested overnight with 10 u of enzyme. After a heat inactivation
step (10 min / 70°C) fragments were purified on agarose gels containing
Ethidiumbromide. Depending on fragment length gels containing between 0.5 and
1.5% agarose were used. Fragments were cut out from the gel under UV light and
DNA was isolated from the gel using the GFX Gel Band Purification Kit (Amersham)
Ligation reactions
Ligations were usually performed overnight using T4 DNA ligase (MBI) in a total
volume of 15 µl. The insert was added to the reaction in a five–fold excess in
comparison to the vector. 1µl of enzyme was added on ice before incubation at 16°C.
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2.9.3 Transformation into E. coli DH5α
Before transformation into bacteria the ligation reaction was stopped and enzymes
were inactivated at 70°C for 10 min. A heat shock protocol was used to transform
E. coli DH5α: bacteria were thawed on ice, DNA was added and incubated together
with the bacteria for 20 min on ice. The heat shock was performed for 90 sec at
42°C, after which 1 ml of LB medium was added to the transformation sample. After
an incubation in a shaker at 37°C bacteria were spun down (1.000 g, 3 min). The
pellet was resuspended in 150 µl of LB medium and plated on LB plates containing
the appropriate antibiotic for selection.
2.9.4 Plasmid generation
MLL–VP16–ER–HA expression plasmid (pML37)
A multiple cloning site containing a hemagglutinine tag (HAMCS) was introduced into
pCAG3–SIP (T. Schroeder), thereby generating pML15. The VP16 activation domain
was amplified via PCR using the primer pair "VP16ADXhoI" and pKI14 as a template.
The PCR product was digested with XhoI and BglII and cloned into pML15, creating
pML16. The ERT2 variant of the human estrogen receptor was amplified via PCR,
which was performed using the primer pair "ERT2.2" and pML2 as a template. The
product of this reaction was digested with NotI, gel–purified and and subcloned into a
pBluescript vector (Stratagene) and the resulting construt was termed pML27. The
NotI–fragment was isolated from this vector, purified and ligated into pML16 that had
been linearized using NotI. The vector resulting from this cloning step is pML28.
Finally MLL1–1419 was amplified via PCR using the primer pair "HRXN1" and pML1
as a template. The product was digested with EcoRI and XhoI, purified on an
agarose gel and subcloned into pBluescript. The resulting plasmid was called pML26.
The EcoRI / XhoI–fragment was isolated from this vector and ligated with the
corresponding sites in pML28. The resulting vector is called pML37.
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Cloning of GST fusion proteins (pML13, pML14)
Primer pairs "mllab4" and "mllab5" have been used to amplify the MLL cDNA regions
coding for amino acids 612–935 (pML13) and 3620–3969 (pML14), respectively.
PCR products were digested with EcoRI and BamHI, purified on an agarose gel and
ligated into the GST–expression vector pGEX–B, which had been linearized using
the same enzymes.
Generation of an episomal reporter vector (pML73)
An episomal reporter plasmid was generated by transfer of the luciferase gene from
pGL2 basic (Promega) into pREP4 (Invitrogen). The RSV promoter was removed
from pREP4 by removal of the SalI / XbaI–fragment. The remaining vector backbone
was ligated with the luciferase gene isolated from pGL2 basic by restriction digest
using NheI and SalI. This vector was termed pML94. For easier cloning a multiple
cloning site was introduced ("pREP4MCS4") upstream of the luciferase coding
region. This plasmid was called pML73.
p21 episomal reporter constructs (pML76, pML78)
PCR reactions were performed using pLS23 as a template. Specific primers were
used to generate p21 –2325 / +8 (pML76) and p21 –215 / +8 (pML78). PCR products
were digested with NheI and KpnI, agarose–gel purified and ligated to pML73, which
had been linearized using the same enzymes.
Hoxa9 episomal reporter constructs (pML74, pML82, pML84, pML86, pML93)
Hoxa9 promoter constructs comprising Hoxa9 –1953 / +46 (pML84),
Hoxa9 –1010 / +46 (pML74), Hoxa9 –510 / +46 (pML86), Hoxa9 –207 / +46 (pML82)
and Hoxa9 –207 / +98 (pML93) were generated as described for the p21 promoter
constructs.  A RZPD clone contain ing the human genomic
Hoxa locus (RPCIP704019170Q2) was used as a template for PCR reactions.
Primers are listed below.
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Generation of Hoxa9 –78 / +46 (pML105) and Hoxa9 –118 / +46 (pML115)
pML82 was digested with KpnI and PmlI and religated after blunting of restriction
sites to generate the construct Hoxa9 –78 / +46 (pML105).
Hoxa9 –118 / +46 (pML115) was created by removal of the KpnI / PmlI–fragment
from pML82 and insertion of the oligonucleotide "a9_WT".
2.9.5 Site directed mutagenesis of the human Hoxa9 promoter
The Hoxa9 –118 / +46 point mutants were generated in a similar way to pML115: the
KpnI / PmlI–fragment was removed from pML82 and oligonucleotides comprising the
region –118 to –78 of the Hoxa9 promoter were inserted using the KpnI and
PmlI sites. Different point mutants were generated by this procedure:
pML109 Hoxa9 –118 / +46 CpG mutant 2
pML111 Hoxa9 –118 / +46 GGGC mutant
pML113 Hoxa9 –118 / +46 Hox site mutant
The longer Hoxa9 mutant constructs (–207 / +46) were created by transfer of the
KpnI / NheI–fragment from a series of vectors synthesized by Geneart that are
containing mutant variants of Hoxa9 –207 / +46 into pML73 linearized using KpnI and
NheI.
pML146 Hoxa9 –207 / +46 Hox site mutant
pML147 Hoxa9 –207 / +46 GC mutant
pML151 Hoxa9 –207 / +46 GGGC mutant
pML152 Hoxa9 –207 / +46 GGC mutant
pML155 Hoxa9 –207 / +46 TATA–less mutant 1
pML156 Hoxa9 –207 / +46 AdML–TATA box
pML157 Hoxa9 –207 / +46 AdML–Inr
pML158 Hoxa9 –207 / +46 core promoter C–stretch mutant
pML160 Hoxa9 –207 / +46 TATA–less mutant 2
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2.9.6 Generation of Hoxa9 –78 / +46 containing additional binding sites
After removal of the KpnI / PmlI–fragment from pML82 oligonucleotides containing
binding sites for different transcription factors were inserted to generate
pML123 (MAZR1), pML124 (MAZR3), pML126 (MAZR2), pML128 (MZF1),
pML131 (E–BOX1), pML133 (E–BOX2), pML135 (GAL).
2.10 Cell culture
All cell lines were grown at 37°C, 5% CO2 and 95% humidity in an incubator (WJ311,
Forma Scientific). A Neubauer chamber was used to determine cell densities. Dead
cells were excluded from the count  by staining with Trypan Blue.
2.10.1 Separation of viable and dead cells via density gradient centrifugation
Centrifugation on a Ficoll cushion was used to remove dead cells from U937 and
FDCP–mix cell suspensions. Ficoll with an appropriate density for myeloid cells
(1.077, Amersham) was overlaid with cells suspended in growth medium. and
centrifuged for 20 min at 400 g (RT). Viable cells were enriched in a layer separating
on top of the lower phase and were transferred to a new tube using a pipette. These
cells were then washed and kept in culture.
2.10.2 Freezing and thawing of cell lines
Long term storage of cell lines was performed by keeping frozen aliquots in liquid
nitrogen. To generate these aliquots 5 x 106 – 1 x 107 cells were resuspended in the
corresponding growth serum and cooled down slowly using freezing
containers (Nalgene) that provide for decrease of temperature at a rate of 1°C per
minute when transferred from room temperature to – 80°C.
To thaw cells these aliquots were brought to 37°C and 10 ml of growth medium were
added drop-wise. After 10 min of incubation at room temperature cells were
centrifuged and the pellet was resuspended in 6 to 8 ml of growth medium and
incubated at standard conditions.
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2.10.3 Isolation of monoclonal cell lines using semisolid medium
For the generation of monoclonal cell lines and for determination of the colony
forming capacity of cell populations U937 and FDCP–mix cells were resuspended in
growth medium in a serial dilution. The clonogenicity of a population of
undifferentiated FDCPmix cells is in the range of 5 – 10% of the total number of
viable cells. For practical reasons it is therefore advisable to seed roughly
300 to 500 cells per 6-well. The cell suspensions were mixed with Bakto–Agar (Difco,
Germany) to reach a final agar concentration of 0.33% and 3ml each were
transferred to 6-well plates. After 10–12 days of incubation cell clusters of more than
100 cells were counted using a microscope.
For isolation of stable monoclonal puromycin-resistant cell lines puromycin (Sigma,
Germany) was added to the growth medium at a concentraion of 1–1.5 µg / ml.
Single colonies were picked using a 200 µl–Gilson pipette and were transferred for
expansion to a 96–well plate containing liquid growth medium.
2.10.4 Preparation and staining of cytospins
Suspension cells can be immobilized on glass slides and stained for morphological
analysis in a light-microscope. So–called Cytospins are prepared by centrifugation
(400 rpm, 4 min, RT) of suspension cells in a Cytospin centrifuge (Shandon,
England). The slides are air-dried after centrifugation, stained with May-Gruenwald
solution (Merck, Germany) for 4 min, rinsed with water, stained with 5% Giemsa
solution (Merck, Germany) for 16 min, rinsed thoroughly and left for drying. The
number of different cell types was determined in blind studies involving microscopical
analysis of 100–200 cells per sample.
2.10.5 Culture of FDCPmix cells
FDCPmix cell lines A4 and A7 were grown in Iscove´s Modified Dulbecco´s Medium
(IMDM, Invitrogen, Germany) with an osmolarity of 310–320 mosmol / kg. The
medium was containing 20% horse serum (Invitrogen, Germany) and 10 – 15% of
interleukin 3 – conditioned medium (IL3–cm). Cell density was checked and kept in a
range between 2 x 105 and 1 x 106 / ml.
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2.10.6 Culture of U937 cells and THP-1 cells
The cell lines U937 and THP-1 were treated equally and were grown in
RPMI medium (Invitrogen, Germany) containing 10% fetal bovine serum. In some
cases Penstrep (Invitrogen, Germany) was added to the medium to reduce the risk of
contamination.
2.10.7 Production of interleukin 3 – conditioned medium
To provide for IL3 in the FDCPmix growth medium conditioned medium is added.
This is basically comprised of a supernatant from a cell line secreting murine IL3. The
cell line used for this work was mIL3 (T. Schroeder, personal communication), which
carries an episomal expression vector for murine IL3, which mediates
neomycin–resistance. The cell line can be grown and expanded in RPMI (Invitrogen,
Germany) supplemented with 10% fetal bovine serum and 1 mg / ml of neomycin
(Sigma, Germany). After expansion a given number of cells was pelleted, washed
and seeded in IMDM containing 5% horse serum at a density of 2 x 105 / ml. After
60 hours the supernatant was collected using centrifugation in combination with
bottle top–filters with a pore size of 0.44 µm (Nalgene, Germany). Aliquots were
prepared and stored at – 20°C. IL3cm prepared in this way can be stored for
6 – 12 months.
For determination of the biological activity of a certain batch of IL3cm colony forming
assays were performed. IL3cm was serially diluted and added to IMDM containing
20% horse serum. FDCPmix cells were washed with IL3-free medium and added to
the different dilutions of IL3cm. The concentration of IL3cm leading to the highest
conlony numbers was considered the optimal working concentration. This usually
corresponded to 10 – 15% depending on the batch of IL3cm. As a control
recombinant murine IL3 (Roche, Germany) can be used. The optimum final
concentration in this case is 150 u / ml.
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2.10.8 Differentiation of FDCPmix cells into granulocytes and macrophages
FDCPmix cells were washed twice in IL3–free growth medium and resuspended at a
cell density of 1–2 x 105 cells per ml in differentiation medium, which is containing
20% pre–tested FCS. 2 units recombinant murine IL3 (Roche) / ml, 250 units
GM–CSF (Aventis) / ml and 1000 units recombinant G–CSF (Aventis) were
contained as well in the medium for the first three days of differentiation. On day 4
cell density was adjusted again to 2 x 105 per ml by dilution with differentiation
medium without IL3. Granulocytes are usually developing in the course of 7 days,
macrophage differentiation takes 8–10 days.
2.11 Transfection experiments
2.11.1 Electroporation of suspension cells
For electroporation 4 x 106 cells (FDCPmix) and 1 x 107 cells (U937) were
resuspended in 400 µl of standard growth medium and transferred to 4mm–cuvettes
(BioRad, Germany). GenePulser2 (BioRad, Germany) was set to 260 V and 1050 µF
while the capacitance extender (BioRad, Germany) was set to maximum output. The
resulting time constants were usually in the range of 30 – 35 ms.
2.11.2 Transient transfection of FDCPmix cells
FDCPmix cells were electroporated as outlined above. In general 10 µg of reporter
plasmid DNA were used in combination with different amounts of expression vector
(usually 1 – 15 µg). After electroporation cells were transferred to a 6–well plate
containing 4 ml of growth medium. Luciferase–assays were performed 24 hours after
transfection.
For normalization a β–galactosidase assay was performed. 5 µg of
pML48 (CMV–β–Gal) were co–transfected with the constructs of interest. In general
20 µl of the lysate that was used for luciferase detection were added to 180 µl of
β–Gal substrate solution. The color conversion was measured at 415 nm using a
plate reader.
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β–Gal substrate solution: 1.1mM MgCl2,
1mg / ml ONPG,
82mM Na2HPO4,
18mM NaH2PO4,
50mM β–Mercaptoethanol.
2.11.3 Stable transfection of FDCPmix cells
For the generation of stable cell lines electroporations were performed as outlined
above using 15 µg of linearized plasmid DNA. 24 hours after transfection the medium
was replaced by fresh growth medium containing puromycin at a concentration of
0.3 µg / ml. After another two days the majority of cells were non-viable. Dead cells
and debris was removed using separation over a Ficoll gradient. The remaining cells
were resuspended in fresh growth medium at a density of 2 x 105 / ml. Stably
transfected cells usually started proliferating at day 6 or day 7 after electroporation.
From that point on puromycin concentration was gradually increased up to
1.5 µg / ml. If necessary medium was replaced and / or cells were separated using
Ficoll gradient centrifugation. In general it took about two weeks to obtain a stably
proliferating population of puromycin-resistant cells. An aliquot of these was frozen
as a back–up, the rest was used for selection of monoclonal cell lines in semisolid
medium.
2.11.4 Transient transfection of U937 cells
U937 cells were electroporated following basically the protocol described for the
transient transfection of FDCPmix cells. In the case of U937, however, 1 x 107 cells
were used for each sample and therefore the medium volume for the following
incubation was increased to 8 ml and was performed in tissue culture flasks.
Luciferase–assays were performed after 36 hours. A β–Gal assay was used for
normalization (see 2.11.2).
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2.11.5 Stable transfection of U937 cells
The protocol closely resembles the one outlined for FDCPmix. Like in the transient
assays, however, 1 x 107 U937 cells were used for electroporation. The following
selection procedure was carried out exactly as described for FDCPmix cells.
2.11.6 Transfection of 293T cells
Calcium phosphate transfection
293T and HepG2 cells were transfected using the classical calcium phosphate
transfection method. In brief, one day before transfection cells were seeded in a
10 cm plate, in 10 ml growth medium, at 20% confluency in order to be
30–50% confluent at the moment of transfection. 16 to 24 hours later, a total amount
of 20µg DNA at a concentration of 1µg / µl in 0.1 x TE was mixed with 0.5 ml of a
0.25 M CaCl2 solution followed by addition of 0.5 ml 2xBES–buffered–saline (BBS)
solution, mixed and incubated for 10–20 min / RT. Before using them, the two
solutions were also pre–equilibrated to a temperature of 20–25°C. The
DNA–CaCl2–BBS mixture was then added dropwise to the cells and the dishes were
gently swirled to ensure equal distribution of the solution. After incubation of the cells
at 3.4% CO2 for 18–24 hours at 37°C, the medium was replaced followed by normal
growth conditions at 5% CO2 for another 24 hours. After about 48 hours after
transfection cells were rinsed with PBS and harvested after incubation for a minimum
of 30 min in 3 ml of cold PBS / 0.5 mM EDTA solution.
2x BBS: 1.07g BES (N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid)
1.6g NaCl
0.027g Na2HPO4.
adjust to pH 6.96 with NaOH
H2O ad 100ml
pass through a 0.22µm filter and store aliquots at –20oC.
PolyFect transfection
293T cells were transfected using PolyFect reagent (Qiagen, cat. no. 301105)
according to the manufacturers protocol.
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2.12 Preparation of protein extracts from mammalian cells
2.12.1 Whole cell lysates from U937 cells
About 5 x 106 U937 cells were pelleted and washed with cold PBS. The cell pellet
was resuspended in 50 µl of extraction buffer, snap–frozen in liquid nitrogen and
thawed at 37°C. This procedure was repeated twice before centrifugation at
13.000 rpm in a table top centrifuge for 15 min at 4°C. The supernatant was collected
and transferred to a new tube on ice and protein concentrations were determined as
follows: 5 µl of lysate were added to 500 µl 0.1% SDS. OD was measured at 230 and
260 nm. Protein concentrations were calculated according to the following equation:
concentration µg / ml = 100 x (183 x A230 – 75.8 x A260)
Extraction Buffer 20 mM Hepes pH 8.0 4 ml (0.5 M Hepes pH 8.0)
350 mM NaCl 35 ml (1 M NaCl)
10% Glycerol 10 ml (100% Glycerol)
0.1% Tween-20 1 ml (10% T-20)
2mM EDTA 400 ml (0.5 M EDTA)
49.5 ml H2O
sterile filter and add before use:
1 mM DTT
1 mM PMSF
protease inhibitors (Sigma P8340, 10 µl / ml)
2.12.2 Isolation of nuclear extract from 293T
48 hours after transfection cells were washed with cold 1x PBS and harvested using
a rubber policeman. Cell pellets were then resuspended in cold NEX A buffer and left
swelling on ice for 10 minutes. After addition of 0.2% NP40 cytoplasma membranes
were broken mechanically using a douncer and cytoplasm was removed after
centrifugation at 1.000 g for 10 min (4°C). Pellets were resuspended in NEX B buffer
to a final salt concentration of 0.27 M and rocked at 4°C for a minimum time of
30 min. Finally, samples were centrifuged at 16.000 g and the supernatants (nuclear
extracts) were transfered to new tubes and aliquots were frozen in liquid nitrogen.
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NEX A: 10mM HEPES pH 7.9
10mM KCl
0.1mM EDTA pH 8.0
0.1mM EGTA pH 8.0
Immediately before use add 1.0mM DTT, 0.5mM PMSF,
2µg/µl Aprotinin, 2µg/µl Leupeptin.
NEX B: 20mM HEPES pH 7.9
0.4M NaCl
1mM EDTA pH 8.0
1mM EGTA pH 8.0
10% Glycerin
Immediately before use add 1mM DTT, 1mM PMSF, 2µg/µl Aprotinin,
2µg / µl Leupeptin.
2.12.3 Determination of luciferase reporter gene activity
About 5 x 106 cells were used for the measurement of luciferase activity. Cells were
harvested by centrifugation at 200 g for 6 minutes. The cell pellets were kept on ice,
resuspended in 6 ml of cold PBS and centrifuged again. Supernatants were aspirated
quantitatively and after addition of 100 µl of 1 x Passive Lysis Buffer (Promega)
pellets were resuspended by vortexing for 10 sec. The samples were transferred to
Eppendorf tubes and incubated at RT for 10 min. Lysates were centrifuged in a table
top centrifuge at full speed for 5 min at 4°C. The supernatants were then transferred
to new Eppendorf tubes. 50 µl of the lysate were used for measurement of luciferase
activity which was performed in a microplate using the Luciferase Assay System from
Promega (cat. no. E1501). Measuring time was 10 sec for each well.
In the case of stable cell lines the luciferase values were normalized by calculating
the ratio between enzymatic activity and total protein content. Protein amounts were
determined doing a standard Bradford assay (Bio-Rad, Protein Assay,
cat. no. 500–0006). A minimum of two stable cell lines derived from independent
transfection experiments was used to determine the activity of a given reporter
construct. Mean induction levels were calculated between four independent
luciferase measurements of two different cell lines.
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2.13 Protein analysis
2.13.1 Recombinant protein expression and purification
Recombinant proteins were expressed in E.coli, using expression plasmids encoding
the protein of interest in the BL21 E.coli expression strain. An overnight starter
culture was diluted to an OD600 of 0.1 into 200 ml LB medium and grown at 37°C to
an OD600 of 0.6 - 0.8. At that point the expression of the protein was induced by
addition of 0.5 mM IPTG final concentration. To prevent the formation of inclusion
bodies and to enhance the expression of full–length protein, the culturing
temperature was reduced to 30°C for 2 - 6 hours. The cells were harvested by
centrifugationfor 15 minutes at 3.500 rpm (4°C). Subsequent purification steps are
carried out at 4°C.
2.13.2 Purification of GST-tagged proteins
Bacterial cell pellets were resuspended in 10 ml of lysis buffer and lysed by
incubation with 10 mg of lysozyme for 10 minutes and sonification. For sonification
the microtip and an output amplitude of 30% for a total time of 2 minutes with a
repetitive cycle of 10 seconds on-time and 50 seconds off-time was used. During
sonification the samples were cooled in an ice-water bath. The lysate was cleared by
centrifugation for 10 minutes at 10.000 g (4°C). In the meantime, 200 µl of
Glutathione-Sepharose 4B (Amersham, cat. no. 17-0756-01) were washed
and equilibrated in lysis-buffer. The lysate was incubated together with the beads
for 90 minutes at 4°C on a rotating wheel to allow binding of the recombinant protein
to the matrix. The supernatant was removed and the remaining beads were
subsequently washed with 100 column volumes of BC2000 and BC150 buffer. To
elute the immobilized fusion proteins, the columns were incubated at 4°C in 500 µl of
elution buffer for 10 minutes. For quality control, an aliquot was analyzed in a
Coomassie stained SDS-PAGE gel.
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Lysis buffer: 20 mM HEPES pH 7.5
100 mM KCl
1 mM EDTA
10% Glycerol
0.1% NP-40
5 mM β-Mercaptoethanol
add protease inhibitors before use
Elution buffer: 25 mM Tris-HCl pH 8.2 RT
100 mM KCl
10% Glycerol
0.1% NP-40
30 mM reduced Glutathione
add protease inhibitors before use
2.13.3 Preparation of antigens for immunization of rodents
Recombinant proteins that were used for generation of antibodies were mixed with
adjvants before injection. For this purpose 50 µg of GST–protein was mixed with
10 µl of CPG2000 (Sigma) and 500 µl of Freunds Incomplete Adjuvant (IFA, Sigma).
PBS was added to a total volume of 1 ml. Of this 500 µl were injected
subcutaneously, while 500 µl were injected intraperitoneally. After 4 weeks the
animals were boosted with this antigen preparation to ensure a strong antigenic
reaction.
2.13.4 Immunoprecipitation
Immunoprecipitation (IP) of MLL from 293T nuclear extracts was performed using
monoclonal antibodies against MLL immobilized on Protein G–Sepharose. Columns
were prepared by incubation of 500 µl of Protein G–Sepharose with 50 ml of
monoclonal antibody supernatant. The slurry was rocked overnight at RT, washed
twice with PBS and stored in PBS / 0.01% NaN3. 20 µl of beads were incubated with
400 µg of nuclear extracts. The reaction was brought to a total volume of 410 µl by
addition of 350 µl of BC 150 / 0.1% NP–40. IP was performed at 4°C for four hours.
The batch was then divided into four different samples and different washing
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buffers (washing buffer 1 – 4) were used. The columns were washed five times with
1 ml of washing buffer. Precipitated protein was eluted from the column using 60 µl of
2x SDS loading buffer. 24 µl of this were loaded onto an 5% SDS gel and analyzed
via Western Blot.
washing buffer 1: 20 mM Tris-HCl, pH 7.3
0.2 mM EDTA, pH 8.0
500 mM KCl
20 % (v/v) Glycerin
0.1% NP– 40
washing buffer 2: 20 mM Tris-HCl, pH 7.3
0.2 mM EDTA, pH 8.0
150 mM NaCl
20 % (v/v) Glycerin
1%Triton X–100
0.1% SDS
washing buffer 3: 20 mM Tris-HCl, pH 7.3
0.2 mM EDTA, pH 8.0
500 mM NaCl
20 % (v/v) Glycerin
1% Triton X–100
0.1% SDS
washing buffer 4: 20 mM Tris-HCl, pH 7.3
0.2 mM EDTA, pH 8.0
250 mM LiCl
20 % (v/v) Glycerin
1% NP– 40
1% SDS
2.13.5 Sodium–dodecylsulphate polyacrylamide gel electrophoresis
(SDS–PAGE)
Proteins were separated on an SDS–PAGE using either a maxi-gel system from
Hoefer or the minigel system from Bio-Rad. Depending on the size of the
protein, either 5, 10, 12 or 15% gels were used. To achieve better resolution and
blotting efficiency for large proteins, 170:1 acrylamide / bisacrylamide gels were
used. For electrophoresis, proteins were mixed 1:6 with 6x loading buffer, heat
denatured at 95°C and loaded onto the gel. Proteins were separated applying a
current of 30 mA for minigels and 50 mA for large gels. In both cases TGS was used
as electrophoresis buffer. Maxigels were connected to a cooling system. For
molecular weight determination, unstained marker was loaded in parallel (Bio-Rad,
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SDS-PAGE standards Low Range, cat. no. 161–0304; Bio-Rad, SDS-PAGE
standards High Range, cat. no. 161–0303; MBI Fermentas, Protein MW Marker,
cat. no. SM0431). Following electrophoresis, proteins were stained with Coomassie
Brilliant Blue G250 or transferred to a nitrocellulose membrane by blotting.
6x SDS loading buffer: 0.35 M Tris-HCl (pH 6.8 RT)
0.12 mg/ml Bromphenol blue
40 mM β-Mercaptoethanol
2.13.6 Coomassie staining
For Coomassie staining of polyacrylamide gels, the gels were incubated with staining
solution for at least 30 minutes on an slowly rocking platform. To visualize protein
bands, the gels were destained overnight in destaining solution or in H2O. After
destaining, the gels were scanned and then dried between cellophane film at RT.
Coomassie staining solution: Methanol 400 ml
Glacial acetic acid 100 ml
Coomassie R-250 0.25 g
H2O 500 ml
Destaining solution: Methanol 500 ml
Glacial acetic acid 100 ml
H2O 400 ml
2.13.7 Western Blot analysis of MLL protein expression in U937 cells
Whole cell lysates were prepared as described earlier (see 2.12.1). Proteins were
separated by electorphoresis on a 5% SDS–gel. 20 to 40 µg of whole cell extract
were loaded per lane. Commercial loading buffer was added in this case (NuPage
LDS sample buffer 4x, Invitrogen NP0007) and samples were denatured at 70°C for
10 min immediately before loading. After electrophoresis the gel was blotted onto a
nitrocellulose membran using a semi–dry transfer cell (Bio–Rad). The setting was
25 V constant for 1 hour. After blotting the membrane was blocked for a minimum of
1 hour at RT or overnight at 4°C using TBS / 6% milk. For detection of the
overexpressed MLL fusion protein MLC5A9 was used as a primary antibody.
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Alternatively an antibody against the HA–tag (R001, 3F10) was used as well as an
antibody against the ERα  ligand binding domain (sc-8002, Santa Cruz
Biotechnology). The membrane was incubated with the primary antibody at RT for a
minimum of 2 hours. The secondary antibodies used for this work are commercial
conjugates of anti–mouse, anti–rat and anti–rabbit immunoglobulines with
horseradish peroxidase (Promega). Before addition of the secondary antibody the
membrane was washed three times for 5 min with TBS–T. Secondary antibody
incubation lasted 45 min and was followed by three washing steps with
TBS–T (3 x 15 min at RT). For detection the chemiluminescence kit from Perkin
Elmer (Western Lightning, cat. no. NEL105) was used following the manual.
Transfer buffer (pH 8.3): 2.9 g Glycine 39 mM Glycine
5.8 g Tris base 48 mM Tris base
1850 µl 20% SDS 0.037% SDS
200 ml Methanol 20% Methanol
H2O ad 1000 ml
1x TBS-T: For 1L use 100ml 10x TBS, 2ml 10% TWEEN20
2.13.8 Chromatin–Immunoprecipitation (IP)
Crosslinking
U937 cells were induced with 4–hydroxytamoxifen (OHT) at a final concentration of
1 µM. 1 x 108 – 1 x 109 cells were used while cell density was around 5 x 105 / ml.
After 24 hours cells were harvested by centrifugation in 250 ml buckets (Corning,
300 g, 5 min, RT). Pellets were resuspended in 40 ml of pre–warmed medium
containing fetal calf serum (10%) and pooled in a 50 ml Falcon tube. After another
centrifugation step the pellet was resuspended in 43.78 ml of serum–free
medium (RT). 1.22 ml of formaldehyde (37%, Roth, cat. no. 4979.1) were added and
Falcon tubes were incubated on a roller table for 9 min at RT. Glycine was added to
a final concentration of 125 mM (3 ml of a 2 M solution) and the samples were mixed
quickly and put on ice for 10 min. From that point on all steps of the protocol were
carried out on ice. Cells were centrifuged (300 g, 5 min, 4°C) and the pellets were
washed thrice in cold PBS and transferred to .15 ml Falcon tubes. At this point the
Materials and Methods                                                                                               54
procedure can be interrupted by shock–freezing the pellet and storage at –80°C.
Alternatively one can procede directly.
Cell lysis and sonication
To isolate nuclei pellets were resuspended in 10 ml of Lysis Buffer 1 (LB1) and
rocked gently at 4°C. Nuclei were centrifuged (4.000 g, 10 min, 4°C) and
resuspended in 10 ml of Lysis Buffer 2 (LB2). Again the samples were rocked gently
at 4°C for 10 min before spinning them down again (4.000 g, 10 min, 4°C). Pellets
were resuspended in 5 ml of Lysis Buffer 3 (LB3) without Triton X–100 and glycerol
and sonicated in an ice/ethanol bath using a Branson 250 sonifier with the
microtip (40% output, 6 min total: 15 sec on / 45 sec off). Resulting fragment lengths
were ranging from 300 to 500 bp.
After sonication 1/20th of the total volume of 10% Triton X–100 (0.5% final
concentration) was added to the samples, which were then transferred to 1.5 ml
tubes. Samples were centrifuged (15.000 g, 15 min, 4°C) and supernatants were
transferred to new 15 ml Falcon tubes. Sample volumes were adjusted with LB3 in
order to reach a concentration of double-stranded DNA (as obtained through optical
measurement) of 1–2 mg/ml. Glycerol was added to a final concentration of 10%.
1 ml aliquots were snap–frozen and stored at –80°C. 10 µl of the sample were
digested with 2 µl of Proteinase K (PCR grade, Roche) for 2 h at 65°C. After DNA
purification (Qiaquick, Qiagen) fragment lengths were checked on an agarose gel. If
necessary, further sonication was carried out.
Lysis Buffers: Complete (Roche, cat. no. 11697498001) protease inhibitor mix was added to all lysis
buffers before use.
25x Complete
• Grind 1 tablet in between 2 sheets of balance paper
• Dissolve fine powder in 2 ml of H2O
• Aliquot and store (labeled 25xC) at -20°C
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Lysis Buffer 1 (LB1) final conc.
5,0 ml   1M Hepes-KOH, pH 7.5   50mM
2,8 ml 5M NaCl 140mM
0,2 ml 0,5M EDTA, pH 8.0 1mM
10,0 ml 100% glycerol 10%
5,0 ml 10% NP-40 0,5%
2,5 ml 10% Triton X-100 0,25%
74,5 ml H2O
----------
100,0 ml
• store at 4oC
Lysis Buffer 2 (LB2) final conc.
4,0 ml 5M NaCl 200mM
0,2 ml 0,5M EDTA 1mM
0,1 ml 0,5M EGTA 0,5mM
1,0 ml 1M Tris-HCl pH 8 10mM
94,7 ml H2O
---------
100 ml
store at 4°C
2x Lysis Buffer 3 (LB3) final conc. (1x)
2,8 ml 5M NaCl 140mM
0,4 ml 0,5M EDTA 1mM
0,2 ml 0,5M EGTA 0,5mM
2,0 ml 1M Tris-HCl pH 8 10mM
10,0 ml 10% N-lauroyl sarcosine 0,5%
84,6 ml H2O
--------
100,0 ml
• store at 4°C
• before use, dilute to 1x LB3 and supplement with:
before sonication:
10% Na-deoxycholate 0,1% (freshly prepared) 1x Complete
after sonication:
10% Triton X-100 (at step 2.5) 0,5%
100% glycerol (at step 2.6) 10%
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Immunoprecipitation and isolation of DNA fragments
For one IP 100 µl of chromatin extract (2 mg/ml) were used. For preclearing 10 µl of
blocked beads were used per 100 µl of extract. Samples were incubated under
constant agitation at 4°C for 30–60 min. In parallel blocked beads were
pre–incubated with the appropriate antibody. Typically 2–10 µg of antibody were
used per IP. In the case of hybridoma supernatants 100–200 µl were used. For each
IP 15–20 µl of beads were used. The pre–incubation was done in a total volume of
400 µl and volumes were adjusted with cold PBS. After incubation at 4°C for
30–60 min tubes were centrifuged (200 g, 2 min, 4°C) and washed once with cold
PBS.
100 µl of pre–cleared chromatin extract was added to 20 µl of antibody–coated
beads. The total volume was adjusted to 400 µl using LB3 without glycerol.
IP reactions were incubated under constant agitation at 4°C overnight.
Beads were washed six times with 1 ml of RIPA buffer and once with 1 ml of
TE buffer containing 50 mM NaCl. For elution 100 µl of pre–warmed (65°C)
elution buffer has been added to the beads and samples were rocked for 10 min at
1400 rpm in a thermomixer (65°C). After centrifugation supernatants were transferred
to new tubes (RT). Crosslink reversal took place overnight at 65°C.
1 volume of TE buffer containing RNase (0.2 µg/µl final concentration) was added to
the samples followed by incubation at 37°C for 1–2 hours. Proteinase K was added
to a final concentration of 0.2 µg/µl and samples were incubated at 56°C for 2 hours.
DNA was isolated by PCI extraction and ethanol precipitation in the presence of
10 µg of glycogen. Pellets were resuspended in 50 µl Tris/HCl. DNA concentrations
were determined and 0.5–1 µg were loaded onto an agarose gel to check for
fragment length distribution. 20 ng of this DNA were used as a sample for PCR
reactions. For detection of MLL–VP16–ER–HA bound to the chromosomal Hoxa9
promoter primers "hoxa9end2" and "hoxaend_r" were used for PCR, for the episomal
Hoxa9  promoter the primers "hoxa9F–65" and "lucR_short".
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Wash buffer (RIPA buffer): final concentration
5ml 1M Hepes (pH 7.6) 50 mM
200µl 1M EDTA    1 mM
10 ml 10% NP-40 (IPGEL) 1%
10 ml 5M LiC 0.5 M
7 ml 10% DOC (Na deoxycholate) 0.7% (freshly prepared)
---------
100 ml
Elution buffer: 50mM Tris pH8
10mM EDTA
1% SDS
2.14 RNA expression analysis
2.14.1 cDNA microarray analysis
FDCP mix cells expressing MLL–VP16–ER–HA were induced with 1 µM 4–hydro-
tamoxifen (OHT) and samples of 3 x 107 cells were harvested after 30 min, 3 hours
and 12 hours. After washing with PBS RNA was extracted using the Qiagen RNeasy
Midikit (Qiagen). The RNase–Free DNase set (Qiagen, cat. no. 79254) was used to
eliminate contaminating genomic DNA. RNA concentrations were determined using a
spectrophotometer and 5 µg of each RNA sample were sent to the KFB Regensburg,
where the microarray analyses were performed. Affymetrix GeneChip 430 2.0 was
used, representing more than 39.000 transcripts from the mouse genome thereby
covering the complete murine genome. Statistical analysis of the raw data was done
by the KFB Regensburg, which yielded lists of genes that were deregulated in
comparison to the reference (MLL–VP16–ER–HA cell line before OHT–induction).
These target gene lists were than sorted to eliminate those genes with a deregulation
that was not statistically relevant. To identify genes with robust expression changes
the following procedure was applied to the original target gene lists:
To determine robust increases:
• "absent" calls were eliminated
• "present" calls for increased genes were sorted according to Signal Log Ratio
• probe sets with a Signal Log Ratio < 1.0 were eliminated
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To determine robust decreases:
• "absent" calls were eliminated
• "present" calls for decreased genes were sorted according to Signal Log Ratio
• probe sets with a Signal Log Ratio > –1 were eliminated
2.14.2 RT-PCR
Preparation of whole cell RNA
RNA was isolated from 2 x 106 cells (U937, FDCP mix) using the Qiagen RNeasy
Minikit (Qiagen, cat. no. 74104). The procedure was carried out as described in the
kit protocol. RNA was eluted from the column using 40 µl of RNase free water. Total
yields were usually around 20 µg of RNA as determined by UV measurement.
DNase treatment of RNA
Isolated RNA was treated with DNase I (Invitrogen, cat. no. 18068–015) in order to
eliminate genomic DNA contamination. The reaction volume was 20 µl. 16 µl of RNA
were incubated at RT for 15 min together with 2 µl DNase I (1 u / µl) and 2 µl of
10 x buffer. The digest was stopped by addition of 2 µl of EDTA (25 mM) and heat
inactivation (10 min / 65°C).
Reverse Transcription
2 µg of DNase treated RNA were used for reverse transcription (RT) using the
ThermoScript™ RT-PCR System (Invitrogen, cat. no. 11146-024). The reaction was
carried out following the manual. The oligo dT primer provided in the kit was used for
first strand synthesis which was taking place at 50°C for 60 min followed by a
denaturation step (5 min, 85°C). The resulting cDNA was incubated with 1 µl of
RNase H in order to degrade complementary RNA molecules (20 min, 37°C).
cDNA was stored at –20°C.
Quantitative Real-Time PCR
Transcript amounts were determined using quantitative Real-Time PCR (qPCR). The
reaction was performed using the SYBR Green PCR reagents (Applied Biosystems,
cat. no. 4306736) and gene specific primers. The reaction was set up as follows:
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2.5 µl primer mix (5 pmol / µl each)
2.5 µl SYBR Green buffer
2.5 µl MgCl2 (25 mM MgCl2)
2.0 µl dNTP mix
0.2 µl AmpliTaq Gold DNA Polymerase (5u / µl)
0.2 µl AmpErase UNG (1u / µl)
           13.1 µl H2O
2.0 µl cDNA
Primer pairs were chosen with a Tm of 58°C. 40 cycles of PCR were performed in a
Perkin Elmer GeneAmp 5700 instrument and results were normalized to beta–actin
RNA levels. As a negative control for qPCR RT reactions done without reverse
transcriptase were used as template.
2.15 Bioinformatic analysis
Analyses of promoter sequences for transcription factor binding sites were performed
using the programs from Genomatix (www.genomatix.de)
2.15.1 Identification of transcription factor binding sites using MatInspector
The program MatInspector (Quandt et al. 1995; Cartharius et al. 2005) was used for
identification of binding sites in promoters and promoter fragments. The analyses
presented in this work were performed setting the core similarity to 0.75 and to
"opimized" matrix similarity.
2.15.2 Gene2Promoter
Promoters of genes that were identified in the microarray analysis were searched for
common transcription factor binding sites using the program Gene2Promoter.
50 genes of each dataset showing the strongest deregulation in expression were
used as an input. Transcription factor families are shown that are present in >86% of
all input gene promoters.
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2.15.3 Bibliosphere
Array data were analyzed using Bibliosphere in order to create a hypothetical
network amongst the target genes based on co–citation in literature
databases (Scherf et al. 2005). Networks were generated using microarray target
genes and transcription factors that were co–cited together with the corresponding
gene at the "sentence level", i.e. genes that were found cited in the same sentence in
literature databases.
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3. Results
3.1 Generation and selection of monoclonal antibodies against MLL
At the time of the beginning of this study MLL–specific antibodies were not
commercially available. For protein expression analysis and for ChIP experiments,
however, antibodies are precious molecular tools. Therefore a collaboration was
initiated with E. Kremmer (GSF, Munich) to generate monoclonal antibodies against
MLL. GST–tagged portions of human MLL were injected into rats. The antigens were
chosen according to the following criteria:
a. different regions of the large MLL protein should be targeted therefore one rather
N-terminal antigen was chosen and another one that is closer to the C-terminus.
b. cross-reactivity between human and murine MLL was a desired feature for the
monoclonal antibodies. Since there is a high level of homology between the two
proteins this seemed feasible and conserved regions were chosen accordingly.
Different fragments of the human MLL cDNA were amplified via PCR and cloned into
GST expression vectors. Out of five cloned regions only two could be expressed at
high levels in E. coli BL21. These two proteins were purified on Glutathion-
Sepharose columns and injected into rats.
Both of the antigens show rather high sequence conservation from mouse to human
(94% and 98% respectively). One is located in a region of the protein that has been
associated with a subnuclear distribution function (C1, amino acids 612 – 935) while
the other one is part of the C–terminal SET domain (D1, amino acids 3620 – 3969;
Fig. 5). The rat spleens were isolated and B lymphocytes were used for generation of
hybridoma cell lines that were singled out in order to obtain monoclonal cell lines.
The supernatants of these cell lines were analysed in an ELISA assay and positive
clones were tested further for performance in Western Blot analysis and
Immunoprecipitaion (IP). Whole cell lysates were prepared from 293T cells
overexpressing a C–terminally truncated version of MLL (MLLΔC). Lysates of non-
transfected Jurkat cells were used to investigate the function of the MLL antibodies
directed against the C–terminus of the protein. Three monoclonals could be identified
that precipitate the overexpressed MLL aminoterminus (5A9, 4G10, 5C10; Fig. 5).
Screening a number of antibodies targeting the carboxyterminus it could be shown
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that two monoclonals (7D4, 7E12) were suitable for IP of the C–terminal
moiety (p180) of the processed endogenous MLL (Fig. 5).
Figure 5. Generation of monoclonal antibodies against MLL. Five monoclonal antibodies were
selected: three clones specific for the MLL N–terminus (5A9, 4G10, 5C10), two clones targeting
MLL C–terminus (7D4, 7E12). SNL: subnuclear localization domains, MT domain: methyltransferase
homology domain.
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These initial IP experiments were performed under low stringency
conditions (150 mM KCl, 0.1% NP–40). For many biochemical experiments a higher
stringency is desirable since this leads to higher specificity of the antibody binding
reaction and to increased purity of the bound complexes. The performance of the
monoclonal antibodies directed against the MLL aminoterminus was tested using
washing buffers that were either containing higher concentrations of salt or detergent
or both. Icreasing the concentration of KCl to 500 mM led to disruption of the
complex formed by MLLΔC and any of the three antibodies (Fig. 6, lane1). A similar
tendency could be seen using NaCl in combination with two detergents: at a
concentration of 150 mM interaction was robust, whereas 500 mM NaCl dramatically
reduced the IP efficiency (Fig. 6, lanes2 and 3). LiCl at a concentration of 250 mM,
however, was tolerated (Fig. 6, lane4). Interestingly, even relatively high
concentrations of detergent did not compromise complex stability. MLLΔC could be
detected after washing with 1% Triton X–100 / 0.1% SDS as well as after washing
with 1% NP – 40 / 1% SDS.
Figure 6. MLL–Immunoprecipitation experiments. After washing of IP samples (HA, MLL 5C10,
MLL 4G10) with different buffers (lanes 1–4) a truncated MLL fragment overexpressed in 293T cells
was detected using antibodies against MLL (5A9) or HA.
IP WB
MLL
5A9HA
MLL
5C10
MLL
4G10
HA
HA
input contr. 1 2 3 4
IP washing conditions:
1: 500mM KCl, 0.1% NP-40
2: 150mM NaCl, 1% Triton X-100, 0.1% SDS
3: 500mM NaCl, 1% Triton X-100, 0.1% SDS
4: 250mM LiCl, 1% NP-40, 1% SDS
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Figure 7. Epitope mapping for monoclonal antibodies against MLL. Two different types of peptide
arrays were used comprising the peptides for either the N–terminal (MLC) or the C–terminal (MLN)
antigen. Western Blots using monoclonal antibodies against MLL led to identification of the
corresponding epitopes.
Table 7. Epitopes of the monoclonal antibodies against MLL.
clone antigen epitope aa sequence
5A9 aa 612-935 aa784-806 VSPLATSALNPTFTFPSHSLTQS
4G10 aa 612-935 aa828-846 SSSSPTPLFPWFTPGSQTE
5C10 aa 612-935 aa824-846 AEPFSSSSPTPLFPWFTPGSQTE
7D4 aa 3620–3969 aa3628-3646 ESAEPKTVEEEESNFSSPL
7E12 aa 3620–3969 aa3628-3650
aa3672-3694
aa3784-3810
aa3848-3862
aa3884-3898
ESAEPKTVEEEESNFSSPLMLWL
EISSDDGFQICAESIEDAWKSLT
KHRQPPEYNPNDEEEEEVQLKSARRAT
NIDAGEMVIEYAGNV
MFRIDDSEVVDATMH
Stringency of IP and washing buffers is one way to increase purity of the isolated
protein complex. Another method is the specific elution of precipitated complexes
from the column. If the epitope of an antibody is known a peptide comprising this
amino acid sequence can be used for elution. The peptide is offered in large excess
and competes with the target protein for binding sites on the antibody molecule. This
technique can be applied to standard Chromatin-IP protocols in order to increase
specificity. Determination of the epitopes was performed using peptide arrays. For
this purpose each of the two antigens was covered by 20mers that are overlapping
by 15 amino acids each. These peptides were immobilized on a membrane, which
was then subjected to standard Western Blot procedures for each of the monoclonal
antibodies (Fig. 7). Monoclonals 4G10 and 5C10 turned out to have at least partially
if not identical epitopes (Table 7). Also 5A9 and 7D4 showed a clearly defined target
region. The epitope of the antibody 7E12, however, comprises other peptides in
addition to the epitope of 7D4 and seems to be discontinuous (Fig. 7).
MLC 4G10MLC 5A9 MLC 5C10 MLN 7D4 MLN 7E12
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3.2 An inducible MLL fusion model system
The MLL gene is known to be involved in translocations with a host of fusion partner
genes, many of which contain an activation domain (Daser and Rabbitts 2005). This
observation gave raise to speculations that fusion of the aminoterminal MLL domains
to an activation domain only might be sufficient for tumorigenesis. It could be shown
that a synthetic fusion construct consisting of the activation domain of Herpes
simplex virus protein 16 (VP16) and the MLL N–terminus has transforming capacity
in myeloid progenitor cells (So and Cleary 2003; Zeisig et al. 2003).
To investigate the general mechanism through which MLL–activator fusions influence
transcriptional activation a model system was established using an inducible variant
of MLL–VP16. The mutant ligand binding domain (ERT2) of the human estrogen
receptor (Feil et al. 1997) was fused to MLL–VP16 (Fig. 8). The resulting protein
(MLL–VP16–ER–HA) is kept inactive through the ER–moiety. It is generally believed
that cytoplasmic sequestration of the estrogen receptor fused proteins of interest by
the Hsp90 complex inhibits the biological functions of nuclear proteins like
MLL (Mattioni et al. 1994). There is some evidence, however, that there is an
additional mechanism of inhibition, which presumably involves sterical hindrance of
functional domains of the protein of interest (unpublished results).
Figure 8. Presumptive mechanism of activation of MLL–VP16–ER–HA. The fusion of ER to the
MLL N–terminus renders it a binding partner for the Hsp90 complex, which prevents it from migrating
into the nucleus in absence of Tamoxifen.
MLL aa1-1419 ERVP16 HA
Hsp90
4-OHT
4-OHT
ERT2 fusion construct is bound by Hsp90 complex
→ cytoplasmic retention
→ masking and steric hindrance of active domains
addition of 4–Hydroxytamoxifen leads to dissociation
of Hsp90 complex
→ entry into nuclear compartment
→ active domains fully functinal
ERT2VP16 HA
MLL aa1-1419
AT hooks SNL1,2 MT domain
MLL aa1-1419 ERVP16 HA
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3.2.1 Generations of cell lines stably expressing MLL–VP16–ER–HA or
VP16–ER–HA
The human promonocytic cell line U937 (Sundstrom and Nilsson 1976) was chosen
to create stable cell lines expressing MLL–VP16–ER–HA. U937 cells have been
reported to retain a differentiation potential for final maturation into
macrophages (Koren et al. 1979) suggesting that important myeloid developmental
pathways are still functional in this cell line. This together with convenient culturing
and transfection conditions made it an appropriate cell line for the inducible
MLL–VP16 model system.
Cells were transfected with linearized plasmid DNA coding for MLL–VP16–ER–HA
and stable clones were selected expressing the fusion protein (Fig. 9A). In parallel a
control cell line was established that expresses VP16–ER–HA (Fig. 9B). This
construct was designed to rule out that effects on gene transcription observed as a
consequence of MLL–VP16–ER–HA are due to unspecific binding of the fusion
protein mediated through the ER–moiety.
Figure 9. Expression of MLL–VP16–ER–HA and ER–VP–16–HA in U937. Whole cell lysates from
stable cell lines expressing MLL–VP16–ER–HA (A) or ER–VP–16–HA (B), respectively, were
analyzed in a Western Blot experiment using antibodies directed agains the human
estrogen receptor α, MLL and HA. Correct loading of SDS gels was controlled using PonceauS protein
stain.
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3.2.2 Transcription of human Hoxa9 is upregulated following induction of
MLL–VP16–ER–HA
Having established transgenic cell lines it was important to check whether the
induction of MLL–VP16–ER–HA mimicks the effect of MLL fusion proteins on target
genes. Homeotic genes and in particular Hoxa9 have been reported to be targets for
MLL and Hox gene overexpression is a hallmark of MLL leukemogenesis (Yu et al.
1995; Armstrong et al. 2002). Therefore Hoxa9 expression was chosen as a
biological read–out for the biological activity of the transgene. RT–PCR analysis
showed a 6–fold increase of Hoxa9 mRNA following addition of Tamoxifen to the
MLL–VP16–ER–HA cell line (Fig. 10A, hoxa9 endogenous) indicating that the fusion
protein is functional both in recruitment to target promoters as well as in gene
activation.
One objective of the generation of this cell line was the analysis of the Hoxa9
promoter. For the following experiments an episomal reporter system was
established that allows for comparison of the effect of MLL–VP16–ER–HA on
different Hoxa9 promoter variants. For this purpose Hoxa9 promoter–luciferase
constructs have been cloned into an Epstein–Barr–Virus (EBV)–based vector. It has
been shown that these vectors can be propagated stably as episomal plasmids in cell
lines (Mackey and Sugden 1999; Sugden and Leight 2001). EBNA-1, which is
expressed from these vectors recruits the eukaryotic DNA replication machinery to
the oriP region on the same vector thereby ensuring the propagation of this episome.
For this work an EBV–based vector was used that could be selected for through the
presence of a hygromycin resistance cassette (Fig. 10B). In contrast to transient
reporter assays were several hundred copies of the reporter plasmid can be present
in one cell EBV–based reporters are maintained at a relatively low copy number of
5–20. Since nucleosome formation is taking place on these plasmids they resemble
cellular chromosomes much closer making them a suitable model system for analysis
of chromatin–related events.
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Figure 10. Hoxa9 upregulation by MLL–VP16–ER–HA in U937 cells. A. Upregulation of endogenous
Hoxa9 mRNA as well as luciferase mRNA as determined by RT–PCR. Values were normalized for
beta-actin mRNA levels. Absolute ct values are shown in the table. B. Schematic drawing of an
episomal reporter construct. The regions oriP (yellow) and EBNA–1 (green) are required for host–cell
dependent replication of the plasmid. The luciferase gene and the corresponding polyA sequence is
depicted in red. KpnI and NheI sites were used for insertion of target promoter sequences. Not to
scale. C. Induction rates of luciferase activity are shown for stable U937 cell lines. D. Luciferase
induction levels at different time points after addition of Tamoxifen.
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Addition of Tamoxifen led to robust induction of an episomal Hoxa9–luciferase
reporter in MLL–VP16–ER–HA cells but not in a control cell line expressing
VP16–ER–HA (Fig. 10C). This indicates that MLL–VP16–ER–HA is specifically
targeted to the episomal Hoxa9 promoter activating reporter gene transcription while
VP16–ER–HA has virtually no effect on this process. The elevated luciferase activity
was reflected in an increase of luciferase mRNA–levels (Fig. 10A). The stronger
increase of luciferase mRNA–levels as compared to Hoxa9 mRNA might be due to
negative regulation of MLL–VP16–ER–HA activated transcription, which is taking
place only at the endogenous locus, but not on the episome. One possible
explanation could be heterochromatin formation taking place on the chromosome but
not on the episome. This would render the reporter more accessible to the
transcription machinery. Absolute Hoxa9 mRNA–levels before induction of
MLL–VP16–ER–HA, however, seem to be higher than luciferase
mRNA–levels (Fig. 10A, table ct values). These values rather argue for solid
transcription of the Hoxa9 gene in U937 cells even without MLL–VP16–ER–HA
activity. Therefore another explanation for the higher induction levels of the episomal
reporter gene seems more likely: the short promoter fragment present in the reporter
plasmid might simply lack inhibitory elements, which might negatively influence
MLL–VP16–ER–HA activated transcription of the endogenous Hoxa9 gene.
One reason to choose the ER system for the inducible cell lines had been reports
about the fast induction kinetics of ER–fused proteins (Mattioni et al. 1994). To
estimate the time–spans needed for the induction of MLL–VP16–ER–HA a
time–course experiment was performed where luciferase samples were measured
after different induction periods. In fact already after 90 minutes a significant increase
in luciferase activity could be measured (Fig. 10D) hinting at transcriptional
processes that must start even earlier. Maximum levels of reporter gene activity,
however, could be measured only after 12 hours and 24 hours, respectively.
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3.2.3 MLL–VP16–ER–HA is targeted to the Hoxa9 promoter upon induction
Since an increase of transcriptional activity following MLL–VP16–ER–HA induction
was observed the next question to be addressed was whether this is a direct effect
mediated through binding of the fusion protein to the Hoxa9 promoter. Therefore
ChIP experiments were performed analysing endogenous and episomal Hoxa9
promoter occupancy. U937 cells stably expressing MLL–VP16–ER–HA and stably
propagating a Hoxa9 (-207 / +46)–luciferase reporter plasmid were induced with
Tamoxifen and proteins were cross–linked to DNA after 24 hours by addition of
formaldehyde. A mixture of three monoclonal antibodies against the MLL N–terminus
(5A9, 5C10, 4G10; see 3.1) was used to precipitate MLL–VP16–ER–HA. PCR
reactions were performed using primers specific for the chromosomal Hoxa9
promoter region and another primer pair specific for the episomal Hoxa9 sequence.
In both cases an increased signal was obtained after induction of
MLL–VP16–ER–HA indicating its binding not only to the chromosomal gene promoter
but also to the promoter present in the episomal reporter construct (Fig. 11). This
argues that the upregulation of transcription from these promoters is a direct effect of
MLL–VP16–ER–HA. The observed promoter occupancy 24 hours after induction
taken together with elevated reporter gene levels already 90 minutes after addition of
Tamoxifen argues for fast induction kinetics leading to early recruitment of
MLL–VP16–ER–HA to the promoter where the protein is still present after 24 hours.
Figure 11. Induced binding of MLL–VP16–ER–HA to Hoxa9 promoter sequences. ChIPs were
performed in a cell line expressing MLL–VP16–ER–HA and a Hoxa9 (–207 / +46)–luciferase reporter
plasmid. Following IP with a mixture of antibodies specific for MLL (MLL mix) PCR reactions were
performed with primers specific either for the endogenous (top panel) or the episomal Hoxa9
promoter (lower panel). Different amounts of IP input material were used to control the PCR reaction.
IP reactions performed with sepharose beads only were used as a specificity control for the IP of MLL.
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3.3 Identification of a promoter region critical for regulation of Hoxa9 by
MLL–VP16–ER–HA
To define more precisely the region of the Hoxa9 promoter through which
MLL–VP16–ER–HA is acting a deletion analysis of the human Hoxa9 promoter was
carried out. Different promoter variants were generated via PCR and cloned
upstream of a luciferase gene. U937 cells stable for MLL–VP16–ER–HA or for
VP16–ER–HA, respectively, were transfected with five different variants of the
human Hoxa9 promoter and hygromycin resistant cell lines were selected.
No significant change in luciferase expression was observed after induction of
VP16–ER–HA (data not shown). Strong increase of luciferase activity was seen,
however, with all five Hoxa9 constructs after MLL–VP16–ER–HA
induction (Fig. 12A). Even though the larger promoter segments had the strongest
effect the major capacity for activation through MLL–VP16–ER–HA seems to reside
in the region –207 / +46, which in this experiment led to almost 15–fold increase in
luciferase activity. Extending this region further downstream (–207 / +98) did not
augment the activation.
Therefore the –207 / +46 region was chosen for further investigation and shorter
constructs were designed for fine–mapping of the MLL–responsive region.
Shortening the region to –118 / +46 led to a reduction of luciferase activity of
about 34 percent in comparison with the original construct (Fig. 12B).
Hoxa9 –78 / +46, however, showed a dramatic loss not of basal activity (Fig. 12C)
but of induction by MLL–VP16–ER–HA: the induction rate dropped to 11 percent in
comparison to Hoxa9 –118 / +46, showing that the region from
–118 to –79 (Fig. 12D) is critical for regulation of MLL–VP16–ER–HA induced
transcription of Hoxa9.
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Figure 12. Hoxa9 promoter deletion analysis. A. and B. Reporter gene induction levels as determined
by luciferase measurements in U937 cells. Numbers are referring to the start point of transcript
NM_152739. C. Basal levels of the experiment shown in B. D. Sequence of the critical region
–118 / –79.
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3.4 Site-directed mutagenesis of the human Hoxa9 promoter region
In the next step individual transcription factor binding sites and other defined motifs in
the Hoxa9 promoter sequence were to be analyzed. Towards this goal point
mutations were introduced into the longer (i.e. –207 / +46) and shorter
(i.e. –118 / +46) fragments (Fig. 13).
Figure 13. Overview of fragments used in the site–directed mutagenesis analysis. For sequence
alignments see appendix 6.1. For the comprehensive plasmid list see 2.8.
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3.4.1 Hox protein binding sites have a dual role for Hoxa9 regulation
One intriguing feature of the Hoxa9 promoter is the presence of binding sites for
homeobox proteins. Their presence raises the possibility that Hoxa9 underlies
autoregulatory control by Hox factors. Therefore, the significance of these sites for
basal transcription as well as for MLL–VP16–ER–HA dependent transcription was
investigated. Of three putative Hox factor binding sites H3 is the most
well–conserved (consensus: ATGATTTAT). It is furthermore the only one present in
the shorter construct (Fig. 13; H1, H2, H3).
Luciferase levels were measured before and after induction of stable cell lines.
Interestingly basal transcriptional levels were raised for both of the mutant variants
indicating that homeobox proteins might be involved in Hoxa9 transcriptional
regulation (Fig. 14A). The increased reporter gene levels in the mutants, however,
indicate that Hox factor binding to the Hoxa9 promoter exerts an inhibitory effect on
gene activation. In contrast to this finding the mutations seemed to affect gene
activation by MLL–VP16–ER–HA in a negative way: mutation of all three sites in
Hoxa9 –207 / +46 reduced the induction rate by about 20 percent (Fig. 14B).
Mutation of only H3 in Hoxa9 –118 / +46 led to an approximately 2–fold decrease of
induction. This supports the previous conclusion of a critical role of the
–118 / +46 region. Furthermore together with the increased basal transcription rate
observed in these mutants these findings indicate that Hox factors might function as
negative regulators of Hoxa9 transcription. MLL–VP16–ER–HA seems to act through
the same target sites on the DNA to activate transcription, possibly by competition
with these negative regulators.
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Figure 14. Effects of Hox protein binding site mutations on Hoxa9 transcription. Two mutant
constructs of different lengths were compared with the corresponding wild type sequences.
A. Induction rates of the mutant constructs after activation of MLL–VP16–ER–HA are shown in
comparison to wild type induction levels. B. Basal transcription rates of mutant reporter constructs are
shown in comparison to wild type levels. WT: wild type. H1, H2, H3: Hox protein binding sites (for
alignment see appendix 6.1).
3.4.2 A GC rich region in the Hoxa9 promoter is mediating epigenetic
regulation
It has been published that the MLL MT domain binds to GC rich DNA (Birke et al.
2002; Ayton et al. 2004). Along this line one striking feature of the Hoxa9 promoter
region is the presence of a sequence stretch with very high GC content (Fig. 13,
GC block). This raises the question whether this is critical for the effect of
MLL–VP16–ER–HA on this promoter. The highest GC density is found in the region
between residues –78 and –36 that has been termed "GC block" (Fig. 15). Notably
the Hoxa9 –78 / +46 construct retains a residual activity that is sufficient to mediate
five–fold induction of transcription by MLL–VP16–ER–HA (Fig. 10B). Furthermore
this region might function cooperatively with other sequences that are positioned
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more 5'. Hence four different mutant variants affecting several motifs were employed
to investigate the specificity of this process (Fig. 15 and appendix 6.1).
Figure 15. Mutants affecting the GC block region of the human Hoxa9 promoter. Nucleotide sequence
alignments of the point mutants in the GC block region and the Hoxa9 wild type promoter
region –78 / –36. Motifs are indicated in red, mutations were underlined in black. Asterisks are
indicating the CpG dinucleotides that are affected by both the CpG mutant 1 and the
SP1 sites upmutant.
3.4.2.1 CpG mutations in the Hoxa9 promoter lead to strong activation of
transcription by MLL–VP16–ER–HA
All MLL fusion proteins contain a domain of high homology with DNA
methyltransferases (Ma et al. 1993). In vitro this domain binds DNA with a preference
for non–methylated CpG rich sequences (Birke et al. 2002; Ayton et al. 2004). It was
hence particularly interesting to test whether CpG rich sequences that are present in
the Hoxa9 promoter play a critical role in transcriptional control by MLL fusion
proteins.
The GC block (Fig. 15) contained in Hoxa9 –78 / +46 is harbouring seven
CpG dinucleotide sequences all of which have been mutated in the construct
"CpG mutant 1" (Fig. 13 and 15). In order not to change the GC content of the
DNA sequence CpGs were mutated to GpG. Reporter gene levels were measured
before and after induction of MLL–VP16–ER–HA activity. In contrast to the reporter
constructs described so far great variations were observed between different cell
batches: while some batches behaved in a manner very similar to wild type, other
samples that were transfected and selected independently, diverged dramatically
GGGC mutant           CAC GTGACGCGCA CGGCCAATGG GTGCGCGTGC GCCGGCAACT
WT                    CAC GTGACGCGCA CGGCCAATGG GGGCGCGGGC GCCGGCAACT
                                                     *      **
CpG mutant 1          CAC GTGAGGGGCA GGGCCAATGG GGGGGGGGGG GGGGGCAACT
WT                    CAC GTGACGCGCA CGGCCAATGG GGGCGCGGGC GCCGGCAACT
                                                     *      **
SP1 sites upmutant    CAC GTGACGCGCA CGGCCAATGG GGGCGGGGGC GGGGTCAACT
WT                    CAC GTGACGCGCA CGGCCAATGG GGGCGCGGGC GCCGGCAACT
GGC mutant            CAC GTGTCGCGCA CGACCAATGG GGACGCGGAC GTCGACAACT
WT                    CAC GTGACGCGCA CGGCCAATGG GGGCGCGGGC GCCGGCAACT
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from wild type and showed very high induction rates. Furthermore inducibility seemed
to change over the culturing period. Figure 16 is showing representative experiments.
While the basal transcription level is hardly affected in the case of CpG mutant 1,
induction rates after OHT–addition show an approximately four–fold increase over
wild type (Fig. 16, CpG mutant 1, 23 days) indicating that elimination of
CpG dinucleotides facilitates activation by MLL–VP16–ER–HA.
Figure 16. CpG mutant analysis in Hoxa9 –207 / +46 background. Stable cell lines were generated
containing Hoxa9–luciferase reporter carrying different point mutations affecting CpG dinucleotides.
Luciferase levels were measured before and 24 hours after addition of Tamoxifen. The figure shows
two measurements, that were performed 20 and 23 days after transfection, respectively. A. Induction
levels following activation of MLL–VP16–ER–HA. B. Basal reporter gene levels.
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Figure 17. Effect of CpG mutations in Hoxa9 –118 / 46. Luciferase levels were measured before and
24 hours after induction of MLL–VP16–ER–HA. Reporter gene activity was analysed 26, 31 and
43 days after transfection.
Similar effects were observed with other mutant reporter constructs where
CpG dinucleotides were affected: "SP1 sites upmutant" (Fig. 13 and 15) was initially
designed to investigate whether SP1 sites might mediate activation through
MLL–VP16–ER–HA. The same region was targeted as in CpG mutant 1. In
SP1 sites upmutant, however, the GC block (Fig. 13 and 15) was changed at four
nucleotide positions to create two consensus SP1 sites. These mutations affected
two of the seven CpG dinucleotides that were also changed in CpG
mutant 1 (Fig. 15) providing for an overlap between these two constructs and adding
another aspect to SP1 site upmutant: this mutant does not only represent a better
target for proteins binding to SP1 sites but independently from this effect it might also
affect binding of factors that specifically recognize CpG dinucleotides and their
methylation status, respectively. As already described for the CpG mutant 1 a
dramatic increase of induction by MLL–VP16–ER–HA could be measured (Fig. 16A),
which decreased after three more days of incubation, however. Basal levels were
raised in this case as well and showed an increasing tendency over the culturing
period (Fig. 16B). These results are basically mirrored in another mutant construct
where CpG dinucleotides were targeted that are located between –118
and –78 (CpG mutant 2, Fig. 13). Similar to the SP1 sites upmutant this construct
leads to increase of activated as well as basal transcription levels (Fig. 17). Three
measurements over a period of 17 days showed a decrease of induction rates as
well as an increase of basal transcription levels.
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These three constructs (CpG mutant 1 and 2, SP1 sites upmutant) have in common
that CpG dinucleotides were mutated to GpG dinucleotides that cannot be
methylated by cellular DNMTs. The increased basal transcription levels observed in
two of these mutants (SP1 sites upmutant, CpG mutant 2) argue for a loss of
silencing due to a lack of DNA methylation. This effect might be augmented by the
presence of two SP1 sites in one of the constructs. For all three constructs the
induction levels were increased indicating that CpG dinucleotides negatively regulate
activation through MLL–VP16–ER–HA possibly via reduced binding to methylated
DNA. In all three constructs cytosine residues were replaced by guanosine residues.
This argues for a model, where MLL is recruited to G–rich sequences, while
methylated CpG dinucleotides exert an inhibitory function. Support for this hypothesis
comes from another Hoxa9 promoter mutant: in "GC mutant" (Fig. 13)
CpG dinucleotides were eliminated not by substitution through GpG, but by
replacement with ApG reducing the G–content in comparison to the three mutants
discussed above. Noteworthy activation rates by MLL–VP16–ER–HA were raised as
well but did not reach the same levels that had been observed with the CpG to GpG
mutants (Fig. 16A). This result might reflect the loss of repression of
MLL–VP16–ER–HA activation mediated through the lack of methylated DNA without
the positive effect of increased G–content.
Three additional mutants were designed to monitor the effect of changes in
G–content in a background where integrity of CpG–dinucleotides was not
affected (GGC mutant and GGGC mutants 1 and 2, Fig. 13 and 15). In both cases
G–rich motifs were changed by replacing single G residues by A or T (see also
alignments, appendix 6.1). In the case of GGC mutant slightly decreased induction
rates in comparison to wild type were observed (Fig. 16A). Mutation of the G–rich
motif "GGGC" (GGGC mutants 1 and 2) led to similar results. While mutation of
GGGC motifs 2 and 3 negatively affected basal transcription rates, GGGC1 (located
in the critical –118 / -79 region) was impeding activation of the reporter by
MLL–VP16–ER–HA (Fig. 18A and B). This might indicate impaired recruitment of
MLL–VP16–ER–HA in a background where the negative control through
DNA methylation is still functional resulting in reduced transcription levels.
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Figure 18. Mutation of GGGC motifs in the Hoxa9 promoter sequence. Mutant promoter fragments of
different lengths (–207 / +46 and –118 / +46) have been analysed in reporter gene assays. Luciferase
levels of stable reporter cell lines were measured. A. Induction rates of the mutant constructs after
activation of MLL–VP16–ER–HA are shown in comparison to wild type induction levels. B. Basal
transcription rates of mutant reporter constructs are shown in comparison to wild type levels. For
sequence alignment see appendix 6.1.
3.4.2.2 SP1 protein overexpression does not facilitate gene activation by
MLL–VP16–ER–HA
The GC block present in Hoxa9 –78 / +46 contains two non–consensus SP1 sites.
As described above (see 3.4.2.1) the introduction of two consensus SP1 sites (which
affects two CpG dinucleotides; see alignments, appendix 6.1) has dramatic effects on
basal as well as activated transcription. Comparison with other mutant variants
reveals similarities between SP1 sites upmutant and the constructs specifically
mutated for CpG dinucleotides. This raises the question whether the activator SP1
might recruit MLL–VP16–ER–HA to the promoter or whether the effect is due to
sequence–specific effects that are independent from SP1 protein.
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Figure 19. Effect of GAL–SP1 on MLL–VP16–ER–HA driven activation of a GAL–Hoxa9 promoter.
Induction rates of luciferase activity after activation of MLL–VP16–ER–HA are shown for cells
transfected with a GAL–SP1 expression vector or a GAL–control, respectively.
To clarify whether SP1 protein might be recruiting MLL–VP16–ER–HA to the Hoxa9
promoter a reporter construct was designed that contained the –78 / +46 fragment of
the human Hoxa9 promoter, which was shown to be only weakly inducible in
comparison to the –118 / +46 construct. Two GAL–binding sites were cloned 5' of
this promoter sequence and stable cell lines were created by transfection of
U937 / MLL–VP16–ER–HA cells with this DNA construct. Cells that were stably
propagating the EBV reporter plasmid were then transfected transiently with an
expression vector for GAL–SP1 or the empty vector, respectively.
MLL–VP16–ER–HA activity was induced by addition of Tamoxifen 17 hours after
transfection and luciferase levels were measured 24 hours later. In this experiment
no significant influence of SP1 on MLL–VP16–ER–HA activated transcription could
be detected (Fig. 19) indicating that SP1 protein is not involved in the activation of
Hoxa9 through MLL–VP16–ER–HA. This result is rather suggesting that the positive
effect of SP1 sites upmutant is more likely due to loss of DNA methylation or to
sequence–specific binding events of either MLL–VP16–ER–HA itself to these sites or
other factors that could in turn recruit MLL–VP16–ER–HA.
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3.4.3 Introduction of synthetic binding sites into the Hoxa9 minimal promoter
Based on the finding that SP1 binding sites and GGGC motifs are important for
Hoxa9 regulation it was to be tested whether these sequences can reconstitute
activation by MLL–VP16–ER–HA in Hoxa9 –78 / +46. Deletion analyses showed that
this promoter fragment retains a residual capacity for induction through
MLL–VP16–ER–HA but the effect is minor in comparison to –118 / +46 (Fig 12B).
Synthetic sequences were cloned 5' of the Hoxa9 –78 / +46–luciferase reporter in an
epsiomal vector. Different oligonucleotides of 32 nucleotides length were designed
that vary in GC content and binding sites that are present in the sequence. Three
copies of the GGGC motif are present in MAZR1, MAZR2 and MAZR3. These
constructs differ in spacing and orientation of the GGGC motifs as well as in the
intervening sequences. Bioinformatic analysis revealed binding sites for different
proteins (Table 8). Notably all three of these constructs contain at least one binding
site for MAZR (myc–associated zinc finger protein related transcription factor). Stable
reporter cell lines were generated containing these vectors and luciferase levels were
measured before and after induction of MLL–VP16–ER–HA activity. Three different
Hoxa9 constructs were measured as positive controls with Hoxa9 –78 / 46
representing the baseline (Fig. 20). As an unspecific control for the effect of
introduction of synthetic sequences into the –78 / +46 construct GAL sites were
used.
MAZR1, MAZR2 and MAZR3 all led to induction rates between 3 and 6–fold over the
GAL–control levels. Induction of these constructs also exceeds the one of
Hoxa9 –118 / +46 even though the synthetic constructs are 8 nucleotides shorter in
comparison. Together the results from these three constructs are consistent with
earlier observations that GGGC motifs positively modulate activation by
MLL–VP16–ER–HA. Noteworthy, however, the highest induction levels have been
measured with MAZR1 although considerable variations were noted in between
experiments. The sequence of MAZR1 shows that GGGC motifs are located on the
same DNA strand and are evenly spaced. Shifting the central GGGC motif to one
side thereby generating uneven 5' and 3' intervals (MAZR2) leads to a decrease in
activation by MLL–VP16–ER–HA. This effect is even stronger in MAZR3, where
GGGC boxes are not only unevenly distributed but also located on different
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DNA strands. These findings indicate that GGGC boxes act cooperatively to recruit
MLL–VP16–ER–HA. Cooperativity furthermore seems to depend on regular spacing
between these motifs and location on the same strand of the DNA.
Mutation analysis of the GC block in the Hoxa9 promoter led to the hypothesis that
G–rich DNA might be important for MLL–VP16–ER–HA recruitment while cytosine
redidues might rather be required fo rmodulation of this process via
methylation (see 3.4.2.1). A series of GGGG motifs are present in the MAZR
constructs as well, all of which showed increased induction rates by
M L L – V P 1 6 – E R – H A .  T o  a d d r e s s  t h e  q u e s t i o n  w h e t h e r
G nucleotide–repeats (GGGG) alone are sufficient to mediate activation by
MLL–VP16–ER–HA a construct was designed containing three of these motifs in
evenly distributed over the length of the oligonucleotide (MZF1). Like this two binding
sites for the myeloid zinc finger protein 1 (MZF1) were generated as revealed by
bioinformatic analysis. The induction rate of this construct was approximately
2.5–fold higher than the GAL control indicating that guanosine repeats positively
affect activation via MLL–VP16–ER–HA. Direct comparison with constructs MAZR1,
MAZR2 and MAZR3 is possible only to a limited extent because the intervening
sequences between the motifs tested in each case are not identical.
A third class of constructs is represented by E–BOX1 and E–BOX2. As another
representative of GC–rich motifs E–boxes should be tested for their capacity to
facilitate induction by MLL–VP16–ER–HA. Two different constructs were designed,
each of them containing three E–box motifs. While the spacing between these motifs
is regular in E–BOX1, the motifs are distributed irregularly in E–BOX2. Interestingly,
this seems to greatly affect activation through MLL–VP16–ER–HA: E–BOX2
induction levels were only slightly raised in comparison with the GAL–control, while
E–BOX1 significantly augmented reporter gene transcription after
MLL–VP16–ER–HA induction. These findings suggest that E–box motifs might be
involved in MLL fusion protein recruitment to target gene promoters. Furthermore as
described before for the GGGC motif also in this case cooperativity between several
motifs seem to play a certain role. The fact that shifting one of the E–box motifs by
only one nucleotide position leads to loss of activation indicates that spacing between
single motifs is absolutely critical.
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It is intriguing that introduction of either one of the three motifs (GGGC, GGGG,
E–box) reconstitutes the induction levels that were observed with the
Hoxa9 –118 / +46 reporter construct. A bioinformatic analysis of binding sites present
in each of these constructs revealed no overlap between the three classes of
synthetic constructs (Table 8, boxes in colors). Most strikingly, however, none of the
binding sites present in the Hoxa9 –118 / –79 fragment was identified in any of the
synthetic constructs.
Figure 20. Reconstitution of MLL–ER–VP16–HA activated transcription from the Hoxa9 –78 / +46
promoter. Synthetic oligonucleotides were cloned in front of Hoxa9 –78 / +46. Cells were selected that
were stably replicating the EBV–based reporter constructs. Luciferase induction rates were
determined following activation of MLL–ER–VP16–HA by addition of Tamoxifen. GGGC motifs were
boxed in orange, GGGG motifs were boxed in light blue and E–box motifs were boxed in yellow.
GGGG motifs present in the mutants MAZR1,2 and 3 are underlined in light blue.
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Table 8. Predicted binding sites introduced into Hoxa9 –78 / +46.
MAZR
1
MAZR
2
MAZR
3
MZF1 E-Box
1
E-Box
2
WT
CDE.01 
CHREBP_MLX.01  
E2F.01 
XBP1.01    
MYCMAX.02  
MYCMAX.03 
USF.01    
EGR1.02  
BKLF.01 
KKLF.01   
ZIC2.01 
HAND2_E12.01 
HELT.01      
ARNT.01  
DEC2.01    
HIF1.01 
HNF1.03 
PBX_HOXA9.01 
HOXA9.01 
MAZR.01       
MUSCLE_INI.02  
VMYB.04 
MZF1.01  
PAX6.01 
PBX1_MEIS1.02 
PLAG1.01  
RREB1.01  
SOX5.01 
GC.01  
SP1.01  
ZF9.01   
Oligonucleotide sequences present in MAZR1, MAZR2, MAZR3 (orange), MZF1 (light blue)
and E–BOX1, E–BOX2 (yellow) have been analyzed using MatInspector. In parallel the
region –118 / –79 of the Hoxa9 promoter has been analyzed (green). The number of black
points symbolizes the number of binding sites identified.
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3.4.4 A consensus TATA box stimulates activation of Hoxa9 by
MLL–VP16–ER–HA
Besides the regulation of Hox gene expression a more global role has been
proposed for MLL and it has been shown that MLL binds to regions around the
transcriptional start point in many genes. To investigate whether core promoter
features influence the effect of MLL fusion proteins on Hoxa9 expression a series of
constructs was created containing point mutations in the region around the TATA box
and the Initiator sequence (Fig. 21).
Figure 21. Hoxa9 promoter variants carrying mutations in core promoter sequences. TATA box,
C–stretch and Initiator are boxed in red in the wild type sequence. Point mutations are boxed in black.
AdML-TATA box
-207 +46
TATA-less mutant 1
TATA-less mutant 2
-207 +46
-207 +46
AdML-Initiator
-207 +46
-207 +46
downstream C-stretch mutant
Hoxa9 -207/+46
-207 +46
TATA Inr
wild type CAACTTATTA GGTGACTGTA CTTCCCCCCC GGTGCCACCA AGTTGTTACA
AdML TATA box CAACCTATAA AAGGACTGTA CTTCCCCCCC GGTGCCACCA AGTTGTTACA
TATA–less 1 CAAC-CATCA GGTGACTGTA CTTCCCCCCC GGTGCCACCA AGTTGTTACA
TATA–less 2 CAACTCATCA GGTGACTGTA CTTCCCCCCC GGTGCCACCA AGTTGTTACA
AdML Inr CAACTTATTA GGTGACTGTA CTTCCCCCCC GGTGCCCCTC ACTCGTTACA
C-strech mutant CAACTTATTA GGTGACTGTA CTTCTCACTC GGTGCCACCA AGTTGTTACA
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Exchange of the non–consensus endogenous TATA box in the Hoxa9 (Fig. 21) by
the TATA box sequence from the Adenovirus Major Late Promoter (AdMLP)
increased induction rates by MLL–VP16–ER–HA more than 2–fold in comparison to
the wild type sequence (Fig. 22A). Also mutating the Initiator sequence (Inr) to the
corresponding sequence of AdMLP led to an increase in transcriptional activtiy
induced by MLL–VP16–ER–HA although large variations were observed in
independent experiments. In order to eliminate a consensus TATA box sequence
from the Hoxa9 promoter sequence was changed from TATTA to CATCA  (Fig. 21,
TATA-less2). As a consequence the induction was diminished to 50% compared to
the wild type promoter (Fig. 22, TATA-less-2). Interestingly the additional deletion of
another cytosine residue immediately 5' of the Hoxa9 TATA box (Fig. 21,
TATA–less 1) could rescue this effect almost completely (Fig. 22A).
Based on the observation that core promoter sequences are capable of modulating
Hoxa9 regulation by MLL–VP16–ER–HA it was to be investigated whether the Hoxa9
core promoter is containing a specific motif that is targeted by the fusion protein. In
this respect a cytosine heptanucleotide repeat (Fig. 21, C–stretch) located between
the TATA box and the Inr sequence raised the question whether this motif might be
important for activation by MLL–VP16–ER–HA. Substitution of three of these
C residues by A or T led to a decrease of the induction rate of about one
third (Fig. 22A) indicating that this C–stretch might play a role in Hoxa9 activation by
MLL–VP16–ER–HA. Interestingly this mutation had the strongest impact on basal
transcription levels (Fig. 22B). This is intriguing because it is not known that
components of the basal machinery specifically recognize this motif. Together with
decreased induction rates after MLL–VP16–ER–HA activation this might indicate
direct targeting of both MLL and MLL fusion proteins to this site with full–length MLL
maintaining low-level basal transcription and MLL–VP16–ER–HA leading to activated
transcription on a high level.
Taken together these results suggest that both the presence of a cosensus
TATA box sequence and a cytosine heptanucleotide repeat between TATA box and
Initiator facilitate recruitment of MLL–VP16–ER–HA to the Hoxa9 promoter.
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Figure 22. Mutation of core promoter sequences has an influence on activiation through
MLL–VP16–ER–HA. A. Reporter gene induction rates are shown derived from measurements
performed in cells stably expressing MLL–VP16–ER–HA and episomally propagating one of the
Hoxa9 reporter plasmids. B. Basal luciferase levels of the corresponding reporter constructs. Absolute
luciferase counts are shown in the diagram.
3.5 Identification of new genomic target sites for MLL fusion proteins
As described so far the MLL–VP16–ER–HA model system was used to analyze the
regulation of Hoxa9 by MLL fusion proteins. Critical features of this promoter were
identified that mediate specifically the activation by MLL–VP16–ER–HA. Specific
targeting of Hoxa9 by MLL fusion proteins is in line with many reports showing Hoxa9
and Meis1 overexpression in human leukemias. Recently, however, it has been
suggested that the actual target gene population for MLL and MLL fusion proteins
might be much larger (Guenther et al. 2005; Kohlmann et al. 2005).
The MLL–VP16–ER–HA system has been employed in an approach to identify new
target genes for MLL fusion proteins. The ER system is particularly suitable for this
application since induction of the gene of interest is not depending on de novo
transcription and translation. As described earlier relocation (possibly in concert with
a finishing step in protein folding) is enough to induce activity of the gene. The fast
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kinetics of this process facilitates analysis of the early events following activation of
an oncogene.
3.5.1 FDCPmix cells as a myeloid progenitor model system
MLL is described as a stem cell disease and it is clear that only cells of a certain
population have the capacity to establish this type of leukemia. As an in vitro system
of high physiological relevance hematopoietic progenitor cells were chosen for
MLL fusion protein target gene analysis.
FDCP mix cells were transfected with the previously described expression constructs
for MLL–VP16–ER–HA and VP16–ER–HA (see 3.2.1). After selection of cells that
had stably integrated the construct single clones were selected as described in
Material and Methods. Expression levels were very low in this case and no protein
could be detected in Western Blot analysis (data not shown). Functional assays,
however, showed that upon treatment of the cells with Tamoxifen some known
MLL fusion protein target genes were upregulated.
A Hoxa7–luciferase reporter was induced more than 25–fold in cells transgenic for
MLL–VP16–ER–HA, but not in stable cells harbouring the empty vector
backbone (Fig. 23). Several different cell clones were behaving in the same
way (data not shown). For practical reasons subsequent experiments were
conducted with one clone each. The Hoxa7–luciferase experiment showed that
MLL–VP16–ER–HA activity is under tight control. Luciferase levels measured in non-
induced MLL–VP16–ER–HA cells were comparable to the levels detected in the
control cell line. Titration of Tamoxifen showed that at a concentration of 1000 µM led
to robust induction while 200 µM were not enough. In another set of experiments the
concentration was raised further to 2500 µM Tamoxifen, which led to induction rates
that were marginally higher (data not shown). In order to avoid toxic effects due to
high drug levels subsequent experiments were performed at a Tamoxifen
concentration of 1000 µM.
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Figure 23. Hoxa7 reporter gene activation by MLL–VP16–ER–HA. FDCPmix cells stably expressing
MLL–VP16–ER–HA were transfected with a Hoxa7–luciferase reporter plasmid and incubated with
different concentrations of Tamoxifen (OHT). Depicted in the graph are absolute luciferase values
measured 24 hours after induction.
Regulation of endogenous target genes by MLL–VP16–ER–HA was controlled by
RT–PCR. For Meis1, a well–known MLL fusion protein target, it could be shown that
mRNA amounts were significantly increased already 3 hours after addition of
Tamoxifen (Fig. 24).
Figure 24. Upregulation of Meis1 mRNA concentrations by MLL–VP16–ER–HA but not by
VP16–ER–HA. RT–PCR analysis of RNA samples derived from stable FDCPmix cells incubated with
1 µM Tamoxifen for 30 min, 3 hours and 12 hours.
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Figure 25. Induction of the ER–fused activation domain of VP16 has toxic effects in FDCPmix cells.
Viable cells have been counted two and five days after addition of Tamoxifen. The graphs show a
representative experiment.
It has been observed that treatment of the MLL–VP16–ER–HA cell line with
Tamoxifen greatly slowed down the growth rate. Viable cell numbers decreased
dramatically after 4 days if the growth medium contained 1 µM Tamoxifen (Fig. 25).
Comparison with two other cell lines provided evidence for the dependency of this
effect on the induction of VP16–ER–HA. A control cell line expressing this variant
showed the same toxic effects while a MLL–ER–HA cell line was not affected by the
presence of Tamoxifen.
To ensure that the cell clone that was used for subsequent experiments was not
compromised by manipulations required to establish the stable monoclonal cell line
the cells were analyzed morphologically before and after differentiation. The myeloid
differentiation potential of the transgenic MLL–VP16–ER–HA cell line was checked in
an in vitro differentiation experiment. Non–transfected FDCP mix cells as well as the
induced and non–induced MLL–VP16–ER–HA cell line were cultured in medium
lacking IL 3 and containing GM–CSF and G–CSF. It has been shown that these
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cytokines are required for differentiation of FDCP mix cells into granulocytes and
macrophages and that this process is not impeded by the presence of
Tamoxifen (Schroeder 2001). Cells were analyzed morphologically after
Giemsa / May–Gruenwald staining (Fig. 26A). The relative numbers of
undifferentiated blast cells, myelocytes / promyelocytes, granulocytes and
macrophages / monocytes were counted at three different time points after induction
of differentiation (Fig. 26B). After 11 days of culture under differentiation conditions
the FDCP mix sample contained no undifferentiated cells (Table 9). More than half of
the population was comprised of granulocytes and 20 percent of living cells were
differentiated into macrophages or monocytes. The non Tamoxifen–treated
MLL–VP16–ER–HA cell line showed a very similar distribution. Active
MLL–VP16–ER–HA, however, led to a different outcome: almost half of the living cell
population was still consisting of non–differentiated blast cells and only 15 percent of
terminally differentiated cells could be observed in total.
Table 9. Cell numbers after GM differentiation of stable FDCPmix cells
blasts myelocytes/
promyelocytes
granulocytes macrophages/
monocytes
day0 88 10 0,5 1,5FDCPmix WT
day11 0 28 52 20
day0 90 9 0 1MLL-ER-VP16-HA
non-induced day11 0 17 49 34
day0 90 9 0 1MLL-ER-VP16-HA
induced day11 41 47 9 6
Results                                                                                                                       93
Figure 26. Induction of MLL–VP16–ER–HA blocks GM–differentiation. Stable FDCPmix cells were
induced for GM differentiation and simultaneously treated with Tamoxifen. A. May–Gruenwald/Giemsa
stain of cytospin preparations of differentiated cells. B. Shown in the graph is the relative
representation of cell types at different time points as determined by morphological analysis.
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Figure 27. Effect of MLL–VP16–ER–HA activation on different reporter genes. Stable FDCPmix cells
were transfected with reporter plasmids and induction of luciferase was measured 24 hours after
induction with Tamoxifen.
This cell system was used for a series of different reporter experiments in order to
investigate the influence of MLL fusion proteins on potential target gene promoters.
One early experiment was performed in order to clarify whether the activation of the
Hoxa7 reporter gene was specific for the Hoxa7 upstream sequences or whether any
upstream region combined with a minimal promoter as found in the pGL2 basic
vector would be sufficient to mediate the effect. A number of different luciferase
reporter constructs were used for transfection of the stable MLL–VP16–ER–HA cell
line (Fig. 27). While the Hoxa7 upstream region mediated a strong response upon
induction of MLL–VP16–ER–HA by Tamoxifen some other promoters (CD4,
TCR–Vb8.1, GAS, ISRE) showed only slightly upregulated transcription rates.
Noteworthy, the pGL2 promoter plasmid, however, was induced by a factor of more
than 30–fold indicating that the SV40 promoter contained in that vector is a suitable
target for MLL–VP16–ER–HA and that the target gene spectrum for this protein might
well exceed the range of so far known target genes.
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3.5.2 c–myc promoter sequences as targets for MLL–VP16–ER–HA
Expression profiling of acute lymphoblastic and myeloblastic leukemias revealed
upregulation of the proto–oncogene c–myc (Rozovskaia et al. 2003). Furthermore
c–myc is one of the genes on whose promoters MLL was found to be present in a
recent ChIP-chip study (Milne et al. 2005a). It was intriguing to follow these
observations and investigate whether MLL plays a role in regulation of transcription
from the c–myc promoter.
Using a series of c–myc luciferase reporter constructs it could be shown that the
full–length construct (–2332 / +513) was induced by MLL–VP16–ER–HA more than
15–fold (Fig. 28A). Shorter constructs comprising only one of the two promoters of
c–myc at at time were leading to similar rates, however, and there was no striking
difference to be seen between P1 and P2. To find out whether the Igκ enhancer was
playing a role in the induction of the c–myc reporter by MLL–VP16–ER–HA
constructs were used in addition that contained the enhancer sequence which was
cloned into the vector 3' of the luciferase gene. No dramatic change of the effect was
observed with any of the constructs. Since the goal was to identify possible new
MLL fusion target sites the shortest construct was also the most attractive object for
the study since complexity could be reduced simply by the small size of the target
sequence. Therefore the –101 / +66 construct was chosen for further investigation.
Mutant constructs of this promoter stretch, which for reasons of simplicity have been
termed "distal" and "proximal" almost completely abolished the response to induction
of MLL–VP16–ER–HA activity (Fig. 28B). In contrast basal transcription levels of the
mutant reporter constructs were hardly affected.
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Figure 28. c–myc promoter analysis. A. and B. Deletion and point mutant c–myc luciferase reporter
constructs were transfected into FDCPmix cells. The graphs show induction rates of luciferase activity
after MLL–VP16–ER–HA activation and basal reporter gene levels, respectively. C. Mutated regions in
the c–myc promoter were analyzed for protein binding sites using MatiInspector. Nucleotide changes
in mutant constructs are indicated in red. GGGC motifs are underlined in yellow.
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The complete loss of activation in both of these mutants could lead to the assumption
that both of the mutated regions contain target sequences through which MLL fusion
proteins exert their effects. The two sequences, however, do not display a high
degree of homology and bioinformatic analysis could not reveal common binding
motifs for transcription factors (Fig. 28C). Noteworthy the proximal mutant contains a
binding site for Hoxa9 suggesting that presence of this motif alone is not sufficient for
activation by MLL–VP16–ER–HA. Interestingly, a G–rich motif, mutation of which
leads to impaired activation of the Hoxa9 promoter (see 3.4.2.1), is also present in
the wild type c–myc promoter but not in the mutant constructs (Fig. 28C, yellow
boxes). One of these GGGC motifs is contained in a SP1 binding site, which is lost
upon mutation in the proximal mutant supporting previous findings where introduction
of SP1 sites facilitated activation by MLL–VP16–ER–HA.
The fact that the two regions that were targeted in this mutagenesis are located next
to each other (see alignment, appendix 6.1) and the presence of multiple copies of
the GGGC motifs might also indicate cooperativity between two elements. This could
also explain complete loss of activation as a consequence of changes in only one of
the two regions.
3.5.3 p21 as MLL fusion protein target
3.5.3.1 MLL–VP16–ER–HA strongly activates a p21–luciferase reporter gene
It has been published that the cell cycle regulators p18 and p27 are MLL
targets (Milne et al. 2005b; Xia et al. 2005). It is tempting to speculate that
chromosomal translocation and expression of MLL fusion proteins interfere with
normal transcriptional regulation and thereby destabilize cellular proliferation control.
This raises the question whether this could be a general mechanism of
transformation through MLL fusions and whether also other cell cycle regulators
might be targeted. Based on the observation that GC rich DNA stretches mediate
activation by MLL–VP16–ER–HA the human p21 promoter was to be tested. The
upstream region of the p21 gene is not only rich in GC content but also contains SP1
sites, which had a positive effect on MLL–VP16–ER–HA driven transcription of
Hoxa9 and c–myc.
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Several p21 promoter luciferase reporter constructs were tested in transfection
experiments using inducible FDCP mix cell lines. A 2.3 kb upstream
fragment (–2325 / +8) of the human p21 gene led to robust induction of luciferase
activity (Fig. 29A). A deletion mutant related to this construct was
tested (deletion –122 / –66). The activation of transcription by MLL–VP16–ER–HA
dropped dramatically with an observed induction rate that was about 17–fold lower
than the one measured using the wild type sequence. A shorter construct (–215 / +8)
was tested as well and proved to be sufficient for mediating the response to the
MLL fusion protein. In fact the observed induction was almost 10–fold higher than
that of the WT construct. This strong activation was also reflected in the absolute
luciferase activity. The basal transcription rate of the –215 / +8 reporter was only
about one fourth of the one of the long construct (Fig. 29B). Following induction of
MLL–VP16–ER–HA, however, absolute luciferase counts were about two–fold higher
using the short construct.
Further shortening of this construct by deletion of the region –215 / –144 led to a
construct that showed induction rates which were close to the –2325 / +8 values. In
comparison to –215 / +8, however, the activation rate by MLL–VP16–ER–HA is only
10 percent, showing that the –215 / –144 region is containing one or more elements
that are responsive to the MLL fusion construct. Bioinformatic analysis of the two
regions (–215 / –144 and –122 / –60) revealed binding sites for different subsets of
transcription factors (Fig. 29C). It is also published that E2F activates p21 through
noncanonical binding sites in both regions (Gartel et al. 1998). Noteworthy, a G–rich
motif (GGGC), which has been shown to influence regulation of Hoxa9 by
MLL–VP16–ER–HA (see 3.4.2.1) is present in both regions. Three copies of this
motif were identified in the c–myc P1–promoter, which is strongly activated by
MLL–VP16–ER–HA (see 3.5.2). Both mutant variants of this promoter that do not
respond to induction of MLL–VP16–ER–HA lack these motifs. Taken together these
data indicate a general role for the GGGC motif in MLL fusion protein recruitment.
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Figure 29. Induction of MLL–VP16–ER–HA in FDCPmix cells leads to strong transcriptional activation
of p21 luciferase reporter constructs. FDCPmix cells stably expressing MLL–VP16–ER–HA were
transiently transfected with reporter plasmids. 24 hours addition of Tamoxifen luciferase activity was
measured. A. Fold induction rates after activation by MLL–VP16–ER–HA. B. Basal reporter gene
activity (absolute values). C. Shown are the two regions –122 / -60 and –215 / –144. Transcription
factor binding sites are indicated as identified by MatInspector (see appendix 6.3 and
www.genomatix.de). GGGC motifs are boxed in yellow.
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The p21 –215 / +8 reporter plasmid was also transfected into a control cell line
expressing VP16–ER–HA where no significant change in luciferase activity could be
detected after induction with Tamoxifen (data not shown). In a transient transfection
experiment reporter response was compared in two batches transfected with an
expression plamid for either VP16–HA or MLL–VP16–HA. This control excludes an
ER / Tamoxifen–dependent artifact. Robust induction was seen again with the
MLL fusion construct in comparison to which the background activity due to the
expression of VP16–HA was rather marginal (Fig. 30).
Figure 30. p21 reporter activation by transiently overexpressed MLL–VP16–HA in FDCPmix cells.
Expression plasmids for MLL–VP16–HA as well as for the VP16–HA control construct were transiently
overexpressed in FDCPmix and transcription from a –215 / +8 p21  reporter was measured by
luciferase assay. The graph is showing the induction rates.
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3.5.3.2 p21 promoter sequences are activated by MLL and MLL fusion proteins
One interesting question concerning MLL leukemogenesis is whether MLL and
MLL fusion proteins are targeted to the same promoters. To address this question for
the human p21 promoter expression plasmids for MLL, MLL–AF4 and MLL–AF9
were co–transfected with the p21 –215 / +8 reporter plasmid. Expression of each of
the three constructs led to significant induction of p21 luciferase reporter
activity (Fig. 31A). MLL–AF9 had the strongest effect. However, the induction
rate (>12–fold) was lower than in the case of MLL–VP16–HA (>40–fold, Fig. 30).
Expression of the full–length MLL protein was driven from a different type of
expression vector (see 2.8), which may be responsible for the milder effect as
compared with MLL fusion proteins. However, these data show that both MLL fusion
and full–length protein affect the p21 promoter in a transient analysis.
HepG2, a hepatic cell line frequently used for analyses of p21 regulation was
employed to verify these results within a different cellular background. Three different
p21 reporter gene constructs were co-transfected together with expression plasmids
coding for FLAG–MLL or for MLL–VP16–HA, respectively. While the two proteins
performed almost identically in co–transfections with p21 –2325 / +8, MLL–VP16–HA
had a much stronger effect on the –215 / +8 construct (Fig. 31B). FLAG–MLL in
contrast led to higher induction rates than the fusion protein when used together with
the full–length construct harboring the –122 / –60 deletion.
These findings suggest that both the fusion and the full–length protein to the
promoter through the MLL aminoterminus. The differential effects as seen for the
–215 / +8 promoter construct might indicate, however, the differences in promoter
complexes that are formed upon recruitment of MLL or MLL–VP16–ER–HA,
respectively. The activation domain present in the full–length MLL protein might
contact other factors than the VP16 activation domain. Furthermore
MLL–VP16–ER–HA lacks the C–terminal SET–domain, which might as well recruit
factors that are important for modulation of the activating function of MLL.
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Figure 31. Full–length MLL as well as leukemic MLL fusion proteins activate p21 promoter
sequences. A. Transcriptional activation of p21 –215 / +8 as shown in a transient transfection
experiment in FDCPmix. B. MLL and MLL–VP16–HA were compared in their capacity to activate
different regions of the p21 promoter. Reporter and expression constructs were transfected transiently
into HepG2 cells.
3.5.3.3 SP1 overexpression does not affect p21 activation by
MLL–VP16–ER–HA
Hoxa9, c–myc and p21 promoters all contain binding sites for SP1. However
Gal–SP1 failed to recruit MLL–VP16–ER–HA to the Hoxa9 promoter (see 3.4.2.2).
Using the p21 promoter this finding was to be controlled in a transient transfection
experiment. U937 cells stably expressing MLL–VP16–ER–HA were transiently
transfected with either one of two different p21 reporter plasmid variants and an
expression plasmid for SP1 protein. The cells were incubated for 17 hours before
induction of MLL–VP16–ER–HA activity via addition of Tamoxifen. Eventually
luciferase levels were measured 24 hours post induction. No significant change in
activation could be seen, however, depending on SP1 expression (Fig. 32). Taken
together with results from the Hoxa9 and the c–myc promoter analyses this finding
supports a model according to which MLL–VP16–ER–HA is recruited to SP1 sites in
a SP1 protein independent manner.
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Figure 32. SP1–overexpression does not enhance MLL–VP16–ER–HA activated transcription of an
episomal p21 reporter construct. U937 cells stably expressing MLL–VP16–ER–HA were
co–transfected with an expression construct for SP1 and two different variants of p21 reporter
plasmids. MLL–VP16–ER–HA activity was induced by Tamoxifen and luciferase expression was
determined.
3.5.3.4 Expression of endogenous p21 mRNA after induction of
MLL–VP16–ER–HA activity
Given that all p21 constructs were tested in transient reporter assays the obvious
question was whether changes in transcriptional activity of the chromosomal
p21 locus could be observed as a consequence of MLL–VP16–ER–HA induction. In
order to determine p21 mRNA levels RT–PCR was performed. RNA was isolated
from different cell lines and quantitative PCR technology was used for amplification of
cDNA sequences. In the case of MLL–VP16–ER–HA FDCP mix cells only a minor
increase of p21 mRNA synthesis could be detected following induction of the
MLL fusion construct (Fig. 33) in comparison with a control cell line expressing
VP16–ER–HA. A similar picture was obtained in U937 cells transgenic for
MLL–VP16–ER–HA. Here the concentration of p21 mRNA increased by about
20 percent after induction (Fig. 33).
One explanation for the lack of activation of endogenous p21 by MLL–VP16–ER–HA
could be heterochromatin formation on the chromosomal site, which would render the
promoter inaccessible. RT–PCR results, however, showed that the endogenous p21
gene is not transcriptionally silenced as indicated by relatively low ct values (Fig. 33,
0
10
20
30
40
50
60
70
1 2 3 4
fo
ld
 in
du
ct
io
n 
by
 M
LL
–E
R
–V
P
16
–H
A
p21 -2325/+8p21 -215/+8
CM
V-
SP
1
CM
V-
SP
1
co
ntr
ol
co
ntr
ol
Results                                                                                                                      104
table). This led to the idea that constitutive transcription (possibly driven by
endogenous MLL), which is taking place without induction of MLL fusion protein
activity, is high that the MLL–VP16–ER–HA effect is not detectable in this situation.
To circumvent this scenario mouse embryonic fibroblasts (MEFs) harbouring a
homozygous MLL deletion were analyzed. Stable cell lines were created that
expressed inducible MLL–VP16–ER–HA or VP16–ER–HA, respectively, in a
MLL – / – background. These cells do not express any endogenous MLL protein,
hence MLL dependent transcriptional activation is only expected after induction of
MLL–VP16–ER–HA. However, no striking difference as compared to a wild type
background could be observed. Induction of VP16–ER–HA led to a slight
downregulation, while p21 mRNA amounts increased marginally after induction of
MLL–VP16–ER–HA (Fig. 33). This argues against the hypothesis that endogenous
MLL–driven transcription of the gene is responsible for the lack of induction by the
fusion protein. These results underline the fact that the chromosomal gene obviously
underlies an additional level of regulation, which does not apply to the reporter
plasmids.
Figure 33. Expression of endogenous p21 measured by RT–PCR. Different cell lines all stably
expressing MLL–VP16–ER–HA or ER–VP16–HA were induced with Tamoxifen, mRNA was isolated
and p21 expression was analyzed using gene–specific primers for Real–Time–PCR. The table shows
ct values of the Real–Time–PCR reactions of the non–induced samples. Values were normalized to
β–actin levels and induction rates were calculated, which are shown in the diagrams.
ct values p21 actin
FDCPmix 22.54 +/– 0.29 16.36 +/– 0.20
U937 21.63 +/– 0.19 16.32 +/– 0.11
MLL –/– MEFs 20.25 +/– 0.06 15.66 +/– 0.07
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3.5.3.5 MLL–VP16–ER–HA activated transcription of episomally stable p21
reporters
The striking difference between the effect of MLL–VP16–ER–HA in transient reporter
assays and the transcriptional regulation of the endogenous p21 gene was the
starting point for another experiment. It is known that EBV–based vector DNA that is
maintained stably in mammalian cell lines is bound by histones and nucleosomes are
formed (Zhou et al. 2005). These vectors can therefore be considered an
intermediate between transient DNA and chromosomal loci and provide for a genetic
tool in mammalian cells that can be used to study chromatin–dependent processes.
Both the longer and the shorter versions of the human p21 promoter have been
cloned into an EBV–based luciferase vector. U937 cells stably expressing
MLL–VP16–ER–HA were transfected with these constructs and luciferase levels
were measured after selection of stable cells. The shorter –215 / +8 construct was
induced approximately 30–fold, while the longer –2325 / +8 construct was induced
about 75–fold (Fig. 34). This is in striking contrast with the results of the transient
analysis where the shorter construct showed a 10–fold higher induction rate than the
–2325 /+8 construct (Fig. 29). Furthermore the overall induction levels observed in
the transient analysis were much higher. It is tempting to speculate that the reduced
overall induction rates of the episomal reporters as compared to the transient
analysis are a consequence of chromatin formation. Obviously the p21 promoter
constructs contained in the episomal constructs are subject to an additional level of
transcriptional control that leads to lower expression rates. This might reflect the
intermediate state of the EBV–based constructs between transient reporter plasmids,
which are dramatically induced, on the one hand and the chromosomal gene, whose
transcription is hardly upregulated on the other hand. Considering the role of the
full–length MLL protein as transcription maintenance factor it is intriguing that gene
activation through MLL–VP16–ER–HA is controlled on the epigenetic level.
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Figure 34. MLL–VP16–ER–HA is activating the p21 promoter on episomally stable reporter vectors.
EBV–based reporter plasmids containing p21 promoter sequences were used for transient reporter
assays as well as for generation of cell batches stably propagating these reporters. Luciferase levels
were measured after induction of MLL–VP16–ER–HA activity.
3.5.3.6 Influence of DNA methylation on activation of p21 transcription
To further explore the epigenetic control of activation by MLL–VP16–ER–HA it should
be tested whether DNA methylation might have an effect on this process. DNA
methylation presents a major cellular pathway for gene silencing. The MT domain
present in the N–terminus of MLL in particular suggests specificity for binding to DNA
depending on its methylation status (Birke et al. 2002). Drugs are available that block
DNA methylation. Deoxy–azacytidine, a nucletide analog that is incorporated into
DNA during replication and that, unlike cytosine, cannot be methylated, was applied
to test whether DNA methylation affects p21 activation by MLL–VP16–ER–HA.
U937 cells stably expressing MLL–VP16–ER–HA and propagating the EBV reporter
plasmid containing the p21 –215 / +8 fragment were were cultured in presence of
Azacytidine for 72 hours before induction of MLL–VP16–ER–HA activity by addition
of Tamoxifen. Luciferase levels were measured and RNA was prepared for analysis
of transcriptional activity via RT–PCR. As expected the basal transcription rate of
both p21 and luciferase increased following Deoxy–azacytidine treatment (Fig. 35A).
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Figure 35. MLL–VP16–ER–HA dependent transcription of p21 after inhibition of DNA methylation.
U937 cells stably expressing MLL–VP16–ER–HA and episomally replicating a reporter construct
containing p21 –215 / +8 were treated with Deoxy–azacytidine for 72 hours before induction with
Tamoxifen. A. RT–PCR analysis of the influence of Deoxy–azacytidine on basal expression levels of
p21 and luciferase. B. Luciferase levels measured in Tamoxifen–induced cells that were cultured in
presence or absence of Deoxy–azacytidine. C. and D. RT–PCR analysis of the effect of
MLL–VP16–ER–HA on mRNA levels of luciferase and p21, respectively. The graphs are showing the
fold increase of mRNA after induction of MLL–VP16–ER–HA activity.
The luciferase induction rate, however, was decreased (Fig. 35B), while absolute
levels increased. Also luciferase mRNA induction levels were reduced (Fig. 35C).
The impairment of MLL–VP16–ER–HA activation of the reporter gene is unexpected
since the MLL MT-domain is thought to bind CpG dinucleotides with a preference for
non–methylated DNA, which would supposedly lead to higher induction rates. One
explanation might be impaired binding of MLL–VP16–ER–HA to Deoxy–azacytidine
containing DNA as compared to cytidine–containing DNA.
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p21 induction rates were very low as observed earlier and not significantly increased
after treatment of the cells with Deoxy–azacytidine (Fig. 35D) suggesting that
methylation alone of the endogenous p21 is not sufficient to block activation through
MLL–VP16–ER–HA. Considering the close link of DNA methylation and other
silencing mechanisms like histone deacetylation it might be possible that more than
one regulatory mechanism render the p21 gene non–responsive to
MLL–VP16–ER–HA.
3.5.4 Overview: results from reporter gene experiments
In an effort to summarize the results from the analyses of three different target gene
promoters described in this work the different promoter variants were compared with
the wild type sequences using a bioinformatic tool called MatInspector. Based on an
archive of binding matrices (appendix 6.3) this program assigns all known
transcription factors to a given input sequence. By comparison of luciferase induction
levels the mutants were rated as "gain of function" or "loss of function" mutants,
respectively. Any binding site that was introduced in a gain of function mutant was
assumed to have a positive regulatory role for activation by
MLL–VP16–ER–HA (orange boxes) and binding sites lost in the same mutant in
comparison with the WT sequence were assumed to have a negative function (green
boxes, Table 10). In the same way binding sites of the loss of function mutants were
treated: sites only present in the WT sequence were rated as positive regulatory
elements (orange boxes), sites only present in the mutant sequences as negative
regulatory elements (green boxes). This classification per se is simplifying and
therefore any picture emerging from this analysis has to be considered only in
context of the corresponding experimental evidence. It can be used, however, as a
preliminary approximation.
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Table 10. Overview reporter assay results.
Rows represent transcription factor binding matrices as identified by MatInspector (www.genomatix.de;
for a comprehensive list of Genomatix matrices see also appendix 6.3). Positive influence on the effect of
MLL–VP16–ER–HA as observed in reporter assays is indicated by an orange square in the column
representing a given mutant promoter construct. Green squares indicate matrices that led to impaired
induction by MLL–VP16–ER–HA. Matrices that have been identified as positive regulatory sequences in
at least three different constructs are highlighted in blue and represent candidate binding sites for
MLL–VP16–ER–HA.
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V$GATA/GATA1.02  
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V$HNF1/HNF1.03   
V$HOXC/PBX_HOXA9.01    
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V$MINI/MUSCLE_INI.02  
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V$RREB/RREB1.01  
V$RXRF/VDR_RXR.03  
V$RXRF/VDR_RXR.05  
V$SATB/SATB1.01  
V$SORY/SOX5.01  
V$SORY/SOX9.01  
V$SP1F/GC.01   
V$SP1F/SP1.01     
V$SP1F/SP1.02   
V$SP1F/SP2.01  
V$STAF/ZNF76_143.01  
V$STAT/STAT1.01  
V$ZBPF/ZBP89.01   
V$ZBPF/ZF9.01     
V$ZBPF/ZNF219.01    
V$ZF5F/ZF5.01    
Matrices that have been rated "activating" (orange) in at least three mutant
constructs have been highlighted in blue. These matrices comprise candidate binding
sites for MLL–VP16–ER–HA (Table 11). With the exception of E2F.01 there is a clear
bias for GC rich matrices. Most of the sites are characterized by the presence of
either a GGG or a GGGG motif confirming the earlier findings that G–rich motifs
mediate activation by MLL–VP16–ER–HA.
Alternatively the proteins binding to these sequences can be considered candidates
for interactors or recruitment factors, respectively, of MLL fusions. In this respect it
seems to be intriguing that most of the proteins in this list are zinc finger proteins
raising the possibility MLL proteins generally contact DNA through zinc finger
proteins.
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Table 11. Candidate matrices for MLL–ER–VP16–HA action.
Matrix1 Factor IUPAC consensus sequence2
V$E2FF/E2F.01 E2F, p107 protein gcgcGAAAa
V$EGRF/WT1.01 Wilms Tumor Suppressor gYGGGgg
V$EKLF/BKLF.01 Basic krueppel-like factor (KLF3) GGGTg
V$EKLF/KKLF.01 Kidney-enriched kruppel-like factor,KLF15 GGGGmg
V$MAZF/MAZR.01 MYC-associated zinc finger proteinrelated transcription factor gggGGGG
V$PLAG/PLAG1.01 Pleomorphic adenoma gene (PLAG) 1 GRGGsncnnnnnrggg
V$SP1F/SP1.01 Stimulating protein 1 GGGCggg
V$ZBPF/ZF9.01 Core promoter-binding protein (CPBP)with 3 Krueppel-type zinc fingers CCRCccc
V$ZBPF/ZNF219.01
Kruppel-like
zinc finger protein 219
CCCCc
1: for more detail see www.genomatix.de
2: according to MatInspector. Core matrices are indicated by capital letters. G–rich sequences present
in this core are shaded in red.
3.6 Microarray analysis of MLL–VP16–ER–HA target genes
A genome-wide expression analysis was carried out using microarray technology.
The Affymetrix GeneChip 430 2.0 was used, representing more than 39.000
transcripts from the mouse genome. For detection of target gene populations of
physiological relevance the FDCP mix cell line stably expressing MLL–VP16–ER–HA
was chosen for the experiment. Total RNA was isolated 30 minutes, 3 hours and
12 hours after induction of the fusion protein. RT–PCR analysis was performed using
Meis 1–specific primer pairs in order to check for the response of a known
physiological target of MLL fusion proteins. After 3 hours Meis 1 mRNA amounts had
already increased 3–fold (Fig. 24). After 12 hours the mRNA concentration was still
at a higher level than before induction. Interestingly, in the case of the control cell
line (VP16–ER–HA) a even faster kinetic could be observed: after 3 hours Meis 1
was already downregulated. It has been reported many times that overexpression of
transcriptional activators lead to a phenomenon called "squelching": limiting factors
are titrated out by the large amount of activation domains and the general
transcription rate is reduced. The strong downregulation after 30 minutes of
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induction, however, is illustrating nicely the fast response of the ER–system. It also
suggests that Meis 1 mRNA molecules have a rather short half–life. In contrast to the
MLL–VP16–ER–HA cell line mRNA levels were back to pre–induction levels after
3 hours. Together these results show that both protein variants can be activated
quickly with a certain variation possibly depending on size differences and higher
expression levels. The fact that a known target gene is activated by induction of
MLL–VP16–ER–HA but not by another ER fusion protein is providing evidence for
the physiological relevance of the experimental set–up.
The numbers of deregulated genes suggest that MLL–VP16–ER–HA after induction
exerts mainly an activating effect (Table 12). Even after 12 hours the expression of
only 57 genes was reported to be downregulated as opposed to 223 upregulated
genes. At the earlier time points this becomes even more obvious. For complete lists
of genes see appendix 6.2.
Table 12. Total number of deregulated genes following induction of
MLL–ER–VP16–HA.
30 min 3 hours 12 hours
upregulated 23 112 223
downregulated 1 6 57
One way to analyze microarray data is to classify the target genes according to Gene
Ontology terms. There were some biological processes whose representation
changed over the course of induction. The numbers of upregulated genes involved in
morphogenesis, organ development and cell communication increased from 3 to
12 hours after induction while the number of genes with negative regulatory functions
decreased in comparison with the total number of upregulated genes (Fig. 36 A).
However, it should be noted that the absolute number of negative regulators for
example does not change and most of those, which are upregulated after 3 hours are
also upregulated after 12 hours, e. g. the cell cycle regulators p27 and p18. The
observed upregulation of these kinases is in one line with earlier reports that these
genes are targeted by MLL.
Target genes can also be sorted according to the molecular function which is
assigned by Gene Ontology. An upregulation of proteins with nucleic acid binding
capacity was observed as well as an transient increase in expression of
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transcriptional activators after 3 hours of induction (Fig. 36 B). This result might
indicate the upregulation of activators and DNA binding proteins through
MLL–VP16–ER–HA, which as a consequence could lead to subsequent
reprogramming of transcriptional activity which has to be considered a secondary
effect. Especially in the 12 hours sample a considerable number of genes might not
be subject to direct regulation through MLL fusion proteins.
Figure 36. Classification of microarray targets according to Gene Ontology terms. The graphs are
showing the relative numbers of certain classes at a given time point. A. Genes grouped due to
assignment to certain biological processes. B. Classification according to molecular functions
assigned to the genes by the Gene Ontology system.
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In an independent microarray experiment analysis of gene expression patterns
23 hours after induction revealed downregulation of several genes, which are related
to myeloid differentiation (Table 13). This is in line with the general property of
oncogenes to support proliferative processes and counteract final differentiation of
stem cells.
Table 13. Genes that are downregulated 23 hours after MLL–ER–VP16–HA
induction
Mpo myeloperoxidase
MMP8 neutrophil collagenase precursor
matrix metalloproteinase 8
Ngp neutrophilic granule protein
Lcn2 Neutrophil gelatinase-associated lipocalin precursor
(NGAL) (P25)
lipocalin 2
EL2 neutrophil elastase
Ly6c lymphocyte antigen 6 complex, locus C
IL3R; IL3RB2 Interleukin-3 receptor class II beta chain precursor
Mbp2 eosinophil major basic protein 2
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Upregulated gene populations were analyzed using Bibliosphere
(www.genomatix.de), a bioinformatic tool developed recently to facilitate
literature–based array data–mining. This web–based search engine is sorting genes
according to co–citation in the NCBI database. Analysing the list for genes
upregulated after 0.5 hours a correlation was detected with four transcription factors,
one of which is c–jun. It is intriguing that out of 15 analysed target genes 6 were co-
cited together with c–jun and analysis of their promoter regions also revealed binding
sites for the protein (Table 14). Using these data a network was generated proposing
a central role for c–jun (Fig. 37A). Analysis of later time points after induction of
MLL–VP16–ER–HA led to a much higher complexity of the proposed regulatory
networks (Fig. 37B,C).
Table 14. Microarray target
genes that were co-cited
together with c–Jun. Presence
of a binding site for c–Jun or
AP1, respectively, is indicated
by shaded boxes and +.
Gene Jun / AP1site
Tox
Ptpn12 +
D230007K08Rik +
Pfn3
Mbnl1
Gpbp1
Krit1
Zfhx1b +
Ern1 +
Nedd4l
Dgkd
Myo1b
Pacs1 +
Clpx
Exoc4 +
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Figure 37. Predicted regulatory network based on microarray data leading to upregulation of genes
whose expression increased following MLL–ER–VP16–HA induction. A. Genes upregulated after
30 min. B. Genes upregulated after 3 hours. C. Genes upregulated after 12 hours. Blue boxes: genes
identified via microarray. White boxes: transcription factors that are co–cited together with target
genes. Green lines: positive regulatory effects.
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A more direct bioinformatic approach is to analyze promoter sequences with respect
to binding matrices for transcription factors. Using the Gene2Promoter software the
lists of upregulated genes were analyzed in this way. Interestingly matrices that were
statistically over–represented in the 30 min sample as well as in the 3 hours sample
were the matrix families for cut–like homeobox (CLOX) and for homeobox (HOXF)
factors, the latter of which could also be found in the 12 hours sample (Table 15).
The same type of analysis was performed using three known targets of
MLL–VP16–ER–HA, Hoxa9, p21 and c-myc, as an input. It was intriguing to find
amongst the matrices that were identified to be statistically over–represented also the
CLOX and HOXF matrices. The CLOX matrix family comprises several binding sites
that are recognized by the Cut–like homedomain protein Cutl1. Cutl1 codes for a
transcriptional repressor that binds to CCAAT motifs in eukaryotic promoters
negatively regulating gene expression. The fact that Cutl1 binding sites are present in
the majority of genes upregulated by MLL–VP16–ER–HA could indicate that these
motifs are also targeted by MLL fusion proteins. In this case they would compete for
these binding site with a transcriptional repressor leading to upregulation of the gene.
The HOXF matrix family contains binding sites for several homeobox proteins
amongst which notably is Hoxa9. The presence of these sites in genes upregulated
after induction of MLL–VP16–ER–HA activity could indicate either direct targeting of
these genes by the MLL fusions or by Hoxa9, which is itself targeted by MLL fusions.
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Table 15. Predicted matrix families common to target gene promoters
matrix
family1:
microarray
30 min
microarray
3 hours
microarray
12 hours
Hoxa9
p21
c-myc
AP1R
CLOX
CREB
E2FF
EGRF
EKLF
FKHD
GATA
HOXF
INSM
MZF1
NKXH
NR2F
PAX5
SP1F
ZBPF
1: as identified by Gene2Promoter (www.genomatix.de)
Discussion                                                                                                                 122
4. Discussion
4.1 Definition of critical regions in the Hoxa9 promoter
Hox genes are the paradigm for MLL target genes. Early mouse knockout studies
indicated a role for MLL in the transcriptional regulation of the developmental gene
Hoxa9 (Yu et al. 1995). Over the last decade a body of data was collected showing
that Hoxa9 upregulation by MLL fusion proteins is a key feature of
11q23 leukemias (Kawagoe et al. 1999; Rozovskaia et al. 2001; Armstrong et al.
2002; Imamura et al. 2002; Ferrando et al. 2003; Zeisig et al. 2004b). Using ChIP
technology physical association of the MLL protein with the Hoxa9 upstream region
could be demonstrated (Milne et al. 2002; Nakamura et al. 2002).
However, the mechanism of MLL recruitment to this promoter is largely unknown. No
functional data were available so far as to which upstream sequences are required
for activation by MLL and MLL fusions. MLL target sites had not been identified and
no detailed information was available up to this point as to what are the elements in
the Hoxa9 promoter sequence that mediate the response to MLL proteins. In this
study the effect of an inducible MLL fusion protein on Hoxa9 reporter constructs was
investigated. The fusion with the viral activation domain VP16 was reported to be
functional as an oncogene (So and Cleary 2003; Zeisig et al. 2003). In concordance
with this finding the inducible MLL–VP16–ER–HA protein used in this study not only
strongly activated MLL target gene reporters (e.g. Hoxa9, Hoxa7) but also
upregulated endogenous target genes as assessed by RT–PCR (Hoxa9, Meis1).
Episomally stable reporter cell lines allowed the analysis of reporter gene effects on a
more physiological level than possible in transient transfection assays. The stable
propagation has some consequences that render results more biologically relevant:
1. The transfected constructs are replicated by the host cell DNA replication
machinery and therefore chromatin formation takes place like on mammalian
chromosomes making these vectors more similar to a genomic template (Zhou et al.
2005).
2. Cells can be selected that propagate the EBV–based reporter plasmid. Since also
the inducible MLL fusion protein is expressed stably in the same cells analysis of a
homogenous cell population is possible. The copy numbers of these episomes range
between 5 and 20 which also resembles the situation of a chromosomal target gene
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much more than a transiently transfected reporter plasmid, which is usually present
at much higher copy numbers (Mackey and Sugden 1999).
ChIP experiments employing monoclonal antibodies raised against the
MLL aminoterminus showed induced binding of MLL–VP16–ER–HA not only to the
endogenous Hoxa9 promoter but also to the episomal reporter plasmid.
Using a series of different Hoxa9 promoter fragments it was possible to identify a
genomic region of only 164 bp (–118 / +46) as being critical for the induction by
MLL–VP16–ER–HA. Fine–mapping revealed that the major activation capacity
resides in a short sequence stretch of only 40 nucleotides (-118 / -79). Deletion of
this region decreased dramatically the response to the MLL fusion protein indicating
that MLL fusion protein binding is taking place in this region.
4.2 MLL–VP16–ER–HA acts on the core promoter region of Hoxa9
The shortened construct (–78 / +46), however, retains some capacity to mediate the
response to MLL–VP16–ER–HA. This might hint at MLL fusion protein recruitment to
this fragment as well, even if only to a lesser extent, raising the question whether
MLL fusion proteins act at core promoter regions. Recently a role for MLL as a
general transcription factor has been proposed since ChIP–chip studies showed
co–occupancy with RNA polymerase II on the majority of gene promoters (Guenther
et al. 2005). In fact both the aminoterminal and the carboxyterminal moiety of MLL
interact with the CTD of RNA polymerase II in vitro (Milne et al. 2005a). On some
genes MLL was seen to be required for RNA polymerase II recruitment, as examined
by single gene ChIP analysis, but this does not hold true on a global scale (Milne et
al. 2005a). There are genes where binding of MLL seems to be a prerequisite for
RNA polymerase II binding and transcription but other genes are transcribed
independently of MLL binding.
 In this study site–directed mutagenesis of core promoter features revealed the
involvement of Hoxa9 core promoter sequences in MLL fusion protein recruitment. It
was demonstrated that upmutation of the endogenous Hoxa9 TATA box to the
consensus sequence as present in the AdML promoter augments transcription
suggesting that MLL fusion proteins are recruited to the core promoter region through
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proteins specifically binding to TATA–box motifs. TFIIA, which associates with
TBP–TATA box complexes is a good candidate since it has been reported that TFIIA
is processed by Taspase (Zhou et al. 2006), the same protease that is also involved
in MLL protein processing (Hsieh et al. 2003a). It could be speculated that Taspase
establishes a contact between TFIIA and MLL. This contact could stabilize binding of
MLL proteins to upstream activating sequences and facilitate transcriptional
activation (Fig. 38A). Alternatively, the interaction of MLL with the CTD of
RNA polymerase may be the link between motifs in the core promoter and
MLL fusion protein driven activation of transcription.
It is not the case, however, that core promoter mutations lead to induction rate
changes that mirror the effect of MLL–VP16–ER–HA on basal transcription. This
would be expected for a model where impaired MLL function is a direct consequence
of impaired binding of general transcription factors as described above. The
differential effects of core promoter mutations on basal and MLL–VP16–ER–HA
driven transcription favor a model in which MLL fusion protein binding to Hoxa9
promoter sequences is taking place independent of components of the basal
machinery. Particularly intriguing are the effects observed with mutants where a
cytosine heptarepeat was targeted that is located between TATA box and Inr. No
general transcription factors are known that specifically bind to this sequence
element, nevertheless basal transcription levels are significantly decreased. The
same mutation is also affecting activated transcription induced by
MLL–VP16–ER–HA. Based on these observations a model can be envisaged where
both the wild type and MLL fusion proteins bind to this motif in a competitive manner.
In normal hematopoiesis full–length MLL might bind this sequence and modulate
Hoxa9 expression leading to maintenance of transcription on a low level. In the
heterozygous state MLL fusion proteins might compete with wild type protein for this
motif. Given that these two MLL protein variants very likely have a different spectrum
of interaction partners the protein complexes assembled on the promoter might be
completely different. It has been reported that full–length MLL can be found in a
complex together with a variety of complexes and proteins involved in transcriptional
regulation. Also negative regulators like the NuRD complex and Sin3A are found in
this complex (Nakamura et al. 2002). These interactions have not been mapped
precisely, hence one could speculate that the C–terminal MLL moiety is binding
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these factors. To date no protein complex has been purified clarifying the interactions
that MLL fusion proteins are involved in. It is likely, however, that those binding
partners, which contact the MLL C–terminus do not interact with MLL fusion proteins.
Factors might be lost that in the wild type situation ensure a delicate equilibrium of
transcription of Hoxa9 (Fig. 38B). Furthermore the C–terminal MLL moiety might itself
exert negative effects on promoter complexes. Loss of these repressing functions in
MLL fusion protein complexes and the presence of strong activation domains could
lead to overexpression of Hoxa9 as observed in leukemias (Fig. 38C).
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Figure 38. Model for the interplay between MLL and core promoter sequences. A. Model for an
indirect contact throug Taspase. Binding of the basal transcriptional machinery (grey) to the TATA box
via TBP. TFIIA (brown) interacts with Taspase (violet), which might simultaneously contact the
MLL N–terminus (red), which is recruited to the promoter by upstream activating sequences (UAS,
yellow). The contact to Taspase might stabilize MLL fusion protein binding so that transcription can be
activated through interaction with coactivator complexes (dark green). The binding of MLL fusion
proteins to UAS might also be stabilized by interaction with the CTD of hRpb1. B. Direct binding of
full–length MLL protein to core promoter features like the C–stretch (yellow) identified in Hoxa9 might
maintain transcription on a moderate level through multiple interactions with transcriptional
co–repressors and co–activators (light blue and pink). The MLL C–terminus (light green) might itself
exert regulatory effects on transcription contributing to a balanced transcription level. C. In the case of
MLL–VP16–ER–HA binding to these core promoter sequences overexpression might result from the
presence of the activation domain without the compensating effects of factors found in the promoter
complexes containing wild type MLL.
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4.3 A model for MLL binding to upstream activating sequences
4.3.1 Heterogeneity in the sequence motifs recruiting MLL–VP16–ER–HA
The models proposed above for MLL protein action on core promoter sequences
illustrate a general uncertainty in this field of research as to what might be the binding
specificities of MLL proteins. Structural features of the MLL aminoterminus have led
to a model according to which this part of the protein is responsible for DNA binding.
The presence of three AT hooks is intriguing and it was reported that the MLL
AT hooks bind DNA depending less on the sequence than on cruciform structure of
the target (Zeleznik-Le et al. 1994). The MLL MT domain on the other hand was
shown to bind DNA with a preference for non–methylated CpGs (Birke et al. 2002).
No sequence elements, however, have been identified in mammals that recruit MLL
or other TrxG or PcG proteins. In Drosophila genomic fragments of typically some
kilobases in length have been identified that are responsible for the transcriptional
maintenance of a given region (Orlando 2003). Polycomb/Trithorax Response
Elements (PRE/TREs) have been identified that can be transferred to another
genomic context where they exert similar effects. It has been difficult so far to
discover a consensus sequence in these response elements. Using bioinformatics it
has been possible, however, to identify short sequence motifs that are common to all
these elements (Ringrose et al. 2003).
In the study presented here the promoter sequences of Hoxa9 and two other MLL
targets, p21 and c–myc, have been analyzed in detail to understand the mechanism
of MLL and MLL fusion protein recruitment to promoters. Several motifs could be
identified that mediate the response to MLL–VP16–ER–HA:
• Predicted Homeobox protein binding sites (in particular H3; TGATTTA) in the
Hoxa9 promoter facilitate activation by MLL–VP16–ER–HA. Interestingly mutation
of these sites led to increased basal levels suggesting that Hoxa9 protein binding
to its own promoter might negatively regulate transcription. Instead of recruitment
of MLL–VP16–ER–HA through Hoxa9 protein direct binding of
MLL–VP16–ER–HA to these motifs and competition with Homeobox proteins
seems more likely.
• E–box sites (CTCGAG) were identified that could reconstitute
MLL–VP16–ER–HA driven activation of a Hoxa9 promoter mutant. Known
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interactors with these sequence motifs include for example the transcription factor
USF or the myc/Max-heterodimer none of which have been reported to interact
with MLL or MLL fusion proteins.
• Noteworthy it could be demonstrated that a G–rich motif, which is present in the
promoters of Hoxa9, p21 and c–myc plays a pivotal role in activation through
MLL–VP16–ER–HA. Three copies of the motif GGGC are present in the
Hoxa9 –207 / +46 promoter and it could be shown that point mutation of these
motifs leads to a reduction in activation by MLL–VP16–ER–HA. Two regions were
identified in the human p21 promoter (–122 / –60 and –215 / –144) that are
essential for transcriptional activation of a luciferase reporter gene through
MLL–VP16–ER–HA. Strikingly multiple copies of the same GGGC motif can be
found in these regions. Also the promoter of the cellular proto–oncogene c–myc
contains three GGGC motifs, which are absent in the mutant promoter versions
that could no longer be activated by MLL–VP16–ER–HA indicating that
MLL fusion proteins are targeted to promoters through GGGC motifs. Mutation of
these motifs from GGGC to GGGG in the context of Hoxa9 –207 / +46 did not
impair activation by MLL–VP16–ER–HA, however (see CpG mutant 1,
alignments). Interestingly, the promoter sequences of Cutl1, a new candidate
target gene for MLL–VP16–ER–HA identified in this work and also the promoter
sequences of the MLL targets p18 and p27 are characterized by multiple copies of
GGGC / GGGG motifs (suppl. Fig. 1, appendix 6.4). Furthermore, the GGGG
sequence motif is present in the artificial Hoxa9 variant constructs MZF1 and
MAZR1,2 and 3, which showed increased induction rates. Taken together these
data suggest that MLL fusions bind to both GGGC and GGGG motifs.
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4.3.2 MLL–VP16–ER–HA might compete with other transcription factors.
The presence of these motifs in the consensus sequences of other transcription
factors is intriguing and leads to the question whether MLL fusion proteins are
recruited through other DNA binding proteins. The GGGC motif is found in the
binding matrix for SP1 (GGGCggg) and one could speculate about targeting of
MLL fusions to promoters via interaction with SP1 protein. The data presented here,
however, do not support this hypothesis. Targeting of GAL–SP1 to a GAL–Hoxa9
promoter did not affect activation by MLL–VP16–ER–HA. Furthermore no increase of
induction of a p21 reporter gene by MLL–VP16–ER–HA was observed after
overexpression of SP1 protein. The results of this study rather argue for a direct
binding mechanism, where MLL contacts DNA directly, e.g. through its MT domain.
In such a scenario SP1 would probably compete with MLL and MLL fusion proteins
for binding to DNA target sequences. In particular for promoters, in which multiple
SP1 binding sites are present this might mean that normal transcription of these
genes is driven by both SP1 and MLL binding to the promoter (Fig. 39A). Competition
of the two factors will, however, in some cases lead to occupancy of the promoter by
MLL only. Due to the balancing functions that full–length MLL might exert in contrast
to MLL fusions (see also 4.2) this might not significantly change transcription rates of
the gene in wild type cells (Fig. 39C). In leukemic cells expressing a MLL fusion
protein this statistic event in which both sites are occupied by MLL fusion proteins
might lead to a different outcome: lacking the balancing effects of the wild type
protein that could counteract the strong transcriptional activation these proteins might
induce overexpression of the gene (Fig. 39D).
The GGGG motif is contained in both the binding matrices of myc–associated zinc
finger protein related transcription factor (MAZR, matrix: gggGGGG) and the myeloid
zinc finger protein 1 (MZF1, matrix: GGGGa). MAZR contains a BTB/POZ domain
(Bardwell and Treisman 1994; Zollman et al. 1994), which has been shown to be
involved in formation of homo–oligomers and hetero–oligomers together with
Bach2 (Kobayashi et al. 2000). The BTB/POZ domain has been reported to contact
the co–repressor complexes SMRT and N–CoR (Deweindt et al. 1995; Huynh and
Bardwell 1998; Wong and Privalsky 1998). Recently it was shown that MAZR binds
Discussion                                                                                                                 130
to the Cd8 enhancer and negatively regulates transcription through recruitment of
N–CoR (Bilic et al. 2006).
MZF1 is expressed in myeloid progenitor cells and binds to DNA through its zinc
finger domains (Morris et al. 1994). Deletion of MZF1 in mice leads to lethal
neoplasia and MZF1 –/– hematopoietic progenitor cells show an increase in
autonomous proliferation indicating a role for MZF1 as a tumor suppressor (Gaboli et
al. 2001).
In the light of the biological functions of MAZR and MZF1 a model might be proposed
where MLL fusion proteins bind to GGGC and GGGG in competition with other
transcription factors. Leukemogenesis could be triggered through MLL fusion
proteins binding to GGGG motifs instead of MAZR: repression might be substituted
by strong transcriptional activation leading to overexpression of MLL target genes like
Hoxa9. This might happen in a similar fashion to the one described for SP1 above.
Figure 39B illustrates a situation where normal transcription is regulated by MLL and
MAZR, which is acting as a repressor. The consequence of MLL and MLL fusion
binding would be the same as described above: negative regulation of the gene
through MAZR might be lost, while the MLL fusion protein is providing for strong
activation (Fig. 39D). If MLL fusions compete efficiently with MZF1 protein the
functions of the tumor suppressor might be impaired leading to a similar phenotype
as observed in MZF1 –/– mice: autonomous proliferation of myeloid cells that could
ultimately lead to leukemia. As discussed before for MLL–VP16–ER–HA targeting
core promoter sequences the differences between the effector domains associated
with wild type MLL and MLL fusions might be critical. Disturbances in a delicate
equilibrium maintained by wild type MLL might be enough for transformation of
heterozygous cells. Additional experiments are required to clarify the relationship
between MLL fusion proteins and these proteins. Co–transfection with
MLL–VP16–ER–HA and overexpression of MAZR and MZF1 might provide insights
into the mechanism by which MLL fusions are targeted to the G–rich motifs.
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Figure 39. Competition of MLL with other transcription factors. A. SP1 (yellow) binding to its binding
site in the promoter (light blue) positively regulates transcription of the gene. MLL wild type
protein (red and light green) exerts both positive and negative effects and stabilizes transcription on a
moderate level. The basal machinery and the mediator complex are shown in grey and dark green,
respectively. B. Binding of MAZR (dark blue) to its binding site negatively affects the transcription rate
through interaction with the corepressor complex N–CoR (pink), while MLL sustains transcription at a
low level. C. MLL wild type protein binding without SP1 or MAZR does not lead to overexpression due
to the balancing effects that are mediated through the C–terminal part of MLL and the complexes
interacting with it (not shown). D. Promoter occupancy by MLL–VP16–ER–HA only leads to loss of
transcriptional control and overexpression of the target gene.
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4.3.3 A two–module hypothesis for MLL binding
An interesting feature of the G–rich motifs is their presence in multiple copies in each
promoter. The analysis of the promoters of c–myc and p21 was particularly
instructive in this respect. Deletion of GGGC motifs in the p21 promoter through
deletion of either the region –215 / -144 or –122 / +60 led to dramatic loss of
induction by MLL–VP16–ER–HA. In the case of c–myc there were two different point
mutants analyzed, both of which lacked at least one GGGC motif present in the wild
type sequence.
The mutations are located in two adjacent regions of about 60 nucleotides each,
hence the spatial distribution of the mutated motifs resembles the one in the p21
promoter (see above). Just like in the case of the p21 mutation of only one of these
regions leads to loss of induction by MLL–VP16–ER–HA. If each of the regions would
be sufficient to bind MLL–VP16–ER–HA independent from the binding event taking
place on other such motifs in the promoter such a dramatic effect would not be
expected. The results demonstrated here rather argue for co–operative binding of
MLL–VP16–ER–HA to two adjacent regions of the p21 or the c–myc promoter,
respectively. Based on this hypothesis a model is proposed in which recruitment of
MLL–VP16–ER–HA requires two adjacent modules in a promoter sequence that
contain binding motifs. As illustrated by the schematic drawing each of these
modules might contain one or more binding sites for MLL–VP16–ER–HA (Fig. 40A).
In a simplified approximation two different mechanisms are possible:
A. Considering the large size of MLL and MLL fusion proteins and the flexibility of
DNA it is theoretically possible that one molecule contacts both modules (Fig. 40B).
The affinity of MLL–VP16–ER–HA to GGGC motifs is not known. The
MLL MT domain alone binds to DNA with a relatively low KD in the range of
10–8 M (Birke et al. 2002). One might speculate, however, that two contacts are
necessary to tether the protein tightly to the promoter. Another reason for the
requirement of two contacts could be correct positioning of MLL–VP16–ER–HA. This
could be the case if MLL–VP16–ER–HA has to be oriented in a certain way for
promoter complex assembly.
B. Two or more molecules of MLL–VP16–ER–HA might be involved (Fig. 40C).
Synergism in this case might be due to interaction of MLL–VP16–ER–HA with itself.
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Binding of one molecule to one module might greatly facilitate binding of other
molecules to the adjacent module.
Figure 40. Two–module binding model for MLL fusion proteins. A. Modular structure of promoter
elements mediating activation by MLL fusions. Grey boxes indicate regions that have been targeted by
mutagenesis and loss of which impairs activation. Red bars indicate the presence of putative MLL
fusion binding motifs. B. Model for the interaction of one MLL fusion protein molecule with both
modules at the same time. C. Model for promoter occupancy by more than one MLL fusion protein
molecule at a time. Both molecules could bind individual motifs, while binding of one molecule might
facilitate binding of another molecule in the close vicinity.
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4.3.4 Spatial distribution of binding sites is critical for MLL fusion protein
function
The analysis presented here indicates that not only GGGC can function as a binding
site for MLL–VP16–ER–HA. Also the related motif GGGG seems to recruit
MLL fusion proteins to target gene promoters. Furthermore other motifs like the
Hoxa9 binding site or E–box motifs have been shown in this study to stimulate
activation by MLL–VP16–ER–HA. These observations argue for moderate sequence
specificity of the MLL–DNA interaction. There seem to be multiple ways, however, to
compensate for the lack of stringency in sequence specific binding. The model
described above is postulating a requirement for two modules in a MLL target gene
promoter both of which contain one or more binding sites for MLL. This adds another
level of specificity to the process of promoter recognition by MLL, which is based on
combinatorial constraints. Using oligonucleotides, which resemble one of these
modules, however, an additional level of control was observed: three copies of an
E–box motif evenly distributed over 26 nucleotides led to significant increase of
transcriptional activation by MLL–VP16–ER–HA in comparison with a control
sequence. Shifting the 3' E–box only one nucleotide further downstream led to
induction rates only slightly over background. Irregular spacing of GGGC motifs in
the MAZR constructs decreased induction rates moderately. These findings indicate
that multiple copies of binding sites in MLL target modules can co-operate in MLL
recruitment. This co–operativity, however seems to depend on regular spacing
between the single binding motifs.
4.3.5 Epigenetic control of Hoxa9 transcriptional activation by
MLL–VP16–ER–HA
Published binding studies using the MLL MT domain as a bait have shown that this
part of the protein binds preferentially to non–methylated CpG rich DNA (Birke et al.
2002). Using site–directed mutagenesis of CpG dinucleotides in the Hoxa9 promoter
sequence it was demonstrated in this study that cytosine residues are not essential
for MLL recruitment. G–rich motifs (GGGC, GGGG), E–box motifs and a binding site
for Hoxa9 present in the Hoxa9 promoter could be shown to mediate activation by
MLL–VP16–ER–HA. Interestingly, mutation of cytosine residues in CpG rich regions
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of the Hoxa9 promoter dramatically increased induction by MLL–VP16–ER–HA.
Since methylation of DNA by cellular enzymes is blocked by substitution of cytosine
with guanosine nucleotides this phenomenon appears to provide a link between
DNA methylation and MLL fusion protein binding. This is in line with reports about
methylated DNA at the Hoxa locus (Hershko et al. 2003). The observed increase in
transcriptional activation by MLL–VP16–ER–HA might indicate a negative regulatory
role for cytosine residues in MLL target promoters. Specific binding to
non–methylated sites on the DNA has been reported for a number of transcription
factors like USF, NFkB and SP1 (Cowled et al. 2005; Fujii et al. 2006; Mulero-
Navarro et al. 2006). Based on the observation that MLL binding to the Hoxa9
promoter is mediated by GGGG as well as by GGGC a model is proposed in which
guanosine, not cytosine residues recruit MLL to CpG rich DNA. Cytosine residues in
these genomic reasons might rather function as modulators. Some of the stable cell
lines containing CpG mutant Hoxa9 constructs showed induction rates similar to wild
type while other (genetically identical) cell lines showed dramatically increased rates.
This could indicate a role for methylated cytosine residues in regulation of MLL
binding to the Hoxa9 promoter. The human Hoxa9 promoter is obviously targeted
very efficiently by MLL proteins. In order to maintain moderate expression levels
negative regulation of MLL binding might be required. A certain number of
methylated CpGs could be necessary to prevent excessive MLL recruitment. If this
critical threshold would be crossed by mutation of CpG to GpG uncontrolled
recruitment of MLL to the promoter could lead to overexpression.
A recent publication demonstrated that disruption of the MLL SET domain leads to
abnormal DNA methylation patterns at the Hoxd4 locus and homeotic transformation
in transgenic mice (Terranova et al. 2006). These results suggest that this truncated
protein variant somehow interferes with DNA methylation. There is no evidence so
far that MLL fusion constructs influence methylation patterns. The MT domain,
however, which is likely to be involved in this process, is retained in all fusion
proteins. Therefore one could think of transcriptional deregulation of certain
MLL target genes as a consequence of promoter methylation changes following
11q23 translocation.
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4.4 Identification and characterization of new target promoters
4.4.1 The human p21 promoter is targeted by MLL and MLL fusion proteins
Using inducible hematopoietic cell lines of human and murine origin in combination
with luciferase reporter constructs two new target genes for MLL fusion proteins were
identified.
It has been reported earlier that cyclin dependent kinase inhibitors are targets for
transcriptional regulation by MLL (Milne et al. 2005b). In the present study a new
target for MLL and MLL fusion proteins was identified that belongs to the same class:
experiments using different variants of the human p21 promoter could show that
MLL fusions as well as MLL full length protein activate transcription from these
sequences. The specificity of this process was shown not only by parallel
experiments using a stable control cell line expressing ER–VP–16–HA but also by
results from transient transfection experiments carried out in several cell lines that all
support the observations made initially in stable FDCPmix cells. RT–PCR analysis of
several cell lines could show only marginal increases in endogenous p21 mRNA
amounts, however. One possible reason for this could be the cell cycle dependent
transcription of the gene, which makes it difficult to detect transcriptional changes in
non-synchronized cell populations (Gartel and Radhakrishnan 2005). Alternatively,
epigenetic modifications of the endogenous locus might render it non–responsive to
induction of MLL–VP16–ER–HA activity.
A short sequence element (–215 / +8) conferred the highest induction rate, whereas
robust induction was also seen with a longer promoter variant (-2325 / +8). Via
mutation analysis two critical regions could be identified: –122 / –60 and –215 / +8.
Deletion of either one of these two sites was sufficient to reduce induction levels to
less than 10 percent. GGGC motifs are present in both of these regions and might
directly target MLL–VP16–ER–HA to these modules (see 4.3.3).
It could be shown that not only the synthetic protein MLL–VP16 fusion but also
MLL–AF4, MLL–AF9 and MLL full length activate transcription from the p21
promoter. Interestingly, the ∆ –122 / –60 mutation had a much stronger effect on
activation by MLL–VP16–HA than on activation by FLAG–MLL. This could be hinting
at different binding specificities of the full–length protein in comparison with
MLL fusion constructs. These differences in specificity are closely linked to the
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question whether there are certain "leukemogenic" subsets of genes that are only
targeted by the oncogenic fusion proteins but not by MLL.
4.4.2 Activation of p21 by MLL–VP16–ER–HA is dependent from the chromatin
environment
Analysis of p21 expression levels after induction of MLL–VP16–ER–HA in different
cell lines revealed a different response of the chromosomal p21 promoter in
comparison to the episomal reporters. No significant increase of transcription could
be observed analyzing mRNA derived from the chromosomal gene. In the same
cells, however, the increase of transcription from transient and episomal reporter
plasmids was dramatic. It has been reported that transcription from the p21 locus can
be inhibited by promoter methylation (Allan et al. 2000). In the same report it has
been demonstrated that introduction of the genomic p21 locus in a P–1 derived
artificial chromosome (PAC) can restore p21 expression showing that transcription is
taking place on the non-methylated vector but not on the methylated genomic locus
in the same cell. As demonstrated in the present analysis treatment of a stable
p21 reporter cell line with Azacytidine increased basal transcription levels of the
chromosomal gene as well as of the episomal reporter illustrating the relief from
transcriptional repression following loss of DNA methylation. No significant induction
of the chromosomal p21 gene by MLL–VP16–ER–HA could be seen under both
conditions, however. Following Azacytidine treatment the induction rate of the
reporter decreased as assessed by measurement of mRNA amounts and luciferase
activity. This could be due to a secondary effect of the drug that interferes with the
activation process through MLL–VP16–ER–HA. Another explanation would be
reduced recruitment of MLL–VP16–ER–HA to the promoter as a consequence of
decreased affinity to the cytidine analog.
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4.4.3 MLL–VP16–ER–HA activates transcription from the c–myc promoter
Another new target for MLL identified in this work is the c–myc promoter sequence.
c–myc was identified as the human homolog for an avian oncogene that was found to
be involved in chromosomal translocations in Burkitt lymphoma (Marcu et al. 1992).
Immunglobulin loci like the Igk enhancer have been identified as translocation
partners that were leading to c–myc overexpression (Erikson et al. 1983).
Transcription of the c–myc gene is subject to complex regulation. Four
promoters (P0, P1, P2, P3) drive transcription of the gene. Under normal conditions,
however most of c–myc transcription is initiated from the P2 promoter. P1 driven
transcription usually accounts for only 10-25% of the transcripts (Stewart et al. 1984;
Taub et al. 1984; Bentley and Groudine 1986).
Reporter analysis revealed that both promoters of the gene (P1 and P2) are strongly
induced by MLL–VP16–ER–HA. A short fragment of the P1 promoter (–101 / +66),
however, was enough to mediate this effect. The presence of the Igk enhancer did
not affect transcriptional activation by MLL–VP16–ER–HA underlining the fact that
cis–elements in the c–myc P1 promoter mediate the effect. Both mutant promoter
variants that were used for the transfection experiments almost completely abolished
the activation through MLL–VP16–ER–HA (see 4.3.3). Interestingly the G–rich
sequences affected by the proximal mutation were reported early on to be critical for
proper transcription initiation and are conserved between human and
mouse (Nishikura 1986).
Given the function of c–myc as a gene that drives cell proliferation it is intriguing that
the oncogene MLL–VP16–ER–HA is targeted to its promoter. Support for a model in
which MLL and MLL fusion proteins are involved in regulation of c–myc comes not
only from expression analysis of leukemias but also from a recent ChIP-chip study
where MLL was found on the c–myc promoter (Rozovskaia et al. 2003; Guenther et
al. 2005). Further studies will be required, however, to clarify whether MLL and
MLL fusion proteins regulate chromosomal c–myc. ChIP analyses can be used to
analyze promoter occupancy by MLL–VP16–ER–HA on wild type versus mutant
promoter constructs.
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4.4.4 A hematopoietic stem cell system for MLL fusion target gene analysis
One of the major open questions in the MLL research area still is the genome–wide
identification of direct target genes. Human leukemias that arise as a consequence of
chromosomal rearrangement in the MLL locus in hematopoietic stem cells illustrate
the fact that the resulting MLL fusions can only exert their full oncogenic potential in a
certain subset of pluripotent cells (Cozzio et al. 2003; So et al. 2003).
In this work FDCPmix cells were chosen as a model system for MLL fusion target
gene activation. It has been shown earlier that this pluripotent cell line has the
potential to differentiate into the majority of myeloid cell lineages (Schroeder 2001).
In the present study it could be shown that also after introduction of an inducible form
of MLL–VP16 cells could be differentiated to the terminal stages of granulocytic and
monocytic pathways. The estrogen receptor mutant fused variant used for most of
the experiments proved to be a valid research tool: target gene induction as shown
via RT–PCR and reporter gene assays was both fast and specific. This was
demonstrated by the upregulation of Meis1 only 3 hours after induction in the
MLL–VP16–ER–HA cell line but not in the control cell line. In a genome–wide
microarray also other known target genes like the cell cycle regulators p27 and p18
were shown to be induced. Downregulation of genes important for myeloid
differentiation was observed after 23 hours of MLL–VP16–ER–HA induction, which is
reflected in impaired terminal differentiation of these cells. These findings are in line
with the general model of the biological activity of an oncogene, which counteracts
differentiation and stimulates proliferation.
The induction of ER–VP16 fusions by Tamoxifen induced cellular toxicity. For
analysis of the immediate early events after induction of the fusion construct,
however, this hardly matters. Even though the clinical phenotypes of 11q23
translocations are rather diverse gene expression profiling of leukemias derived from
different fusions display a common signature (Armstrong et al. 2002; Kohlmann et al.
2005). The rather abstract approach taken here using the acidic activation domain of
VP16 as a paradigm for acidic activators represents an effort to generate a tool for
detection of the largest possible population of target genes. In fact in transient
transfections the VP16 fusion did not behave in a less specific manner than for
example MLL–AF9 but induction levels of reporter genes were considerably higher.
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Furthermore there are reports showing that fusion of the VP16 activation domain to
the MLL aminoterminus leads to transformation of myeloid progenitor cells and to
leukemia in mice (So and Cleary 2003; Zeisig et al. 2003). Taken together these
properties render the system a specific and sensitive biological tool to investigate the
early events following activation of a leukemogenic fusion protein. The advantage of
having a cell line greatly facilitates the analysis of target gene regulation. Biological
material can be provided for biochemical experiments or ChIP, where larger cell
numbers are usually required. For this type of experiments the monoclonal antibodies
generated in this work that specifically recognize and precipitate both moieties of
MLL will prove useful.
4.4.5 A genome-wide screen for MLL fusion target genes
The results of microarray analysis provide new candidate target genes. A series of
studies have been published reporting aberrant gene expression patterns in leukemia
patients carrying 11q23 translocations (Armstrong et al. 2002; Schoch et al. 2002;
Ferrando et al. 2003; Rozovskaia et al. 2003; Kohlmann et al. 2005). An inherent
problem of these studies is the high heterogeneity of biological material and the
secondary events taking place in cancer cells that prevent discrimination of direct
targets for MLL fusion proteins from genes that are upregulated as a consequence of
leukemogenesis. The approach presented in this work combines a hematopoietic
stem cell background with an oncogenic MLL fusion that can be induced very fast.
Working with a monoclonal cell line ensures a very high degree of homogeneity and
allows for analysis of the early events taking place after activation of MLL fusion
proteins. This increases the chance of finding target genes whose expression is
directly regulated by these oncogenes.
Amongst the targets identified in this study are some genes that had been reported to
be regulated by MLL. Meis1, which is considered a hallmark of MLL leukemogenesis
was stably upregulated already 30 min after induct ion of
MLL–VP16–ER–HA (Kawagoe et al. 1999; Rozovskaia et al. 2001; Imamura et al.
2002; Zeisig et al. 2004b). At the same time cyclin–dependent kinase inhibitors p18
and p27 were upregulated, which recently have been described as MLL target
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genes (Schraets et al. 2003; Milne et al. 2005b; Xia et al. 2005). Comparison with
published array data yielded moderate overlap. The chromatin remodeling factor
Runx2 and the transcriptional corepressor Zfhx1B have been identified as common
MLL target genes in acute lymphoblastic and acute myeloid leukemias (ALL, AML) by
microarray analysis of leukemia cells (Kohlmann et al. 2005). Runx2 normally plays a
role in osteogenesis but there reports about the oncogenic capacity of the
protein (Stewart et al. 1997; Ito 2004). Zfhx1B encoding Smad–interacting
protein 1 (SIP1) directly represses E–cadherin gene transcription and activates
cancer invasion via the upregulation of the matrix metalloproteinase gene
family (Miyoshi et al. 2004). The upregulation of these genes in leukemias is
underlining the physiological relevance of these genes. The fact, however, that they
were independently identified in the model system presented in this study is
indicating that they are probably direct targets of MLL rather than secondary effects
of leukemogenesis. Expression of three other genes, however, that have been
identified recently in an MLL–ENL model (Flt3, Lmo2 and N–myc) did not change
significantly in the system presented here (Zeisig et al. 2004a).
One way of proceeding from this point is to investigate the promoters of some of
these genes using a classical mutagenesis and reporter gene approach like it was
done e.g. for Hoxa9 in this study. The alternative is a bioinformatic approach
employing databases for the identification of common pathways and common
elements in target gene promoters. For the two early time points (30 min. and
3 hours) the predicted common features in target gene promoters were binding sites
for Homeobox proteins and the Cut–like homeodomain protein Cutl1. The potential
role of Hoxa9 binding sites for the activation by MLL–VP16–ER–HA has been
discussed earlier. Taking into account that Hoxa9 is upregulated by MLL fusions one
obvious conclusion would be that these are not direct MLL–VP16–ER–HA targets but
genes that are upregulated as a secondary effect by Hoxa9. The fact, however, that
also in the 30 min. sample genes where upregulated whose promoters contain Hox
binding sites indicates that MLL–VP16–ER–HA is directly targeting these sequences.
A similar situation is found for Cut–like homeodomain proteins and their binding sites
in target gene promoters, respectively. Cutl1 binding sites are significantly
overrepresented already in the promoters of target genes upregulated after 30 min,
arguing either for direct targeting by MLL–VP16–ER–HA or a very fast secondary
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response. However, since Cutl1 itself is one of the genes that are upregulated after
3 hours this could also be interpreted as a secondary effect: MLL–VP16–ER–HA
would target Cutl1 and the upregulation of this gene would subsequently lead to
deregulation of secondary target genes.
In any case the upregulation of Cutl1 by itself is an interesting observation. It has
been reported that Cutl1 binds to the promoter of p21 and inhibits transcription
through recruitment of the histone methyltransferase G9a (Coqueret et al. 1998;
Nishio and Walsh 2004). This finding is shedding a different light again on the lack of
activation of the chromosomal p21 gene by MLL–VP16–ER–HA. Possibly induction
of MLL–VP16–ER–HA leads to increased expression of Cutl1, a repressor of p21
transcription that exerts repression through recruitment of a chromatin modifier. It has
to be tested in ChIP whether H3K9 methylation is present on the chromosomal but
not on the episomal locus. If this would be the case this could indicate that the p21
promoter sequence is a target for MLL fusion. The chromosomal gene would,
however, not be activated because MLL–VP16–ER–HA is upregulating a potent
repressor of p21 transcription at the same time.
Besides p21 several other genes have been reported to be silenced by Cutl1 or its
mouse homolog Cux (Nepveu 2001). There are some reports, however, indicating a
role as a transcriptional activator (Nepveu 2001; Truscott et al. 2003). Interestingly
Cutl1 seems to be involved in tumorigenesis (Zhu et al. 2004; Michl et al. 2005; Michl
et al. 2006), which further reasons for the biological relevance of the gene as a
possible target for MLL fusions.
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6.2 Microarray results
Table 16. Genes upregulated 30 min after induction of MLL–VP16–ER–HA.
fold change:
Ccm1 cerebral cavernous malformations 1 3,2
Phf14 PHD finger protein 14 3,0
Zfhx1b RIKEN cDNA 5830411K21 gene 2,6
Pacs1 RIKEN cDNA D430030G11 gene 2,5
Nedd4l Neural precursor cell expressed, developmentally down-regulated gene 4-like 2,5
D230007K08Rik RIKEN cDNA D230007K08 gene 2,3
Pfn3 profilin 3 2,3
Myo1b myosin IB 2,3
Sec8l1 SEC8-like 1 (S. cerevisiae) 2,1
3110048L19Rik RIKEN cDNA 3110048L19 gene 2,1
Mbnl1 Muscleblind-like 1 (Drosophila) 2,1
4930428J16Rik RIKEN cDNA 4930428J16 gene 2,1
Ern1 Endoplasmic reticulum (ER) to nucleus signalling 1 2,0
A130071D04Rik RIKEN cDNA A130071D04 gene 2,0
1700034P14Rik RIKEN cDNA 1700034P14 gene 2,0
Tox Thymocyte selection-associated HMG box gene 2,0
Trim59 Tripartite motif-containing 59 2,0
5930436O19Rik RIKEN cDNA 5930436O19 gene 2,0
D230040A04Rik RIKEN cDNA D230040A04 gene 2,0
Ptpn12 Protein tyrosine phosphatase, non-receptor type 12 2,0
Ureb1 Upstream regulatory element binding protein 1e 2,0
Clpx Caseinolytic protease X (E.coli) 2,0
Dgkd Diacylglycerol kinase, delta 2,0
Table 17. Genes downregulated 30 min after induction of MLL–VP16–ER–HA
Osm oncostatin M 2
Table 18. Genes upregulated 3 hours after induction of MLL–VP16–ER–HA
Mbnl1 Muscleblind-like 1 (Drosophila) 4.6
Ccm1 cerebral cavernous malformations 1 4.6
Psme4 proteasome (prosome, macropain) activator subunit 4 3.7
2810013C04Rik RIKEN cDNA 2810013C04 gene 3.2
Pcdh7 protocadherin 7 3.0
Erbb2ip Erbb2 interacting protein 3.0
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Ss18 synovial sarcoma translocation, Chromosome 18 2.8
Enah Enabled homolog (Drosophila) 2.8
Dleu2 Deleted in lymphocytic leukemia, 2 2.8
Sdccag33 Serologically defined colon cancer antigen 33 2.6
Pacs1 RIKEN cDNA D430030G11 gene 2.6
D130037M23Rik RIKEN cDNA D130037M23 gene 2.6
Ankib1 Ankyrin repeat and IBR domain containing 1 2.6
4921505C17Rik RIKEN cDNA 4921505C17 gene 2.6
3110048L19Rik RIKEN cDNA 3110048L19 gene 2.6
2900075B16Rik RIKEN cDNA 2900075B16 gene 2.6
Zfhx1a Zinc finger homeobox 1a 2.5
Ssbp2 single-stranded DNA binding protein 2 2.5
Smc4l1 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 2.5
Sca1 Spinocerebellar ataxia 1 homolog (human) 2.5
Phf14 PHD finger protein 14 2.5
Nfe2l2 nuclear factor, erythroid derived 2, like 2 2.5
Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 2.5
Depdc5 DEP domain containing 5 2.5
Bcl2 B-cell leukemia/lymphoma 2 2.5
A130071D04Rik RIKEN cDNA A130071D04 gene 2.5
A130012E19Rik RIKEN cDNA A130012E19 gene 2.5
5830474E16Rik RIKEN cDNA 5830474E16 gene 2.5
5330401F18Rik RIKEN cDNA 5330401F18 gene 2.5
Zfhx1b RIKEN cDNA 5830411K21 gene 2.3
Uty Ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 2.3
Utx Ubiquitously transcribed tetratricopeptide repeat gene, X chromosome 2.3
Usp47 ubiquitin specific protease 47 2.3
Tox Thymocyte selection-associated HMG box gene 2.3
Tbl1x Transducin (beta)-like 1 X-linked 2.3
Nrip1 nuclear receptor interacting protein 1 2.3
Nedd4l Neural precursor cell expressed, developmentally down-regulated gene 4-like 2.3
Meis1 Myeloid ecotropic viral integration site 1 2.3
Lmo4 LIM domain only 4 2.3
Jmjd1c Jumonji domain containing 1C 2.3
Herc4 hect domain and RLD 4 2.3
Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl-
transferase 7
2.3
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E130108L08Rik RIKEN cDNA E130108L08 gene 2.3
Cdk6 Cyclin-dependent kinase 6 2.3
BC025872 cDNA sequence BC025872 2.3
BC013481 CDNA sequence BC013481 2.3
9630026M06Rik RIKEN cDNA 9630026M06 gene 2.3
5930436O19Rik RIKEN cDNA 5930436O19 gene 2.3
5830435C13Rik RIKEN cDNA 5830435C13 gene 2.3
5730555F13Rik RIKEN cDNA 5730555F13 gene 2.3
1810043J12Rik RIKEN cDNA 1810043J12 gene 2.3
St8sia4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 2.1
Ptpn12 Protein tyrosine phosphatase, non-receptor type 12 2.1
Phf3 PHD finger protein 3 2.1
Nfat5 Nuclear factor of activated T-cells 5 2.1
Mospd2 motile sperm domain containing 2 2.1
Map2k4 Mitogen activated protein kinase kinase 4 2.1
Malt1 mucosa associated lymphoid tissue lymphoma translocation gene 1 2.1
LOC432971 hypothetical gene supported by AK038224 2.1
Herc1 Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1
(CHC1)-like domain (RLD) 1
2.1
Ggnbp2 Gametogenetin binding protein 2 2.1
Fli1 Friend leukemia integration 1 2.1
Fancc Fanconi anemia, complementation group C 2.1
D030065N23Rik RIKEN cDNA D030065N23 gene 2.1
Cdkn2c cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 2.1
Cdkn1b Cyclin-dependent kinase inhibitor 1B (P27) 2.1
Cacnb2 Calcium channel, voltage-dependent, beta 2 subunit 2.1
Bhc80 BRAF35/HDAC2 complex 2.1
Arid1b AT rich interactive domain 1B (Swi1 like) 2.1
Ankra2 ankyrin repeat, family A (RFXANK-like), 2 2.1
AA407452 EST AA407452 2.1
A330103N21Rik RIKEN cDNA A330103N21 gene 2.1
9030227G01Rik RIKEN cDNA 9030227G01 gene 2.1
5830407E08Rik RIKEN cDNA 5830407E08 gene 2.1
4833416J08Rik RIKEN cDNA 4833416J08 gene 2.1
2900001A12Rik Ankyrin repeat domain 12 2.1
2810436B12Rik RIKEN cDNA 2810436B12 gene 2.1
2600011C06Rik RIKEN cDNA 2600011C06 gene 2.1
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2010109K09Rik RIKEN cDNA 2010109K09 gene 2.1
1700081L11Rik RIKEN cDNA 1700081L11 gene 2.1
1110001A05Rik RIKEN cDNA 1110001A05 gene 2.1
Wac WW domain containing adaptor with coiled-coil 2.0
Tpm1 tropomyosin 1, alpha 2.0
Tes3 Testis derived transcript 3 2.0
Stk17b serine/threonine kinase 17b (apoptosis-inducing) 2.0
Senp6 SUMO/sentrin specific protease 6 2.0
Sec8l1 SEC8-like 1 (S. cerevisiae) 2.0
Psmd14 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 2.0
Ppp3ca Protein phosphatase 3, catalytic subunit, alpha isoform 2.0
Phip pleckstrin homology domain interacting protein 2.0
Pctk2 PCTAIRE-motif protein kinase 2 2.0
Npat nuclear protein in the AT region 2.0
Mtdh Metadherin 2.0
Mpp6 Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) 2.0
Mbnl3 Muscleblind-like 3 (Drosophila) 2.0
Jarid2 Jumonji, AT rich interactive domain 2 2.0
Irf2 Interferon regulatory factor 2 2.0
Fndc3a fibronectin type III domain containing 3a 2.0
Fkbp5 RIKEN cDNA 6030422H21 gene 2.0
Diap1 Diaphanous homolog 1 (Drosophila) 2.0
Cutl1 RIKEN cDNA 2600010L24 gene 2.0
Chm Choroidermia 2.0
Bcor Bcl6 interacting corepressor 2.0
BC017647 CDNA sequence BC017647 2.0
Axot Axotrophin 2.0
A630072M18Rik RIKEN cDNA A630072M18 gene 2.0
9430034F23Rik RIKEN cDNA 9430034F23 gene 2.0
9030406N13Rik RIKEN cDNA 9030406N13 gene 2.0
6720463M24Rik RIKEN cDNA 6720463M24 gene 2.0
5832424M12Rik RIKEN cDNA 5832424M12 gene 2.0
4631422O05Rik RIKEN cDNA 4631422O05 gene 2.0
2610005L07Rik RIKEN cDNA 2610005L07 gene 2.0
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Table 19. Genes downregulated 3 hours after induction of MLL–VP16–ER–HA
Egr3 early growth response 3 3.2
Nmyc1 neuroblastoma myc-related oncogene 1 2.5
Cxcl2 chemokine (C-X-C motif) ligand 2 2.1
Il6 interleukin 6 2.0
Osm oncostatin M 2.0
2310006J04Rik RIKEN cDNA 2310006J04 gene 2.0
Table 20. Genes upregulated 12 hours after induction of MLL–VP16–ER–HA
D130037M23Rik RIKEN cDNA D130037M23 gene 9.2
Ccm1 cerebral cavernous malformations 1 6.1
Pank1 pantothenate kinase 1 5.3
Mbnl1 Muscleblind-like 1 (Drosophila) 4.6
Lpxn leupaxin 4.6
BC022960 cDNA sequence BC022960 4.6
1110034A24Rik RIKEN cDNA 1110034A24 gene 4.6
Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 4.0
Erbb2ip Erbb2 interacting protein 3.7
Dleu2 Deleted in lymphocytic leukemia, 2 3.7
Cdkn2c cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 3.7
Pcdh7 protocadherin 7 3.5
LOC319225 hypothetical LOC319225 3.5
Jmjd1c Jumonji domain containing 1C 3.5
Clec2i C-type lectin domain family 2, member i 3.5
B930096F20Rik RIKEN cDNA B930096F20 gene 3.5
Ankib1 Ankyrin repeat and IBR domain containing 1 3.5
Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 7
3.2
Elf1 E74-like factor 1 3.2
D5Wsu152e DNA segment, Chr 5, Wayne State University 152, expressed 3.2
5830435C13Rik RIKEN cDNA 5830435C13 gene 3.2
3110048L19Rik RIKEN cDNA 3110048L19 gene 3.2
Ssbp2 single-stranded DNA binding protein 2 3.0
Qk quaking 3.0
Phf14 PHD finger protein 14 3.0
Nedd4l Neural precursor cell expressed, developmentally down-regulated gene 4-like 3.0
Ndufs1 NADH dehydrogenase (ubiquinone) Fe-S protein 1 3.0
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1700108L22Rik RIKEN cDNA 1700108L22 gene 3.0
1110003F05Rik RIKEN cDNA 1110003F05 gene 3.0
Vezf1 Vascular endothelial zinc finger 1 2.8
Utx Ubiquitously transcribed tetratricopeptide repeat gene, X chromosome 2.8
Tes3 Testis derived transcript 3 2.8
Tbc1d5 TBC1 domain family, member 5 2.8
Smc4l1 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 2.8
Senp6 SUMO/sentrin specific protease 6 2.8
Sca1 Spinocerebellar ataxia 1 homolog (human) 2.8
Psme4 proteasome (prosome, macropain) activator subunit 4 2.8
Cdkn1b Cyclin-dependent kinase inhibitor 1B (P27) 2.8
Afp alpha fetoprotein 2.8
2610024H22Rik RIKEN cDNA 2610024H22 gene 2.8
1810043J12Rik RIKEN cDNA 1810043J12 gene 2.8
Sdccag33 serologically defined colon cancer antigen 33 2.6
Ptpn12 Protein tyrosine phosphatase, non-receptor type 12 2.6
Ptbp2 Polypyrimidine tract binding protein 2 2.6
Prkwnk1 Protein kinase, lysine deficient 1 2.6
L3mbtl3 l(3)mbt-like 3 (Drosophila) 2.6
Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 2.6
Foxc1 forkhead box C1 2.6
Enah Enabled homolog (Drosophila) 2.6
Depdc5 DEP domain containing 5 2.6
C130047D21Rik RIKEN cDNA C130047D21 gene 2.6
AI314180 expressed sequence AI314180 2.6
AA407452 EST AA407452 2.6
A630072M18Rik RIKEN cDNA A630072M18 gene 2.6
A430106J12Rik RIKEN cDNA A430106J12 gene 2.6
A130078K24Rik RIKEN cDNA A130078K24 gene 2.6
A130012E19Rik RIKEN cDNA A130012E19 gene 2.6
4921524P20Rik RIKEN cDNA 4921524P20 gene 2.6
4631422O05Rik RIKEN cDNA 4631422O05 gene 2.6
2810436B12Rik RIKEN cDNA 2810436B12 gene 2.6
2810013C04Rik RIKEN cDNA 2810013C04 gene 2.6
2600011C06Rik RIKEN cDNA 2600011C06 gene 2.6
2010109K09Rik RIKEN cDNA 2010109K09 gene 2.6
Zfhx1b RIKEN cDNA 5830411K21 gene 2.5
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Tdrd3 tudor domain containing 3 2.5
Tbl1x Transducin (beta)-like 1 X-linked 2.5
Rnf103 ring finger protein 103 2.5
Rdh10 Retinol dehydrogenase 10 (all-trans) 2.5
Meis1 Myeloid ecotropic viral integration site 1 2.5
Man1a Mannosidase 1, alpha 2.5
Lmo4 LIM domain only 4 2.5
Gulp1 GULP, engulfment adaptor PTB domain containing 1 2.5
Fkbp3 FK506 binding protein 3 2.5
Elf2 E74-like factor 2 2.5
Egr1 early growth response 1 2.5
D030065N23Rik RIKEN cDNA D030065N23 gene 2.5
9630026M06Rik RIKEN cDNA 9630026M06 gene 2.5
5830411K21Rik RIKEN cDNA 5830411K21 gene 2.5
5730555F13Rik RIKEN cDNA 5730555F13 gene 2.5
4933421G18Rik RIKEN cDNA 4933421G18 gene 2.5
Zswim6 zinc finger, SWIM domain containing 6 2.3
Zfp53 Zinc finger protein 53 2.3
Uty Ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 2.3
Usp47 ubiquitin specific protease 47 2.3
Sh3d1B SH3 domain protein 1B 2.3
SEP6 septin 6 2.3
Runx2 runt related transcription factor 2 2.3
Prkar2b protein kinase, cAMP dependent regulatory, type II beta 2.3
Pde3b phosphodiesterase 3B, cGMP-inhibited 2.3
Pctk2 PCTAIRE-motif protein kinase 2 2.3
Matr3 matrin 3 2.3
LOC432971 hypothetical gene supported by AK038224 2.3
Jarid2 Jumonji, AT rich interactive domain 2 2.3
Gm872 gene model 872, (NCBI) 2.3
Glud1 glutamate dehydrogenase 1 2.3
Fbxo30 F-box protein 30 2.3
D230040A04Rik RIKEN cDNA D230040A04 gene 2.3
D230007K08Rik RIKEN cDNA D230007K08 gene 2.3
Cstf3 cleavage stimulation factor, 3' pre-RNA, subunit 3 2.3
Bcor Bcl6 interacting corepressor 2.3
Bcl2 B-cell leukemia/lymphoma 2 2.3
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Arid2 AT rich interactive domain 2 (Arid-rfx like) 2.3
9930116O05Rik RIKEN cDNA 9930116O05 gene 2.3
5930436O19Rik RIKEN cDNA 5930436O19 gene 2.3
5830474E16Rik RIKEN cDNA 5830474E16 gene 2.3
4833416J08Rik RIKEN cDNA 4833416J08 gene 2.3
2700017A04Rik RIKEN cDNA 2700017A04 gene 2.3
1110059E24Rik RIKEN cDNA 1110059E24 gene 2.3
Zmynd11 Zinc finger, MYND domain containing 11 2.1
Zfhx1a Zinc finger homeobox 1a 2.1
Ube3a ubiquitin protein ligase E3A 2.1
Trim59 Tripartite motif-containing 59 2.1
Tox Thymocyte selection-associated HMG box gene 2.1
Tcf4 transcription factor 4 2.1
Tcf12 RIKEN cDNA E430034C17 gene 2.1
Sypl synaptophysin-like protein 2.1
Slmap sarcolemma associated protein 2.1
Sh3kbp1 SH3-domain kinase binding protein 1 2.1
Ranbp9 RAN binding protein 9 2.1
Rab27b RAB27b, member RAS oncogene family 2.1
Phip pleckstrin homology domain interacting protein 2.1
Peli1 pellino 1 2.1
Pacs1 RIKEN cDNA D430030G11 gene 2.1
Obfc1 oligonucleotide/oligosaccharide-binding fold containing 1 2.1
Med12l mediator of RNA polymerase II transcription, subunit 12 homolog (yeast)-like 2.1
Lpin2 Lipin 2 2.1
Herc3 hect domain and RLD 3 2.1
Eif4e Eukaryotic translation initiation factor 4E 2.1
D18Ertd232e DNA segment, Chr 18, ERATO Doi 232, expressed 2.1
Cdk6 Cyclin-dependent kinase 6 2.1
Cacnb2 Calcium channel, voltage-dependent, beta 2 subunit 2.1
C430003N24Rik RIKEN cDNA C430003N24 gene 2.1
Bhc80 BRAF35/HDAC2 complex 2.1
BC017647 CDNA sequence BC017647 2.1
Bbx bobby sox homolog (Drosophila) 2.1
Axot Axotrophin 2.1
Apg12l autophagy 12-like (S. cerevisiae) 2.1
Angpt1 Angiopoietin 1 2.1
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9430091E24Rik
/// LOC434350
RIKEN cDNA 9430091E24 gene /// hypothetical gene supported by AK080922 2.1
5832424M12Rik RIKEN cDNA 5832424M12 gene 2.1
5830411O09Rik RIKEN cDNA 5830411O09 gene 2.1
5830407E08Rik RIKEN cDNA 5830407E08 gene 2.1
5730526G10Rik RIKEN cDNA 5730526G10 gene 2.1
5730405M06Rik RIKEN cDNA 5730405M06 gene 2.1
5530401J07Rik RIKEN cDNA 5530401J07 gene 2.1
5033430I15Rik RIKEN cDNA 5033430I15 gene 2.1
4833412E19Rik RIKEN cDNA 4833412E19 gene 2.1
4632427E13Rik
/// LOC435992
RIKEN cDNA 4632427E13 gene /// similar to 40S ribosomal protein S3a (V-fos
transformation effector protein)
2.1
2810036L13Rik Heterogeneous nuclear ribonucleoprotein L-like 2.1
2310061J03Rik RIKEN cDNA 2310061J03 gene 2.1
1700034P14Rik RIKEN cDNA 1700034P14 gene 2.1
1190002N15Rik RIKEN cDNA 1190002N15 gene 2.1
1110001A05Rik RIKEN cDNA 1110001A05 gene 2.1
Zfp608 zinc finger protein 608 2.0
Zfp36l1 zinc finger protein 36, C3H type-like 1 2.0
Tpm1 tropomyosin 1, alpha 2.0
Top2b topoisomerase (DNA) II beta 2.0
Tax1bp1 Tax1 (human T-cell leukemia virus type I) binding protein 1 2.0
Stxbp6 syntaxin binding protein 6 (amisyn) 2.0
St7 Suppression of tumorigenicity 7 2.0
Ssa2 Sjogren syndrome antigen A2 2.0
Ss18 synovial sarcoma translocation, Chromosome 18 2.0
Sntb2 syntrophin, basic 2 2.0
Snapc3 small nuclear RNA activating complex, polypeptide 3 2.0
Sh3bgrl SH3-binding domain glutamic acid-rich protein like 2.0
Sfrs11 splicing factor, arginine/serine-rich 11 2.0
Sesn1 Sestrin 1 2.0
Robo3 roundabout homolog 3 (Drosophila) 2.0
Rnf12 Ring finger protein 12 2.0
Rapgef2 RIKEN cDNA B930012P20 gene 2.0
Ramp2 receptor (calcitonin) activity modifying protein 2 2.0
Ptprj protein tyrosine phosphatase, receptor type, J 2.0
Psmd14 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 2.0
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Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 2.0
Phtf2 putative homeodomain transcription factor 2 2.0
Parp14 poly (ADP-ribose) polymerase family, member 14 2.0
Ogt O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)
2.0
Nrip1 nuclear receptor interacting protein 1 2.0
Nfe2l2 nuclear factor, erythroid derived 2, like 2 2.0
Mospd2 motile sperm domain containing 2 2.0
Mllt10 Myeloid/lymphoid or mixed lineage-leukemia translocation to 10 homolog
(Drosophila)
2.0
Mbnl3 Muscleblind-like 3 (Drosophila) 2.0
Malt1 mucosa associated lymphoid tissue lymphoma translocation gene 1 2.0
Homer1 homer homolog 1 (Drosophila) 2.0
Fndc3 Fibronectin type III domain containing 3 2.0
Fli1 Friend leukemia integration 1 2.0
Fancc Fanconi anemia, complementation group C 2.0
E2f5 E2F transcription factor 5 2.0
E130308A19Rik RIKEN cDNA E130308A19 gene 2.0
E130108L08Rik RIKEN cDNA E130108L08 gene 2.0
E030024I16Rik RIKEN cDNA E030024I16 gene 2.0
Diap1 Diaphanous homolog 1 (Drosophila) 2.0
D5Ertd798e DNA segment, Chr 5, ERATO Doi 798, expressed 2.0
D10Ucla1 DNA segment, Chr 10, University of California at Los Angeles 1 2.0
Crlf3 cytokine receptor-like factor 3 2.0
C430010P07Rik RIKEN cDNA C430010P07 gene 2.0
B930013M22Rik RIKEN cDNA B930013M22 gene 2.0
B830007D08Rik RIKEN cDNA B830007D08 gene 2.0
Atp10a ATPase, class V, type 10A 2.0
Arid1b AT rich interactive domain 1B (Swi1 like) 2.0
Arhgap21 Rho GTPase activating protein 21 2.0
Akt3 thymoma viral proto-oncogene 3 2.0
Akap13 A kinase (PRKA) anchor protein 13 2.0
Aim1 absent in melanoma 1 2.0
A730095J18Rik Zinc finger protein, subfamily 1A, 2 (Helios) 2.0
A430001F24Rik RIKEN cDNA A430001F24 gene 2.0
A330103N21Rik RIKEN cDNA A330103N21 gene 2.0
A130071D04Rik RIKEN cDNA A130071D04 gene 2.0
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9530028C05 hypothetical protein 9530028C05 2.0
9430034F23Rik RIKEN cDNA 9430034F23 gene 2.0
9130203F04Rik RIKEN cDNA 9130203F04 gene 2.0
9030406N13Rik RIKEN cDNA 9030406N13 gene 2.0
6430585N13Rik RIKEN cDNA 6430585N13 gene 2.0
6430510B20Rik RIKEN cDNA 6430510B20 gene 2.0
6330549H03Rik General transcription factor II A, 1 2.0
6330505F04Rik RIKEN cDNA 6330505F04 gene 2.0
5830472H07Rik RIKEN cDNA 5830472H07 gene 2.0
5630401D06Rik RIKEN cDNA 5630401D06 gene 2.0
2900084O13Rik RIKEN cDNA 2900084O13 gene 2.0
2900001A12Rik Ankyrin repeat domain 12 2.0
2700008G24Rik RIKEN cDNA 2700008G24 gene 2.0
2210420N10Rik RIKEN cDNA 2210420N10 gene 2.0
1700081L11Rik RIKEN cDNA D030002E05 gene 2.0
Table 21. Genes downregulated 12 hours after induction of MLL–VP16–ER–HA.
Lipg lipase, endothelial 4.3
Il6 interleukin 6 3.7
Ccr2 chemokine (C-C motif) receptor 2 3.7
Nmyc1 neuroblastoma myc-related oncogene 1 3.5
Thbs1 thrombospondin 1 3.2
Il1rn interleukin 1 receptor antagonist 3.2
BC035044 cDNA sequence BC035044 3.2
5830411E10Rik RIKEN cDNA 5830411E10 gene 3.2
Tcrg-V4 T-cell receptor gamma, variable 6 3.0
Tcf7 transcription factor 7, T-cell specific 2.8
Gimap3 GTPase, IMAP family member 3 2.8
Mylip myosin regulatory light chain interacting protein 2.6
Ear11 eosinophil-associated, ribonuclease A family, member 11 2.6
Dctd dCMP deaminase 2.6
Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 2.5
Ifitm6 interferon induced transmembrane protein 6 2.5
Idb2 inhibitor of DNA binding 2 2.5
Csf1 colony stimulating factor 1 (macrophage) 2.5
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Cpsf2 cleavage and polyadenylation specific factor 2 2.5
St6galnac4 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 4
2.3
Slc19a1 solute carrier family 19 (sodium/hydrogen exchanger), member 1 2.3
Nolc1 nucleolar and coiled-body phosphoprotein 1 2.3
Mmp9 matrix metalloproteinase 9 2.3
Ly6e lymphocyte antigen 6 complex, locus E 2.3
2610009I02Rik RIKEN cDNA 2610009I02 gene 2.3
Slco4a1 solute carrier organic anion transporter family, member 4a1 2.1
MAR1 membrane-associated ring finger (C3HC4) 1 2.1
Ifrd2 interferon-related developmental regulator 2 2.1
Grwd1 glutamate-rich WD repeat containing 1 2.1
Ccr1 chemokine (C-C motif) receptor 1 2.1
Ccl3 chemokine (C-C motif) ligand 3 2.1
Alox5 arachidonate 5-lipoxygenase 2.1
Adam8 a disintegrin and metalloprotease domain 8 2.1
9430063L05Rik RIKEN cDNA 9430063L05 gene 2.1
2310008H09Rik RIKEN cDNA 2310008H09 gene 2.1
1110007M04Rik RIKEN cDNA 1110007M04 gene 2.1
Thop1 thimet oligopeptidase 1 2.0
Tbl2 transducin (beta)-like 2 2.0
Srm spermidine synthase 2.0
Spp1 secreted phosphoprotein 1 2.0
Rpo1-2 RNA polymerase 1-2 2.0
Pim3 proviral integration site 3 2.0
Myc myelocytomatosis oncogene 2.0
MGI:2136405 glucuronyl C5-epimerase 2.0
MGC58382 similar to Normal mucosa of esophagus specific gene 1 protein 2.0
Krtap8-2 keratin associated protein 8-2 2.0
Kctd12 potassium channel tetramerisation domain containing 12 2.0
Hist1h1c histone 1, H1c 2.0
Gm1960 gene model 1960, (NCBI) 2.0
Fzr1 Fizzy/cell division cycle 20 related 1 (Drosophila) 2.0
Cxcr4 chemokine (C-X-C motif) receptor 4 2.0
C230052I12Rik RIKEN cDNA C230052I12 gene 2.0
Bspry B-box and SPRY domain containing 2.0
BC056485 cDNA sequence BC056485 2.0
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Atad3a ATPase family, AAA domain containing 3A 2.0
4633402N23Rik RIKEN cDNA 4633402N23 gene 2.0
1810015A11Rik RIKEN cDNA 1810015A11 gene 2.0
6.3 List of available binding matrices (Genomatix)
Table 22. Matrices used from Genomatix (www.genomatix.de) for the detection of transcription factors
family matrix description
V$AARF V$AARE.01 Amino acid response element, ATF4 binding site
V$AHRR V$AHR.01 Aryl hydrocarbon / dioxin receptor
V$AHRR V$AHRARNT.01 Aryl hydrocarbon receptor / Arnt heterodimers
V$AHRR V$AHRARNT.02 Aryl hydrocarbon / Arnt heterodimers, fixed core
V$AHRR V$NXF_ARNT.01 bHLH-PAS type transcription factors NXF/ARNT heterodimer
V$AIRE V$AIRE.01 Autoimmune regulator
V$AP1F V$AP1.01 Activator protein 1
V$AP1F V$AP1.02 Activator protein 1
V$AP1F V$AP1.03 Activator protein 1
V$AP1R V$BACH1.01 BTB/POZ-bZIP transcription factor BACH1 forms heterodimers with
the small Maf protein family
V$AP1R V$BACH2.01 Bach2 bound TRE
V$AP1R V$NFE2.01 NF-E2 p45
V$AP1R V$NFE2L2.01 Nuclear factor (erythroid-derived 2)-like 2, NRF2
V$AP1R V$TCF11MAFG.01 TCF11/MafG heterodimers, binding to subclass of AP1 sites
V$AP1R V$VMAF.01 v-Maf
V$AP2F V$AP2.01 Activator protein 2
V$AP2F V$AP2.02 Activator protein 2 alpha
V$AP4R V$AP4.01 Activator protein 4
V$AP4R V$AP4.02 Activator protein 4
V$AP4R V$LYL1_E12.01 LYL1-E12 heterodimeric complex
V$AP4R V$PARAXIS.01 Paraxis (TCF15), member of the Twist subfamily of Class B bHLH
factors, forms heterodimers with E12
V$AP4R V$TAL1ALPHAE47.01 Tal-1alpha/E47 heterodimer
V$AP4R V$TAL1BETAE47.01 Tal-1beta/E47 heterodimer
V$AP4R V$TAL1BETAHEB.01 Tal-1beta/HEB heterodimer
V$AP4R V$TAL1BETAITF2.01 Tal-1beta/ITF-2 heterodimer
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V$AP4R V$TH1E47.01 Thing1/E47 heterodimer, TH1 bHLH member specific expression in a
variety of embryonic tissues
V$AREB V$AREB6.01 AREB6 (Atp1a1 regulatory element binding factor 6)
V$AREB V$AREB6.02 AREB6 (Atp1a1 regulatory element binding factor 6)
V$AREB V$AREB6.03 AREB6 (Atp1a1 regulatory element binding factor 6)
V$AREB V$AREB6.04 AREB6 (Atp1a1 regulatory element binding factor 6)
V$ATBF V$ATBF1.01 AT-binding transcription factor 1
V$BARB V$BARBIE.01 Barbiturate-inducible element
V$BEL1 V$BEL1.01 Bel-1 similar region (defined in Lentivirus LTRs)
V$BCL6 V$BCL6.01 POZ/zinc finger protein, transcriptional repressor, translocations
observed in diffuse large cell lymphoma
V$BCL6 V$BCL6.02 POZ/zinc finger protein, transcriptional repressor, translocations
observed in diffuse large cell lymphoma
V$BNCF V$BNC.01 Basonuclin, cooperates with USF1 in rDNA PolI transcription)
V$BRAC V$BRACH.01 Brachyury
V$BRAC V$TBX5.01 T-Box factor 5 site (TBX5), mutations related to Holt-Oram syndrome
V$BRNF V$BRN2.01 Brn-2, POU-III protein class
V$BRNF V$BRN2.02 Brn-2, POU-III protein class
V$BRNF V$BRN2.03 Brn-2, POU-III protein class
V$BRNF V$BRN3.01 Brn-3, POU-IV protein class
V$BRNF V$BRN3.02 Brn-3, POU-IV protein class
V$BRNF V$BRN4.01 POU domain transcription factor brain 4
V$BRNF V$BRN5.01 Brn-5, POU-VI protein class (also known as emb and CNS-1)
V$BTBF V$KAISO.01 Transcription factor Kaiso, ZBTB33
V$CAAT V$ACAAT.01 Avian C-type LTR CCAAT box
V$CAAT V$CAAT.01 Cellular and viral CCAAT box
V$CAAT V$NFY.01 Nuclear factor Y (Y-box binding factor)
V$CAAT V$NFY.02 Nuclear factor Y (Y-box binding factor)
V$CAAT V$NFY.03 Nuclear factor Y (Y-box binding factor)
V$CABL V$CABL.01 Multifunctional c-Abl src type tyrosine kinase
V$CART V$CART1.01 Cart-1 (cartilage homeoprotein 1)
V$CART V$XVENT2.01 Xenopus homeodomain factor Xvent-2; early BMP signaling
response
V$CDEF V$CDE.01 Cell cycle-dependent element, CDF-1 binding site (CDE/CHR
tandem elements regulate cell cycle dependent repression)
V$CDXF V$CDX1.01 Intestine specific homeodomain factor CDX-1
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V$CDXF V$CDX2.01 Cdx-2 mammalian caudal related intestinal transcr. factor
V$CEBP V$CEBP.02 CCAAT/enhancer binding protein
V$CEBP V$CEBPB.01 CCAAT/enhancer binding protein beta
V$CHOP V$CHOP.01 Heterodimers of CHOP and C/EBPalpha
V$CHRE V$CHREBP_MLX.01 Carbohydrate response element binding protein (CHREBP) and
Max-like protein X (Mlx) bind as heterodimers to glucose-responsive
promoters
V$CHRF V$CHR.01 Cell cycle gene homology region (CDE/CHR tandem elements
regulate cell cycle dependent repression)
V$CIZF V$NMP4.01 NMP4 (nuclear matrix protein 4) / CIZ (Cas-interacting zinc finger
protein)
V$CLOX V$CDP.01 Cut-like homeodomain protein
V$CLOX V$CDP.02 Transcriptional repressor CDP
V$CLOX V$CDPCR3.01 Cut-like homeodomain protein
V$CLOX V$CDPCR3HD.01 Cut-like homeodomain protein
V$CLOX V$CLOX.01 Cut-like homeo box
V$CLOX V$CUT2.01 Cut repeat II
V$COMP V$COMP1.01 COMP1, cooperates with myogenic proteins in multicomponent
complex
V$CP2F V$CP2.01 CP2
V$CP2F V$CP2.02 LBP-1c (leader-binding protein-1c), LSF (late SV40 factor), CP2,
SEF (SAA3 enhancer factor)
V$CREB V$ATF.01 Activating transcription factor
V$CREB V$ATF.02 Activating transcription factor
V$CREB V$ATF2.01 Activating transcription factor 2
V$CREB V$ATF6.02 Activating transcription factor 6, member of b-zip family, induced by
ER stress
V$CREB V$CJUN_ATF2.01 c-Jun/ATF2 heterodimers
V$CREB V$CREB.01 cAMP-responsive element binding protein
V$CREB V$CREB.02 cAMP-responsive element binding protein
V$CREB V$CREB.03 cAMP-response element-binding protein
V$CREB V$CREBP1.01 cAMP-responsive element binding protein 1
V$CREB V$CREBP1CJUN.01 CRE-binding protein 1/c-Jun heterodimer
V$CREB V$E4BP4.01 E4BP4, bZIP domain, transcriptional repressor
V$CREB V$TAXCREB.01 Tax/CREB complex
V$CREB V$TAXCREB.02 Tax/CREB complex
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V$CSEN V$DREAM.01 Downstream regulatory element-antagonist modulator, Ca2+-binding
protein of the neuronal calcium sensors family that binds DRE
(downstream regulatory element) sites as a tetramer
V$DEAF V$NUDR.01 NUDR (nuclear DEAF-1 related transcriptional regulator protein)
V$DICE V$DICE.01 Downstream Immunoglobulin Control Element, interacting factor:
BEN (also termed Mus-TRD1 and WBSCR11)
V$DMTF V$DMP1.01 Cyclin D-interacting myb-like protein, DMTF1 - cyclin D binding myb-
like transcription factor 1
V$E2FF V$E2F.01 E2F, involved in cell cycle regulation, interacts with Rb p107 protein
V$E2FF V$E2F.02 E2F, involved in cell cycle regulation, interacts with Rb p107 protein
V$E2FF V$E2F.03 E2F, involved in cell cycle regulation, interacts with Rb p107 protein
V$E2TF V$E2.01 BPV bovine papilloma virus regulator E2
V$E4FF V$E4F.01 GLI-Krueppel-related transcription factor, regulator of adenovirus E4
promoter
V$EBOR V$DELTAEF1.01 deltaEF1
V$EBOR V$SIP1.01 Smad-interacting protein
V$EBOR V$XBP1.01 X-box-binding protein 1
V$EBOX V$ATF6.01 Member of b-zip family, induced by ER damage/stress, binds to the
ERSE in association with NF-Y
V$EBOX V$MAX.01 Max/Max dimer
V$EBOX V$MYCMAX.01 c-Myc/Max heterodimer
V$EBOX V$MYCMAX.02 c-Myc/Max heterodimer
V$EBOX V$MYCMAX.03 MYC-MAX binding sites
V$EBOX V$NMYC.01 N-Myc
V$EBOX V$SREBP.01 Sterol regulatory element binding protein 1 and 2
V$EBOX V$SREBP.02 Sterol regulatory element binding protein
V$EBOX V$SREBP.03 Sterol regulatory element binding protein
V$EBOX V$USF.01 Upstream stimulating factor
V$EBOX V$USF.02 Upstream stimulating factor
V$EBOX V$USF.03 Upstream stimulating factor
V$EGRF V$CKROX.01 Collagen krox protein (zinc finger protein 67 - zfp67)
V$EGRF V$EGR1.01 Egr-1/Krox-24/NGFI-A immediate-early gene product
V$EGRF V$EGR1.02 EGR1, early growth response 1
V$EGRF V$EGR2.01 Egr-2/Krox-20 early growth response gene product
V$EGRF V$EGR3.01 Early growth response gene 3 product
V$EGRF V$NGFIC.01 Nerve growth factor-induced protein C
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V$EGRF V$WT1.01 Wilms Tumor Suppressor
V$EKLF V$BKLF.01 Basic krueppel-like factor (KLF3)
V$EKLF V$EKLF.01 Erythroid krueppel like factor (EKLF)
V$EKLF V$KKLF.01 Kidney-enriched kruppel-like factor, KLF15
V$EREF V$ER.01 Estrogen receptor
V$EREF V$ER.02 Canonical palindromic estrogen response element (ERE)
V$EREF V$ERR.01 Estrogen related receptor
V$ETSF V$CETS1P54.01 c-Ets-1(p54)
V$ETSF V$ELF2.01 Ets - family member ELF-2 (NERF1a)
V$ETSF V$ELK1.01 Elk-1
V$ETSF V$ELK1.02 Elk-1
V$ETSF V$ETS1.01 c-Ets-1 binding site
V$ETSF V$ETS2.01 c-Ets-2 binding site
V$ETSF V$FLI.01 ETS family member FLI
V$ETSF V$GABP.01 GABP: GA binding protein
V$ETSF V$NRF2.01 Nuclear respiratory factor 2
V$ETSF V$PDEF.01 Prostate-derived Ets factor
V$ETSF V$PU1.01 Pu.1 (Pu120) Ets-like transcription factor identified in lymphoid B-
cells
V$EVI1 V$EVI1.01 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.02 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.03 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.04 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.05 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.06 Ecotropic viral integration site 1 encoded factor, amino-terminal zinc
finger domain
V$EVI1 V$EVI1.07 Evi-1 zinc finger protein, carboxy-terminal zinc finger domain
V$EVI1 V$MEL1.01 MEL1 (MDS1/EVI1-like gene 1) DNA-binding domain 1
V$EVI1 V$MEL1.02 MEL1 (MDS1/EVI1-like gene 1) DNA-binding domain 2
V$EVI1 V$MEL1.03 MEL1 (MDS1/EVI1-like gene 1) DNA-binding domain 2
V$FAST V$FAST1.01 FAST-1 SMAD interacting protein
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V$FKHD V$FKHRL1.01 Fkh-domain factor FKHRL1 (FOXO)
V$FKHD V$FREAC2.01 Fork head related activator-2 (FOXF2)
V$FKHD V$FREAC3.01 Fork head related activator-3 (FOXC1)
V$FKHD V$FREAC4.01 Fork head related activator-4 (FOXD1)
V$FKHD V$FREAC7.01 Fork head related activator-7 (FOXL1)
V$FKHD V$HFH1.01 HNF-3/Fkh Homolog 1 (FOXQ1)
V$FKHD V$HFH2.01 HNF-3/Fkh Homolog 2 (FOXD3)
V$FKHD V$HFH3.01 HNF-3/Fkh Homolog 3 (FOXI1, Freac-6)
V$FKHD V$HFH8.01 HNF-3/Fkh Homolog-8 (FOXF1)
V$FKHD V$HNF3B.01 Hepatocyte nuclear factor 3beta (FOXA2)
V$FKHD V$ILF1.01 Winged-helix transcription factor IL-2 enhancer binding factor (ILF),
forkhead box K2 (FOXK2)
V$FKHD V$XFD1.01 Xenopus fork head domain factor 1 (FoxA4a)
V$FKHD V$XFD2.01 Xenopus fork head domain factor 2 (FoxI1a)
V$FKHD V$XFD3.01 Xenopus fork head domain factor 3 (FoxA2a)
V$GABF V$GAGA.01 GAGA-Box
V$GATA V$GATA.01 GATA binding factor
V$GATA V$GATA1.01 GATA-binding factor 1
V$GATA V$GATA1.02 GATA-binding factor 1
V$GATA V$GATA1.03 GATA-binding factor 1
V$GATA V$GATA1.04 GATA-binding factor 1
V$GATA V$GATA1.05 GATA-binding factor 1
V$GATA V$GATA1.06 Complex of Lmo2 bound to Tal-1, E2A proteins, and GATA-1, half-
site 2
V$GATA V$GATA2.01 GATA-binding factor 2
V$GATA V$GATA2.02 GATA-binding factor 2
V$GATA V$GATA3.01 GATA-binding factor 3
V$GATA V$GATA3.02 GATA-binding factor 3
V$GFI1 V$GFI1.01 Growth factor independence 1 zinc finger protein acts as
transcriptional repressor
V$GFI1 V$GFI1B.01 Growth factor independence 1 zinc finger protein Gfi-1B
V$GKLF V$GKLF.01 Gut-enriched Krueppel-like factor
V$GKLF V$GKLF.02 Gut-enriched Krueppel-like factor
V$GLIF V$GLI1.01 Zinc finger transcription factor GLI1
V$GLIF V$ZIC2.01 Zinc finger transcription factor, Zic family member 2 (odd-paired
homolog, Drosophila)
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V$GREF V$ARE.01 Androgene receptor binding site
V$GREF V$GRE.01 Glucocorticoid receptor, C2C2 zinc finger protein binds
glucocorticoid dependent to GREs
V$GREF V$PRE.01 Progesterone receptor binding site
V$GZF1 V$GZF1.01 GDNF-inducible zinc finger protein 1 (ZNF336)
V$HAML V$AML1.01 AML1/CBFA2 Runt domain binding site
V$HAML V$AML3.01 Runt-related transcription factor 2 / CBFA1 (core-binding factor, runt
domain, alpha subunit 1)
V$HAND V$HAND2_E12.01 Heterodimers of the bHLH transcription factors HAND2 (Thing2) and
E12
V$HEAT V$HSF1.01 Heat shock factor 1
V$HEAT V$HSF1.02 Heat shock factor 1
V$HEAT V$HSF1.03 Heat shock factor 1
V$HEAT V$HSF2.01 Heat shock factor 2
V$HEAT V$HSF2.02 Heat shock factor 2
V$HEN1 V$HEN1.01 HEN1
V$HEN1 V$HEN1.02 HEN1
V$HESF V$HELT.01 Hey-like bHLH-transcriptional repressor
V$HESF V$HES1.01 Drosophila hairy and enhancer of split homologue 1 (HES-1)
V$HESF V$HES1.02 Drosophila hairy and enhancer of split homologue 1 (HES-1)
V$HICF V$HIC1.01 Hypermethylated in cancer 1, transcriptional repressor containing
five Kr√ºppel-like C2H2 zinc fingers, for optimal binding multiple
binding sites are required.
V$HIFF V$ARNT.01 AhR nuclear translocator homodimers
V$HIFF V$CLOCK_BMAL1.01 Binding site of Clock/BMAL1 heterodimer, NPAS2/BMAL1
heterodimer
V$HIFF V$DEC1.01 Basic helix-loop-helix protein known as Dec1, Stra13 or Sharp2
V$HIFF V$DEC2.01 Basic helix-loop-helix protein known as Dec2 or Sharp2
V$HIFF V$HIF1.01 Hypoxia induced factor-1 (HIF-1)
V$HIFF V$HIF1.02 Hypoxia inducible factor, bHLH / PAS protein family
V$HMTB V$MTBF.01 Muscle-specific Mt binding site
V$HNF1 V$HNF1.01 Hepatic nuclear factor 1
V$HNF1 V$HNF1.02 Hepatic nuclear factor 1
V$HNF1 V$HNF1.03 Hepatic nuclear factor 1
V$HNF6 V$HNF6.01 Liver enriched Cut - Homeodomain transcription factor HNF6
(ONECUT)
Appendix                                                                                                                   182
V$HNF6 V$OC2.01 CUT-homeodomain transcription factor Onecut-2
V$HOMF V$DLX1.01 DLX-1, -2, and -5 binding sites
V$HOMF V$DLX3.01 Distal-less 3 homeodomain transcription factor
V$HOMF V$EN1.01 Homeobox protein engrailed (en-1)
V$HOMF V$MSX.01 Homeodomain proteins MSX-1 and MSX-2
V$HOMF V$MSX2.01 Muscle segment homeo box 2, homologue of Drosophila (HOX 8)
V$HOMF V$S8.01 Binding site for S8 type homeodomains
V$HOXF V$BARX2.01 Barx2, homeobox transcription factor that preferentially binds to
paired TAAT motifs
V$HOXF V$CRX.01 Cone-rod homeobox-containing transcription factor / otx-like
homeobox gene
V$HOXF V$GSC.01 Vertebrate bicoid-type homeodomain protein Goosecoid
V$HOXF V$GSH1.01 Homeobox transcription factor Gsh-1
V$HOXF V$GSH2.01 Homeodomain transcription factor Gsh-2
V$HOXF V$HOX1-3.01 Hox-1.3, vertebrate homeobox protein
V$HOXF V$HOXA9.01 Member of the vertebrate HOX - cluster of homeobox factors
V$HOXF V$HOXB9.01 Abd-B-like homeodomain protein Hoxb-9
V$HOXF V$HOXC13.01 Homeodomain transcription factor HOXC13
V$HOXF V$OTX2.01 Homeodomain transcription factor Otx2 (homolog of Drosophila
orthodenticle)
V$HOXF V$PHOX2.01 Phox2a (ARIX) and Phox2b
V$HOXF V$PTX1.01 Pituitary Homeobox 1 (Ptx1, Pitx-1)
V$HOXH V$MEIS1A_HOXA9.01 Meis1a and Hoxa9 form heterodimeric binding complexes on target
DNA
V$HOXH V$MEIS1B_HOXA9.01 Meis1b and Hoxa9 form heterodimeric binding complexes on target
DNA
V$HOXC V$HOX_PBX.01 HOX/PBX binding sites
V$HOXC V$PBX1.01 Homeo domain factor Pbx-1
V$HOXC V$PBX_HOXA9.01 PBX - HOXA9 binding site
V$IKRS V$IK1.01 Ikaros 1, potential regulator of lymphocyte differentiation
V$IKRS V$IK2.01 Ikaros 2, potential regulator of lymphocyte differentiation
V$IKRS V$IK3.01 Ikaros 3, potential regulator of lymphocyte differentiation
V$IKRS V$LYF1.01 LyF-1 (Ikaros 1), enriched in B and T lymphocytes
V$INSM V$INSM1.01 Zinc finger protein insulinoma-associated 1 (IA-1) functions as a
transcriptional repressor
V$IRFF V$IRF1.01 Interferon regulatory factor 1
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V$IRFF V$IRF2.01 Interferon regulatory factor 2
V$IRFF V$IRF3.01 Interferon regulatory factor 3 (IRF-3)
V$IRFF V$IRF4.01 Interferon regulatory factor (IRF)-related protein (NF-EM5, PIP,
LSIRF, ICSAT)
V$IRFF V$IRF7.01 Interferon regulatory factor 7 (IRF-7)
V$IRFF V$ISRE.01 Interferon-stimulated response element
V$LEFF V$LEF1.01 TCF/LEF-1, involved in the Wnt signal transduction pathway
V$LEFF V$LEF1.02 TCF/LEF-1, involved in the Wnt signal transduction pathway
V$LHXF V$LHX3.01 Homeodomain binding site in LIM/Homeodomain factor LHX3
V$LHXF V$LMX1B.01 LIM-homeodomain transcription factor
V$LTUP V$TAACC.01 Lentiviral TATA upstream element
V$MAZF V$MAZ.01 Myc associated zinc finger protein (MAZ)
V$MAZF V$MAZR.01 MYC-associated zinc finger protein related transcription factor
V$MEF2 V$MEF2.01 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.02 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.03 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.04 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.05 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.06 Myocyte-specific enhancer factor 2
V$MEF2 V$MEF2.07 Myocyte-specific enhancer factor 2
V$MEF2 V$RSRFC4.01 Related to serum response factor, C4
V$MEF2 V$SL1.01 Member of the RSRF (related to serum response factor) protein
family from Xenopus laevis
V$MEF3 V$MEF3.01 MEF3 binding site, present in skeletal muscle-specific transcriptional
enhancers
V$MINI V$MUSCLE_INI.01 Muscle Initiator Sequence
V$MINI V$MUSCLE_INI.02 Muscle Initiator Sequence
V$MITF V$MIT.01 MIT (microphthalmia transcription factor) and TFE3
V$MOKF V$MOK2.01 Ribonucleoprotein associated zinc finger protein MOK-2 (mouse)
V$MOKF V$MOK2.02 Ribonucleoprotein associated zinc finger protein MOK-2 (human)
V$MTF1 V$MTF-1.01 Metal transcription factor 1, MRE
V$MYBL V$CMYB.01 c-Myb, important in hematopoesis, cellular equivalent to avian
myoblastosis virus oncogene v-myb
V$MYBL V$CMYB.02 c-Myb, important in hematopoesis, cellular equivalent to avian
myoblastosis virus oncogene v-myb
V$MYBL V$VMYB.01 v-Myb
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V$MYBL V$VMYB.02 v-Myb
V$MYBL V$VMYB.03 v-Myb, viral myb variant from transformed BM2 cells
V$MYBL V$VMYB.04 v-Myb, AMV v-myb
V$MYBL V$VMYB.05 v-Myb, variant of AMV v-myb
V$MYOD V$E47.01 MyoD/E47 and MyoD/E12 dimers
V$MYOD V$E47.02 E47 homodimer
V$MYOD V$MYF5.01 Myf5 myogenic bHLH protein
V$MYOD V$MYOD.01 Myogenic regulatory factor MyoD (myf3)
V$MYOD V$MYOGENIN.01 Myogenic bHLH protein myogenin (myf4)
V$MYOD V$TAL1_E2A.01 Complex of Lmo2 bound to Tal-1, E2A proteins, and GATA-1, half-
site 1
V$MYT1 V$MYT1.01 MyT1 zinc finger transcription factor involved in primary
neurogenesis
V$MYT1 V$MYT1.02 MyT1 zinc finger transcription factor involved in primary
neurogenesis
V$MYT1 V$MYT1L.01 Myelin transcription factor 1-like, neuronal C2HC zinc finger factor 1
V$MZF1 V$MZF1.01 Myeloid zinc finger protein MZF1
V$MZF1 V$MZF1.02 Myeloid zinc finger protein MZF1
V$NEUR V$NEUROD1.01 DNA binding site for NEUROD1 (BETA-2 / E47 dimer)
V$NEUR V$NEUROG.01 Neurogenin 1 and 3 (ngn1/3) binding sites
V$NF1F V$NF1.01 Nuclear factor 1
V$NF1F V$NF1.02 Nuclear factor 1 (CTF1)
V$NFAT V$NFAT.01 Nuclear factor of activated T-cells
V$NFKB V$CREL.01 c-Rel
V$NFKB V$HIVEP1.01 ZAS domain transcription factor: human immunodeficiency virus type
1 enhancer-binding protein-1 (HIVEP1), major histocompatibility
complex-binding protein-1 (MBP-1), positive regulatory domain II-
binding factor 1 (PRDII-BF1)
V$NFKB V$NFKAPPAB.01 NF-kappaB
V$NFKB V$NFKAPPAB.02 NF-kappaB
V$NFKB V$NFKAPPAB50.01 NF-kappaB (p50)
V$NFKB V$NFKAPPAB65.01 NF-kappaB (p65)
V$NKXH V$HMX2.01 Hmx2/Nkx5-2 homeodomain transcription factor
V$NKXH V$HMX2.02 Hmx2/Nkx5-2 homeodomain transcription factor
V$NKXH V$HMX3.01 H6 homeodomain HMX3/Nkx5.1 transcription factor
V$NKXH V$HMX3.02 Hmx3/Nkx5-1 homeodomain transcription factor
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V$NKXH V$NKX25.01 Homeo domain factor Nkx-2.5/Csx, tinman homolog, high affinity
sites
V$NKXH V$NKX25.02 Homeo domain factor Nkx-2.5/Csx, tinman homolog low affinity sites
V$NKXH V$NKX31.01 Prostate-specific homeodomain protein NKX3.1
V$NKXH V$NKX32.01 Homeodomain protein NKX3.2 (BAPX1, NKX3B, Bagpipe homolog)
V$NOLF V$OLF1.01 Olfactory neuron-specific factor
V$NR2F V$ARP1.01 Apolipoprotein AI regulatory protein 1, NR2F2
V$NR2F V$COUP.01 COUP antagonizes HNF-4 by binding site competition or synergizes
by direct protein - protein interaction with HNF-4
V$NR2F V$HNF4.01 Hepatic nuclear factor 4
V$NR2F V$HNF4.02 Hepatic nuclear factor 4
V$NR2F V$HPF1.01 HepG2-specific P450 2C factor-1
V$NR2F V$PNR.01 Photoreceptor-specific nuclear receptor subfamily 2, group E,
member 3 (Nr2e3)
V$NRF1 V$NRF1.01 Nuclear respiratory factor 1 (NRF1), bZIP transcription factor that
acts on nuclear genes encoding mitochondrial proteins
V$NRLF V$NRL.01 Neural retinal basic leucine zipper factor (bZIP)
V$NRSF V$NRSE.01 Neural-restrictive-silencer-element
V$NRSF V$NRSF.01 Neuron-restrictive silencer factor
V$OAZF V$ROAZ.01 Rat C2H2 Zn finger protein involved in olfactory neuronal
differentiation
V$OCT1 V$OCT.01 Octamer binding site (OCT1/OCT2)
V$OCT1 V$OCT1.01 Octamer-binding factor 1
V$OCT1 V$OCT1.02 Octamer-binding factor 1
V$OCT1 V$OCT1.04 Octamer-binding factor 1
V$OCT1 V$OCT1.05 Octamer-binding factor 1
V$OCT1 V$OCT1.06 Octamer-binding factor 1
V$OCTB V$TST1.01 POU-factor Tst-1/Oct-6
V$OCTP V$OCT1P.01 Octamer-binding factor 1, POU-specific domain
V$P53F V$P53.01 Tumor suppressor p53
V$P53F V$P53.02 Tumor suppressor p53 (5' half site)
V$P53F V$P53.03 Tumor suppressor p53 (3' half site)
V$PARF V$DBP.01 Albumin D-box binding protein
V$PAX1 V$PAX1.01 Pax1 paired domain protein, expressed in the developing vertebral
column of mouse embryos
V$PAX2 V$PAX2.01 Zebrafish PAX2 paired domain protein
Appendix                                                                                                                   186
V$PAX3 V$PAX3.01 Pax-3 paired domain protein, expressed in embryogenesis,
mutations correlate to Waardenburg Syndrome
V$PAX3 V$PAX3.02 Pax-3 paired domain protein
V$PAX4 V$PAX4.01 Pax-4 homeodomain binding site, together with PAX-6 involved in
pancreatic development
V$PAX5 V$PAX5.01 B-cell-specific activating protein
V$PAX5 V$PAX5.02 B-cell-specific activating protein
V$PAX5 V$PAX5.03 PAX5 paired domain protein
V$PAX5 V$PAX9.01 Zebrafish PAX9 binding sites
V$PAX6 V$PAX4_PD.01 PAX4 paired domain binding site
V$PAX6 V$PAX6.01 Pax-6 paired domain binding site
V$PAX6 V$PAX6.02 PAX6 paired domain and homeodomain are required for binding to
this site
V$PAX8 V$PAX8.01 PAX 2/5/8 binding site
V$PBXC V$PBX1_MEIS1.01 Binding site for a Pbx1/Meis1 heterodimer
V$PBXC V$PBX1_MEIS1.02 Binding site for a Pbx1/Meis1 heterodimer
V$PBXC V$PBX1_MEIS1.03 Binding site for a Pbx1/Meis1 heterodimer
V$PDX1 V$ISL1.01 Pancreatic and intestinal lim-homeodomain factor
V$PDX1 V$PDX1.01 Pdx1 (IDX1/IPF1) pancreatic and intestinal homeodomain TF
V$PERO V$PPARA.01 PPAR/RXR heterodimers
V$PIT1 V$PIT1.01 Pit1, GHF-1 pituitary specific pou domain transcription factor
V$PLAG V$PLAG1.01 Pleomorphic adenoma gene (PLAG) 1, a developmentally regulated
C2H2 zinc finger protein
V$PLZF V$PLZF.01 Promyelocytic leukemia zink finger (TF with nine Krueppel-like zink
fingers)
V$PRDF V$PRDM1.01 PRDI binding factor 1
V$PXRF V$PXRCAR.01 Halfsite of PXR (pregnane X receptor)/RXR resp. CAR (constitutive
androstane receptor)/RXR heterodimer binding site
V$RARF V$RAR.01 Retinoic acid receptor, member of nuclear receptors, half site
V$RARF V$RAR.02 Retinoic acid receptor, member of nuclear receptors, DR5 site
V$RARF V$RTR.01 Retinoid receptor-related testis-associated receptor (GCNF/RTR)
V$RBIT V$BRIGHT.01 Bright, B cell regulator of IgH transcription
V$RBPF V$RBPJK.01 Mammalian transcriptional repressor RBP-Jkappa/CBF1
V$RBPF V$RBPJK.02 Mammalian transcriptional repressor RBP-Jkappa/CBF1
V$RCAT V$CLTR_CAAT.01 Mammalian C-type LTR CCAAT box
V$REBV V$EBVR.01 Epstein-Barr virus transcription factor R
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V$RORA V$NBRE.01 Monomers of the nur subfamily of nuclear receptors (nur77, nurr1,
nor-1)
V$RORA V$RORA1.01 RAR-related orphan receptor alpha1
V$RORA V$RORA2.01 RAR-related orphan receptor alpha2
V$RORA V$T3R.01 vErbA, viral homolog of thyroid hormone receptor alpha1
V$RORA V$TR2.01 Nuclear hormone receptor TR2, half site
V$RORA V$TR4.01 Nuclear hormone receptor TR4 homodimer binding site
V$RP58 V$RP58.01 Zinc finger protein RP58 (ZNF238), associated preferentially with
heterochromatin
V$RREB V$RREB1.01 Ras-responsive element binding protein 1
V$RXRF V$FXRE.01 Farnesoid X - activated receptor (RXR/FXR dimer)
V$RXRF V$LXRE.01 Nuclear receptor involved in the regulation lipid homeostasis
V$RXRF V$VDR_RXR.01 VDR/RXR Vitamin D receptor RXR heterodimer site
V$RXRF V$VDR_RXR.02 VDR/RXR Vitamin D receptor RXR heterodimer site
V$RXRF V$VDR_RXR.03 Bipartite binding site of VDR/RXR heterodimers without a spacer
between directly repeated motifs
V$RXRF V$VDR_RXR.04 Bipartite binding site of VDR/RXR heterodimers: 2 spacer
nucleotides between the two directly repeated motifs
V$RXRF V$VDR_RXR.05 Bipartite binding site of VDR/RXR heterodimers: 3 spacer
nucleotides between the two directly repeated motifs
V$RXRF V$VDR_RXR.06 Bipartite binding site of VDR/RXR heterodimers: 4 spacer
nucleotides between the two directly repeated motifs
V$SATB V$SATB1.01 Special AT-rich sequence-binding protein 1, predominantly
expressed in thymocytes, binds to matrix attachment regions (MARs)
V$SF1F V$FTF.01 Alpha (1)-fetoprotein transcription factor (FTF), liver receptor
homologue-1 (LRH-1)
V$SF1F V$SF1.01 SF1 steroidogenic factor 1
V$SIXF V$SIX3.01 SIX3 / SIXdomain (SD) and Homeodomain (HD) transcription factor
V$SMAD V$SMAD3.01 Smad3 transcription factor involved in TGF-beta signaling
V$SMAD V$SMAD4.01 Smad4 transcription factor involved in TGF-beta signaling
V$SNAP V$PSE.01 Proximal sequence element (PSE) of RNA polymerase II-transcribed
snRNA genes
V$SNAP V$PSE.02 Proximal sequence element (PSE) of RNA polymerase III-
transcribed genes
V$SORY V$HBP1.01 HMG box-containing protein 1
V$SORY V$HMGIY.01 HMGI(Y) high-mobility-group protein I (Y), architectural transcription
factor organizing the framework of a nuclear protein-DNA
transcriptional complex
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transcriptional complex
V$SORY V$SOX5.01 Sox-5
V$SORY V$SOX9.01 SOX (SRY-related HMG box)
V$SORY V$SRY.01 Sex-determining region Y gene product
V$SP1F V$BTEB3.01 Basic transcription element (BTE) binding protein, BTEB3, FKLF-2
V$SP1F V$GC.01 GC box elements
V$SP1F V$SP1.01 Stimulating protein 1, ubiquitous zinc finger transcription factor
V$SP1F V$SP1.02 Stimulating protein 1, ubiquitous zinc finger transcription factor
V$SP1F V$SP2.01 Sp2, member of the Sp/XKLF transcription factors with three C2H2
zinc fingers in a conserved carboxyl-terminal domain
V$SP1F V$TIEG.01 TGFbeta-inducible early gene (TIEG) / Early growth response gene
alpha (EGRalpha)
V$SRFF V$SRF.01 Serum response factor
V$SRFF V$SRF.02 Serum response factor
V$SRFF V$SRF.03 Serum response factor
V$STAF V$STAF.01 Se-Cys tRNA gene transcription activating factor
V$STAF V$STAF.02 Se-Cys tRNA gene transcription activating factor
V$STAF V$ZNF76_143.01 ZNF143 is the human ortholog of Xenopus Staf, ZNF76 is a DNA
binding protein related to ZNF143 and Staf
V$STAT V$STAT.01 Signal transducers and activators of transcription
V$STAT V$STAT1.01 Signal transducer and activator of transcription 1
V$STAT V$STAT3.01 Signal transducer and activator of transcription 3
V$STAT V$STAT5.01 STAT5: signal transducer and activator of transcription 5
V$STAT V$STAT6.01 STAT6: signal transducer and activator of transcription 6
V$TALE V$MEIS1.01 Binding site for monomeric Meis1 homeodomain protein
V$TALE V$TGIF.01 TG-interacting factor belonging to TALE class of homeodomain
factors
V$TBPF V$ATATA.01 Avian C-type LTR TATA box
V$TBPF V$LTATA.01 Lentivirus LTR TATA box
V$TBPF V$MTATA.01 Muscle TATA box
V$TBPF V$TATA.01 Cellular and viral TATA box elements
V$TBPF V$TATA.02 Mammalian C-type LTR TATA box
V$TCFF V$TCF11.01 TCF11/KCR-F1/Nrf1 homodimers
V$TEAF V$HLF.01 Hepatic leukemia factor
V$TEAF V$TEF.01 Thyrotrophic embryonic factor
V$TEAF V$TEF1.01 TEF-1 related muscle factor
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V$TEAF V$TEF_HLF.01 Thyrotrophic embryonic factor / hepatic leukemia factor
V$TTFF V$TTF1.01 Thyroid transcription factor-1 (TTF1) binding site
V$VBPF V$VBP.01 PAR-type chicken vitellogenin promoter-binding protein
V$WHZF V$WHN.01 Winged helix protein, involved in hair keratinization and thymus
epithelium differentiation
V$XBBF V$MIF1.01 MIBP-1 / RFX1 complex
V$XBBF V$RFX1.01 X-box binding protein RFX1
V$XBBF V$RFX1.02 X-box binding protein RFX1
V$YY1F V$YY1.01 Yin and Yang 1 activator sites
V$YY1F V$YY1.02 Yin and Yang 1 repressor sites
V$ZBPF V$ZBP89.01 Zinc finger transcription factor ZBP-89
V$ZBPF V$ZF9.01 Core promoter-binding protein (CPBP) with 3 Krueppel-type zinc
fingers
V$ZBPF V$ZNF202.01 Transcriptional repressor, binds to elements found predominantly in
genes that participate in lipid metabolism
V$ZBPF V$ZNF219.01 Kruppel-like zinc finger protein 219
V$ZF5F V$ZF5.01 Zinc finger / POZ domain transcription factor
V$ZFIA V$ZID.01 Zinc finger with interaction domain
V$ZF35 V$ZNF35.01 Human zinc finger protein ZNF35
V$ZNFP V$SZF1.01 SZF1, hematopoietic progenitor-restricted KRAB-zinc finger protein
V$ZNFP V$ZBRK1.01 Transcription factor with 8 central zinc fingers and an N-terminal
KRAB domain
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6.4 Promoter sequences of Cutl1, p18 and p27
Cutl1
-221   CTGCTGCATT TGGAGCTATT GTAGGACATC ACAGATCTTA GATGGGGCAC CCCCACCGCA
-161   GCTCACCAGA CATGATGCAA GGTCCCATTT AGCTCAAGTC ATGGGAAGGA AATGTTGGGA
-101   CCTGGCTCTC TGTCAGTACA GATGGGGGCA GGGTACCACC ATGACACCCA AGCCGTTTCC
 -41   TGCGATCTCC TAGGACCCTC AATGTCATCC AGTGGGACCC
p18 (CDKN2C)
-221   TTTTTTTGAA AAGAAAAAAA TTGAGCGCTT TTTGAGTTGA AAAACCCGCC CCCATTTTAA
-161   CGGCAGAGTT TTAAGGAGGC TCCGCCGAGT TAGGGCGCCG CGGGAGCGGG AAGGCCGGGC
-101   CCCGCCCACG CCCCGCCCAA CGCCCTGGCG GCGCAGTGGC CGGCAGCCCG CTCGCTCCGC
 -41   CCTCGCGGCC CTGCGCCCTT CTCTGCCCGC GCTGGGCCTG
p27 (CDKN1B)
-221   GGTTGTTCCT TATTTGCTTT GTTGTACTAC CTGTGTATAT AGTTTTTATC TTTTACTCTG
-161   TAGCACATAA ACGTTAGGGA TGGGAGGGCA GGGTGGGGCT GAGGAGTCAG CATGGGGGTG
-101   AAGAACTTGC TTCAATTTGT AGCAAGGAGA AAAATATTTG ACTTGCATAA AGAGAAGCAA
 -41   CCTGGGTGGG GGTGGGGGGG GGAAGGGTTT GAATTCCTTT
Supplementary Figure 1. Promoter sequences of MLL–VP16–ER–HA target genes. Depicted are
220 bp of the upstream sequences of the genes Cutl1, p18 and p27. GGGC and GGGG motifs are
highlighted in red.
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